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Abstract 
 
The RET receptor tyrosine kinase (RTK) is crucial for embryonic and adult 
development of multiple organs, tissues and neurons. Gain-of-function mutations in 
the RET gene are found in human cancer, while loss-of-function mutations are 
associated with congenital anomalies of the kidney and urinary tract (CAGUT) and 
Hirschsprung's Disease (HSCR). Previous work has identified that some HSCR 
RET mutations result in a bottleneck in RET folding and a subsequent loss of RET 
export. This thesis presents work examining the characteristics of wild type (WT) 
and HSCR RET maturation, export and signalling in stably transfected mammalian 
cell lines. High throughput siRNA screening was used to identify components 
involved in WT and HSCR RET maturation and export; preliminary validation has 
implicated Endoplasmic Reticulum associated degradation (ERAD), autophagy and 
the N-glycosylation pathway.  
 
RET is also a validated cancer target, as a driver of cancers including multiple 
endocrine neoplasia (MEN) 2A and B. While there are several FDA-approved RET 
inhibitors available, their lack of specificity and potency has resulted in high levels 
of off-target toxicity and low life expectancy extensions. As such, a new generation 
of more optimal inhibitors is required. This thesis presents the investigation of the 
molecular basis of RET kinase inhibition, through the elucidation of the RET kinase 
domain (KD) structure bound to several ATP-competitive chemical inhibitors that 
are known to inhibit RET in vitro. Preliminary development of an updated RET 
pharmacophore is described, defining key residue interactions and combining 
observations with biochemical and thermal stability data.  
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Chapter 1. Introduction 
1.1 Receptor tyrosine kinase structure, regulation and function 
Receptor tyrosine kinases (RTKs) are type 1 transmembrane receptors that sense 
and respond to extracellular stimuli by transducing an activating signal across the 
plasma membrane. This signal is transmitted by either allosteric activation or 
dimerisation of RTK extracellular domains to stimulate their intrinsic tyrosine kinase 
activity. RTKs have many crucial biological roles, allowing cells to respond to 
changes in their environment and make contacts with their surroundings. The 
intracellular signalling pathways activated by RTKs regulate processes such as cell 
proliferation, differentiation and survival and are extremely important during 
development and homeostasis. Catalytic activation of RTKs is therefore tightly 
regulated by auto-inhibitory mechanisms preventing aberrant activation. However, 
many diverse mechanisms are found to subvert RTK control – including missense 
mutations, fusion and over-expression – frequently resulting in deregulation 
(Gschwind et al., 2004).  
 
The coupling of extracellular ligand binding and stimulation of the autocatalytic 
tyrosine kinase activity occurs through transmembrane signalling, a poorly defined 
but presumably conformational switch. The repertoire of human RTKs – numbering 
almost 60 in the human genome – shows considerable diversity within their 
extracellular domains (ECD), reflecting the broad spectrum of polypeptide ligands 
recognised (examples are shown in Figure 1.1). In contrast, their single 
transmembrane-spanning (TM) and intracellular domains (ICD) show marked 
sequence and structural similarities. The kinase domain (KD) is highly conserved, 
while the juxtamembrane (JM) region and C-terminal tail flanking the KD are often 
more divergent (Lemmon and Schlessinger, 2010).  
 
In view of the structural similarities of RTKs from the TM through to the ICD, the 
presumption has been that a unifying activation mechanism common to all RTKs 
would be found; for example, ligand-induced dimerisation of RTKs. While common 
principles have been uncovered in some instances, many RTKs of therapeutic 
importance do not follow these principles and exhibit their own private activation 
Chapter 1 Introduction 
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mechanisms, the epidermal growth factor receptor (EGFR) being a prime example 
(Lemmon et al., 2014). It therefore follows that parallel structural, mechanistic and 
cell biology studies are required on the twenty discrete subfamilies of RTKs to 
establish their architecture, their ligand recognition properties and their mechanism 
of ligand-dependent activation.  
 
 
Figure 1.1 Schematic of growth factor receptor tyrosine kinases 
The RTK family demonstrates great diversity in their ECD structures, while the TM and ICD 
regions are very similar both in sequence and structure. Adapted from (Lemmon and 
Schlessinger, 2010). 
 
RTKs respond to ligand binding through activation of their intracellular kinase 
activity, often associated with dimerisation of the receptor (Lemmon and 
Schlessinger, 2010).  RTK activation frequently has two components; removal of 
auto-inhibitory elements and enhancement of catalytic activity, frequently 100-
1000-fold. Activation results in precise sequential trans auto-phosphorylation of 
tyrosine residues within the RTK ICD, which enhance the kinase activity of the 
receptor and act as docking sites for downstream signalling molecules that bind via 
SH2 (Src homology-2) or PTB (phospho-tyrosine binding) domains (Furdui et al., 
2006).  
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1.1.1 RTK KD structure and phosphorylation 
Tyrosine kinases carry out a phosphoryl transfer reaction in which a tyrosine 
nucleophile on a substrate protein accepts the transfer of a terminal γ-phosphate 
from an ATP moiety (Lassila et al., 2011). The reaction requires a catalytic base 
within the kinase to deprotonate the tyrosine acceptor, permitting nucleophilic 
attack by the tyrosine oxygen towards the electrophilic phosphorous atom of the γ-
phosphate (Figure 1.2). The catalytic cycle is completed by release of phospho-
tyrosine product and ADP prior to binding another ATP to continue further rounds 
of catalysis. 
 
The KD of RTKs is composed of a predominantly β-strand N-lobe and a larger α-
helical C-lobe, a structure that is well conserved within serine/threonine and 
tyrosine kinases. A hinge region between the two lobes allows a certain degree of 
flexibility within the kinase, which is crucial for successful catalytic function. A cleft 
exists between the two lobes to accommodate ATP (Knighton et al., 1991). ATP 
binds within this cleft, below a phosphate-binding loop that contains a glycine-rich 
sequence motif (GXGXφG; φ is usually tyrosine or phenylalanine), known as the 
glycine-rich loop (GRL) (Huse and Kuriyan, 2002). The activation loop (A-loop) is 
located between the N- and C-lobes, beginning with a conserved DFG motif and 
ending with a conserved APE motif. The loop usually contains between one and 
three tyrosine residues that can become phosphorylated (Nolen et al., 2004).  
 
1.1.2 Structural elements required for catalytic mechanism 
 
There are several structural elements required for a catalytically productive kinase. 
The αC-helix must be close to the catalytic centre, so that the conserved lysine 
residue (Lys758 in RET numbering) within the ATP cleft is organised as such to 
interact with the α and β phosphate groups of ATP, through a salt bridge with the 
conserved glutamate residue (Glu775 in RET numbering) extending from the αC-
helix. The A-loop must be in an ‘active’ conformation to facilitate substrate binding 
and catalysis (Hubbard, 1997). The DFG motif must be arranged  to allow the 
aspartate to coordinate magnesium binding; the N- and C-lobes must be correctly 
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oriented, positioning crucial catalytic residues in both lobes (Huse and Kuriyan, 
2002, Cowan-Jacob, 2006).  
 
 
Figure 1.2 Protein tyrosine kinase active conformer 
The crystal structure of the insulin receptor (PDB code 1IR3) with an ATP analogue bound 
within the active site and key structural elements highlighted (Hubbard, 1997). Protein – light 
grey ribbon; substrate peptide – coral; ATP analogue – green & purple sticks; magnesium ions 
– purple; activation loop (including substrate-binding P+1 loop)  – pink; αC helix – green; 
glycine-rich loop – cyan. On the right-hand side, key residues are indicated and interactions 
represented using dotted black lines. The catalytic base (Asp1132) interacts with the attacking 
nucleophilic hydroxyl group of the substrate peptide tyrosine residue. Asn1137 is required for 
positioning of both Asp1132 and the magnesium ions.  
 
The glycine residues within the GRL coordinate the ATP phosphate positions via 
interactions with the loop’s backbone, and result in loop flexibility in the absence of 
ATP binding (Huse and Kuriyan, 2002). The A-loop is a regulatable element 
bearing tyrosine residues that act as auto-phosphorylation sites. Phosphorylation of 
the tyrosine residues within the A-loop stabilises the kinase in an ‘active’ 
conformation, boosting enzymatic activity by several orders of magnitude in many 
RTKs. The auto-phosphorylated tyrosine residues within this loop also frequently 
release the loop from an inactive conformation and serve to recruit downstream 
effector molecules that recognise the phospho-tyrosine side chains (Cowan-Jacob, 
2006).  
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1.1.3 RTK autophosphorylation and regulation 
The phosphorylation of three regions within a tyrosine kinase domain – the 
activation loop, the JM region and the C-tail – can occur upon ligand activation and 
RTK dimerisation. This process results in a far less flexible conformer, as the 
flexible regions within phosphorylation sites become tethered to phospho-binding 
pockets (Chen et al., 2007). While inactive kinases appear to have the A-loop in a 
position that occludes the ATP pocket, phosphorylation of the tyrosine residues 
within the loop prevents binding to the cleft and stabilises an active conformation 
(Hubbard et al., 1994, Hubbard, 1997).  
 
The JM region and C-tail of tyrosine kinases can also be phosphorylated and are 
involved in the regulation of kinase activity. Phosphorylation of two tyrosine 
residues within the JM region results in dissociation, allowing the αC helix to move 
into an active conformation (Wiesner et al., 2006, Wybenga-Groot et al., 2001). In 
the case of Tie2, the C-tail has been found to block substrate binding of the kinase 
domain in its unphosphorylated form (Niu et al., 2002).  
1.1.4 Regulation of RTK activity 
While a great deal of progress has been made towards the understanding of how 
many RTKs regulate their activity, the details for several RTKs (e.g. EGFR and 
RET) are far from fully understood. However, there appear to be common 
mechanisms of regulation; namely autophosphorylation (as discussed above), 
allostery and dimerisation. Allostery can be defined as communication between the 
active site of a protein and a distant site of modification or binding. When an event 
occurs at this distant site, it results in a change in structural conformation or 
flexibility. In turn, this change regulates the activity at the active site (Kuriyan and 
Eisenberg, 2007). As an example, ligand-induced dimerisation of EGFR results in 
allosteric activation of the alternate KD (Zhang et al., 2006).  
 
While mechanisms of ligand-dependent dimerisation differ amongst the RTK 
superfamily (Lemmon and Schlessinger, 2010), the process of dimerisation itself 
appears to be required for both allosteric and trans-phosphorylation activation of 
the KD (Chen et al., 2007, Zhang et al., 2006). Several mechanisms have been 
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identified, with examples including: TrkA/NGF: dimeric-ligand mediated 
dimerisation (Wehrman et al., 2007); KIT/SCF: dimeric-ligand and receptor 
mediated dimerisation (Yuzawa et al., 2007); FGFR/FGF: monomeric-ligand and 
receptor mediated dimerisation (Schlessinger et al., 2000); EGFR/EGF: receptor-
mediated dimerisation (Ogiso et al., 2002). 
 
In the case of receptor-mediated dimerisation, the ligand is still relevant due to its 
role in the stabilisation of an active receptor arrangement (Lemmon and 
Schlessinger, 2010). By deduction, receptors that rely on ligand-dependent 
dimerisation for activation need to have mechanisms of inhibition in the absence of 
ligand. Examples include charge repulsion of membrane-proximal Ig-like domains 
in the KIT-ECD and an inaccessible ‘dimerisation arm’ in EGFR (Yuzawa et al., 
2007, Ogiso et al., 2002). Alternatively, dimerisation can be ligand-independent, as 
is the case for the disulphide-linked dimers of the insulin receptor family (McKern et 
al., 2006). There are suggestions that receptors that rely on ligand-dependent 
dimerisation for activation can exist in preformed dimers, with ligand-binding 
resulting in oligomerisation (Whitty and Riera, 2008, Clayton et al., 2005). Again, 
mechanisms of inhibition are required to prevent aberrant activation of the KD. In 
the case of preformed complexes, allosteric activation of the kinase domain would 
be required (Hubbard and Miller, 2007).  
1.1.5 The regulatory spine 
While the majority of conserved motifs within a protein can be defined as linear 
motifs (such as DFG) or an assembly of structural elements, several structural 
motifs have been identified within kinase domains that do not fall under these 
definitions. The F-helix (coloured blue in Figure 1.3) is considered the central 
scaffold of the kinase domain for extending regulatory motifs, due to its rigid and 
central buried position within the C-lobe relative to crucial areas such as the 
substrate binding residues (Kornev et al., 2008, Kannan and Neuwald, 2005).  
 
Protein kinase sequential and structural alignments have led to the discovery of a 
hydrophobic spatial motif consisting of four residues: L96 (αC-helix), L106 (β4 
strand), Y164 (catalytic loop) and F185 (activation loop) (Kornev et al., 2006). The 
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motif is known as the regulatory R-spine and its position (Figure 1.3) – connected 
to the F-helix via D220 – is thought to regulate the activity of the kinase. The 
formation of this spine is influenced by several structural elements within the kinase, 
including the configuration of the activation loop and the position of the αC helix 
(Kornev et al., 2008). In comparison, another hydrophobic spatial motif termed the 
catalytic C-spine was found to form in the presence of ATP (Figure 1.3). The C-
spine connects to the F-helix via Met231, with the motif composing of: Leu227 and 
Met231 (F-helix); Met128 (D-helix); Leu172, Leu173 and Ile174 (β7 strand); and 
Val57 and Ala70 (contacting adenine ring of ATP). In the presence of ATP, this C-
spine connects the N- and C-lobes together (Kornev et al., 2008).  
 
 
Ribbon representation of the RET kinase domain (light grey) with the F helix (dark blue), C-
spine (coral) and R-spine (light green) highlighted. Residues within the spine are annotated. 
The position of adenine within the ATP structure is highlighted in magenta. 
 
1.2 Synthesis, trafficking and degradation of RTKs 
The process of intracellular trafficking is crucial in the transport of RTKs to 
appropriate sites for synthesis, maturation and export to be exposed to ligands.  
The nascent polypeptide is inserted into the endoplasmic reticulum (ER) to be 
correctly folded and modified, before being transported to the Golgi apparatus and 
on to the plasma membrane. Once at the cell surface, RTKs are internalised and 
either recycled once more to the plasma membrane or targeted for degradation 
Figure 1.3 Catalytic and R egulatory spines highlighted within the RET 
kinase domain 
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(Goh and Sorkin, 2013).  Studies have demonstrated that RTKs can transmit 
signals intracellularly, as well as from the plasma membrane, and the subcellular 
location can dictate the signalling specificity (Lemmon and Schlessinger, 2010, 
Miaczynska et al., 2004). The location of the RTK can result in the association of 
different signalling molecules.  This entire process determines the half-life of an 
RTK in a particular cell type; for example, the EGFR half-life in carcinoma cells is 
24 hours (Stoscheck and Carpenter, 1984). In the case of RET, a combination of 
findings from studies examining RET maturation and degradation suggest a half-life 
of approximately 10 hours (Tsui et al., 2006, van Weering et al., 1998). To 
understand RTK maturation, a brief overview of protein folding, glycosylation and 
transport of glycoproteins is given.  
1.2.1 Protein folding and quality control within the ER 
After synthesis on ribosomes, proteins are translocated into the ER, where they are 
folded and modified into their correct structure before being transported to the 
correct cellular compartment (Figure 1.4). Most proteins are targeted to the ER via 
amino-terminal signal sequences that are cleaved co- or post-translationally (Wang 
et al., 2005, Land et al., 2003). Growing evidence suggests that this signal 
sequence is not only responsible for the ER-targeting of proteins, but also 
important for folding and modification of the polypeptide (Piersma et al., 2006, 
Tamura et al., 2011).  
 
 
Figure 1.4 Cotranslational protein folding within the ER 
The nascent polypeptide is inserted into the ER by the ribosome (cyan), through the Sec61 
translocon (orange). The oligosaccharyltransferase (OST; purple) attaches the glycan chain to 
Asn on the polypeptide, while BiP and PDI are involved in protein stability and disulphide bond 
formation. The N-terminal sequence is cleaved by the signal sequence peptidase complex 
(SPC; lime green) and glucosidase I removes the terminal glucose molecule. The trimmed 
polypeptide can then bind to the membrane-associated lectin (malectin; grey) and glucosidase II 
removes another glucose molecule. The monoglucosylated glycan binds to calnexin (CNX; 
blue) and the oxidoreductase ERp57 (brown). This process continues until glucosidase II 
removes the final glucose molecule. Adapted from (Braakman and Hebert, 2013).  
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Upon entering the ER, a large number of proteins are modified by N-linked glycans 
that are attached to the asparagine side chain present in the NXS/T motif (where X 
is any amino acid). This process often occurs during translation into the lumen via 
the enzyme oligosaccharyltransferase (OST) (Nilsson and von Heijne, 1993). The 
carbohydrate attached initially comprises of three glucoses, nine mannoses and 
two N-acetyl glucosamines (Figure 1.5). Glycosylation of a protein can have effects 
on both the final function and the physical properties: N-linked glycans have been 
shown to improve stability, kinetics of folding, solubility and resistance to 
degradation (Hanson et al., 2009).  
 
 
Figure 1.5 Structure of the N-glycan core 
The oligosaccharide is made up of two N-acetylglucosamine (pink squares), nine mannose 
(green circles) and three glucose residues (blue triangles). A-G are added on the cytosolic side 
of the ER membrane, while H-N are added once the substrate is flipped in the membrane. The 
linkages are annotated.  Adapted from (Aebi et al., 2010). 
 
Nascent polypeptides are found in the ER at such a high concentration that 
misfolding is very likely to occur without the assistance of a number of ER 
molecular chaperones (Ellis and Hartl, 1999). Two types of chaperones exist: 
classical chaperones bind directly to the protein and can be found outside of the 
ER as well, while carbohydrate-binding chaperones are ER-specific and interact 
with the glycan moieties (Braakman and Hebert, 2013). Classical chaperones 
comprise of heat shock protein (Hsp) 70 and 90 family members, recognising 
exposed hydrophobic regions on substrates that are indicative of an incorrectly 
folded state. One such chaperone is known as BiP (binding immunoglobulin 
protein), a nucleotide-binding ER-specific protein that binds to substrates and 
protects them from premature folding (Suzuki et al., 1991). BiP is believed to be a 
crucial regulator of ER function due to its roles in protein translocation, protein 
folding, ERAD and activation of the unfolded protein response (Hendershot, 2004).  
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Carbohydrate-binding chaperones include calnexin (membrane-bound) and 
calreticulin, which facilitate the folding of glycoproteins. These chaperones bind to 
folding substrates and stabilise them, preventing aggregation and premature exit 
from the ER (Hebert et al., 1996, Rajagopalan et al., 1994). They also facilitate the 
formation of disulphide bonds and the isomerisation of rare cis-trans Pro peptide 
bonds (Oliver et al., 1997, Kozlov et al., 2010). The N-linked glycan attached to a 
substrate is first trimmed by glucosidase I, reducing affinity for OST, followed by 
further trimming by glucosidase II. The monoglucosylated protein is then able to 
enter the carbohydrate-binding chaperone pathway and can only leave when 
glucosidase II removes the final glucose. At this point, the substrate protein is 
checked by UGT1 (UDP-glucose:glycoprotein glucosyltransferase 1) and 
reglycosylated if further attempts at folding are required (Labriola et al., 1995, 
Hebert et al., 1995).  
 
These chaperone systems are required for the retention of proteins within the ER, 
to allow for protein folding. The folding process is facilitated by a host of ER-
localised enzymes that are either protein disulphide isomerases (PDIs) or prolyl 
peptidyl cis-trans isomerases (PPIases). PDIs catalyse the formation, isomerisation 
and reduction of disulphide bonds and there are currently more than 20 mammalian 
family members identified (Wallis and Freedman, 2013, Ellgaard and Ruddock, 
2005). PPIases are responsible for the inter-conversion of cis and trans Pro-
peptide bonds, a rate-limiting step in protein folding due to the unconventional 
conformation of the bond (Lang et al., 1987, Brandts et al., 1977). It should be 
noted that proline residues are often found in close proximity to disulphide bonds, 
suggesting an inter-related function for each class of enzyme.  
 
The folding and chaperone systems of the ER can persist in futile attempts of 
protein folding for a finite time, before ER-associated degradation (ERAD) takes 
over. ERAD involves the recognition of a misfolded substrate, the transfer of the 
substrate across the ER lipid bilayer, ubiquitylation and proteasomal degradation 
(Olzmann et al., 2013). Problematic proteins that are assessed by UGT1 and re-
entered into the carbohydrate-binding chaperone pathway must eventually be 
removed. While glucosidases are responsible for the trimming of glucose residues, 
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mannosidases – MAN1B1, EDEM1 and EDEM3 – are responsible for 
demannosylation that results in substrates that can no longer be recognised by 
UGT1 (demonstrated in Figure 1.6) (Hosokawa et al., 2010, Gonzalez et al., 1999, 
Hirao et al., 2006). The substrates are instead recognised by OS-9 (osteosarcoma 
amplified 9) and ERLEC1 (endoplasmic reticulum lectin 1) via mannose-6-
phosphate receptor homology (MRH) domains (Hosokawa et al., 2008, Hosokawa 
et al., 2009).  
 
Figure 1.6 Glycan processing within the ER 
N-glycan trimming and modification is carried out by a number of enzymes within the ER (left). 
The N-glycan dictates the fate of the protein: exit or ERAD. Yellow: immature substrate; red: 
misfolded substrate; green: folded substrate. Adapted from (Aebi et al., 2010). 
Chapter 1 Introduction 
 30 
Once recognised, the misfolded substrates need to be exported from the ER. This 
is facilitated by the interaction of misfolded protein-recognition factors with SEL1L 
(sel-1 suppressor of lin-12-like), a transmembrane glycoprotein that in turn 
organises the clustering of essential ERAD components required for substrate 
dislocation (Olzmann et al., 2013). While the entire ER ‘dislocon’ has not been 
identified, several components – such as the Derlin protein family and E3 ligase 
Hrd1 – have been proposed to be involved (Ye et al., 2004, Carvalho et al., 2010). 
Following removal from the ER, substrates are ubiquitinated and degraded via the 
cytosolic 26S proteasome. A large number of E3 ligases have been implicated in 
the ubiquitination of misfolded ERAD substrates, although it is thought that Hrd1 
and gp78 carry out the majority while other ligases have more selective clientele 
(Olzmann et al., 2013, Kikkert et al., 2004, Fang et al., 2001).  
1.2.2 ER to Golgi apparatus transport 
Cell surface proteins that successfully reach their native fold may be transported 
from the ER to the Golgi apparatus, where they are modified further and can then 
continue on to the plasma membrane. This process requires the formation of the 
COPII coat on the cytosolic side of the ER membrane, defining transport vesicles 
that carry proteins forward. The cytoplasmic G-protein Sar1 is activated by ER 
membrane protein Sec12, triggering a conformational shift in Sar1 that is thought to 
result in membrane curvature. The activated and now membrane-bound Sar1 then 
recruits Sec23 and Sec24, a complex that is required for both cargo-binding and 
recruitment of the outer coat components Sec13 and Sec31 (Lord et al., 2013). 
After membrane curvature has been induced and ER cargo has been recruited, the 
vesicle must be excised from the membrane, a process that is thought to be driven 
by Sar1 itself (Lee et al., 2005). Once excised, the vesicles move towards an 
intermediate compartment known as ERGIC (ER-Golgi intermediate compartment), 
where preliminary sorting of substrates can occur. ER-resident proteins can be 
transported back (retrograde transport) and proteins destined for the secretory 
pathway can move forward to the cis-Golgi (anterograde transport). Retrograde 
transport is mediated by the COPI coat complex (Martinez-Menarguez et al., 1999). 
The COPII coated vesicles tether to and fuse with the accepting membrane with 
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the aid of the TRAPP (TRAnsport Protein Particle) and SNARE (Soluble NSF 
Attachment protein Receptor) complexes (Cai et al., 2007).  
1.2.3 Functions of the Golgi 
Proteins that reach the Golgi apparatus are modified further through a range of 
complex glycosylation processes. The Golgi is a host for many 
glucosyltransferases, glucosidases and nucleotide sugar transporters that are 
located throughout the cis- and trans-Golgi. Glycoproteins arrive in the cis-Golgi 
with N-glycans attached, high mannose sugar moieties that can be modified further 
by the Golgi resident UDP-GlcNac into complex N-glycans (Lau et al., 2007). O-
linked glycosylation – single sugar moieties added to Ser/Thr – also occurs within 
the Golgi, and is mainly applicable to mucin type glycans and proteoglycans 
(Schachter and Williams, 1982, Esko and Selleck, 2002). Proteins move through 
the Golgi, from cis to trans, into the trans-Golgi network (TGN): the hub of cargo 
sorting for the early secretory pathway. The presence of sorting motifs and 
glycosylation can act as signals that target cargo proteins to the plasma membrane 
(Yeaman et al., 1997).  
1.2.4 RTK endocytosis and receptor recycling 
Once at the cell surface, RTKs can be internalised and degraded via the process of 
endocytosis (Figure 1.7). Increased activation of cell surface RTKs leads to 
increased turnover, thus controlling the level of RTK signalling. The receptors are 
endocytosed by both clathrin-dependent and –independent mechanisms, with the 
resulting vesicles fusing with the early endosomes (EEs). At this point, some 
ligands dissociate from the receptor in the acidic endosome and both ligand-
occupied and –unoccupied RTKs can be recycled by EE-plasma membrane fusion 
or retro-endocytosis in endosomal-derived vesicles. Slower recycling also occurs in 
EEs that have matured into sorting endosomes (SEs) and multivesicular bodies 
(MVBs), which gradually lose their ability to recycle and mature into late 
endosomes (LEs). LEs fuse with lysosomes containing proteolytic enzymes 
required to degrade the receptors and ligands (Goh and Sorkin, 2013). Several 
Rab GTPases are involved in the endo-lysosomal pathway; particularly, Rab5 is 
found on early endosomes and is crucial for the biogenesis of endosomes, while 
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Rab7 replaces Rab5 on matured late endosomes and is involved in endo-
lysosomal fusion (Gautreau et al., 2014).  
 
Clathrin-mediated endocytosis has been identified as the major internalisation 
pathway for ligand-activated RTKs, with the small interfering RNA (siRNA) 
knockdown of clathrin resulting in the inhibition of EGFR, VEGFR2 and TrkB 
internalisation (Huang et al., 2004, Lampugnani et al., 2006, Zheng et al., 2008). 
Specific motifs within the cytoplasmic domains of RTKs are recognised by 
components of the clathrin coat, along with mono-ubiquitination of lysine residues 
within the auto-phosphorylated kinase domain by E3 ligases such as Cbl (Casitas 
B-lineage Lymphoma) (Goh and Sorkin, 2013, Marmor and Yarden, 2004). It is 
thought that the ubiquitin moieties attached to activated RTKs target the receptors 
to clathrin-coated pits via ubiquitin binding proteins within the pits and are involved 
in the late sorting events of RTKs within MVBs (Hawryluk et al., 2006, Marmor and 
Yarden, 2004).  
 
Figure 1.7 RTK endocytosis 
A schematic model of RTK (orange) endocytosis upon ligand (blue) binding. The receptors and 
ligands are recycling or degraded via the lysosome. CCV – clathrin coated vesicle; EE – early 
endosomes; SE – sorting endosome; MVB – multivesicular bodies; ILV – intraluminal vesicles; 
LE – late endosome. Adapted from (Goh and Sorkin, 2013). 
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RTKs that are subsequently located within the membrane of EEs and MVBs can be 
recycled back to the plasma membrane, while those located within MVB 
intraluminal vesicles (ILVs) cannot be recycled back and are degraded once the 
MVBs mature into LEs. It is currently believed that the ubiquitinated RTKs are held 
back from the recycling process within MVBs by components of ESCRT 
(endosomal sorting complexes required for transport), resulting in their packaging 
into ILVs (Teis et al., 2009).  
 
Receptor recycling has been demonstrated for EGFR, TrkA and the insulin receptor 
(IR), although the mechanisms behind recycling are less well understood (Sorkin et 
al., 1991, Zapf-Colby and Olefsky, 1998, Huecksteadt et al., 1986). Recycling 
appears to be the standard pathway for RTKs that have not been trapped within 
MVBs, with studies based on the EGFR suggesting that saturation of the RTK 
degradative pathway results in higher levels of receptor recycling (Goh and Sorkin, 
2013, French et al., 1994).  
1.2.5 Mechanisms of RTK degradation 
RTK degradation within the mammalian cell can occur via three pathways: (1) 
endocytosis and lysosomal degradation, (2) chaperone-mediated autophagy 
(leading to lysosomal degradation) and (3) the ubiquitin-proteasome system (UPS) 
(Figure 1.8). The decision as to which pathway to select is made depending on the 
location of the protein. For example, activated RTKs at the cell surface are 
internalised and degraded via the lysosome to regulate signalling levels (Goh and 
Sorkin, 2013); misfolded and therefore defective RTKs are often exported from the 
ER via ERAD, ubiquitinated and degraded via the proteasome (Olzmann et al., 
2013); and it is now believed that misfolded and aggregated proteins can be 
targeted for selective autophagy or the ‘aggresome’ (Hyttinen et al., 2014).  
1.2.5.1 Lysosomal degradation 
Proteins can be targeted for lysosomal degradation from both the endocytic and 
autophagic pathways. The lysosome itself, a crucial digestive compartment of the 
cell, has an acidic internal environment containing acid hydrolases that are used to 
digest imported components (Appelqvist et al., 2013). There are approximately 60 
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different hydrolases contained within the lysosome – such as proteases, nucleases 
and phosphatases – with their own specific targets that result in the breakdown of 
all macromolecules (Bainton, 1981).  
 
 
Figure 1.8 Degradative pathways targeting RTKS 
The three pathways involved in RTK degradation: (1) Endocytosis and lysosomal degradation; 
(2) Autophagy and lysosomal degradation; (2) Proteasomal degradation. 
 
1.2.5.2 Proteasomal degradation 
The ubiquitin/proteasome system (UPS) is the other main proteolytic system of the 
eukaryotic cell. While many proteases are present within the lysosome, the UPS 
has only one: the 20S proteasome. Degradation via the proteasome requires target 
proteins to be tagged with ubiquitin, a process that requires three enzymes. The E1 
ubiquitin-activating enzyme is first bound to the ubiquitin protein before transferring 
it to an E2 ubiquitin-conjugating enzyme; an E3 ligase then catalyses the transfer 
from the E2 to (primarily) a lysine residue on the target protein. Poly-ubiquitination 
can occur due to the presence of lysine residues within the ubiquitin molecule itself 
(Wong and Cuervo, 2010). The process of ubiquitination is crucial in the end fate of 
the substrate protein. Due to the presence of lysine residues within ubiquitin, 
several modes of ubiquitination can occur. Mono-ubiquitination tends to result in 
regulation of the substrate protein – through endocytosis, trafficking or transcription 
– while poly-ubiquitination can occur in several ways. Firstly, ubiquitin chains 
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occurring through Lys48 tend to result in proteolysis of the substrate, while chains 
occurring through Lys63 are more associated with signalling and endocytosis. 
Branched ubiquitination through Lys11 has recently been reported to result in 
proteolysis of the substrate as well (Johnson et al., 1996, Winter et al., 2013).  
 
Substrate specificity is regulated by the presence of degradative signals on target 
proteins that are recognised by the array of E3 ligases, known as E3 ligase 
substrate recognition components (Ravid and Hochstrasser, 2008). Alternatively, 
the E3 ligases can be assisted by cytosolic chaperones. For example, the E3 ligase 
CHIP recognises Hsp90 and Hsc70 and can then target the chaperones’ client 
proteins (Murata et al., 2001). Proteins that have been Lys48-linked with at least 
four ubiquitin molecules are classed as substrates for the 26S proteasome 
(Thrower et al., 2000). Substrates are either escorted to the proteasome by shuttle 
factors or they can bind directly to ubiquitin receptors on the proteasome itself 
(Finley, 2009). Deubiquitinating enzymes then remove the poly-ubiquitin chains and 
the substrate can enter the 20S catalytic core of the proteasome for degradation 
(Wong and Cuervo, 2010).  
1.2.5.3 Autophagy 
Autophagy is a crucial degradative process required for the removal of both 
proteins and organelles through the action of lysosomes. The autophagic pathway 
can be divided into three types: macroautophagy (the sequestering of a region of 
the cytosol into a double membrane that is carried to the lysosome); 
microautophagy (the lysosomal membrane itself invaginates around the 
surrounding cytosol to internalise it within the lumen); and chaperone-mediated 
autophagy (CMA) (motifs on substrate proteins are recognised by chaperones that 
target it directly to the lysosome) (Wong and Cuervo, 2010).  
 
Macroautophagy requires the formation of the phagophore; a double-membrane 
structure that engulfs portions of the cytosol and ultimately closes to become a 
vesicle known as the autophagosome. The autophagosomes are then transported 
by microtubules to the late endosomes or lysosomes. This process initially involves 
the formation of the ATG5-ATP12-ATG16L complex, which is required for the 
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conjugation of ATG8 family proteins (divided into the LC3 and GABARAP 
subfamilies) to the phagophore membrane. The ATG8 family members then act as 
receptors for specific proteins until they are released by ATG4B when the 
phagophore closes into the autophagosome (Lamark and Johansen, 2012).  
 
The identification of chaperone-mediated autophagy has altered the conception 
that autophagy is an unselective process. In the case of selective autophagy, 
autophagy receptors identify protein substrates and can bind directly to ATG8 
homologues on the phagophore membrane. Misfolded and aggregated proteins 
can be targeted through this mechanism, which has been termed aggrephagy 
(Overbye et al., 2007). As discussed earlier, aberrant proteins within the ER are 
targeted for ERAD and retrotranslocated into the cytosol for degradation. At this 
point, the presence of cytosolic chaperones such as Hsp70 can induce the binding 
of CMA receptors (such as LAMP2) or E3 ligases (such as CHIP). Alternatively, 
specific aggrephagy receptors (such as Optineurin) can bind to the aggregated 
protein or pathogens (Lamark and Johansen, 2012).  
1.3 RET structure, ligands-co-receptor partners and biological 
functions 
This laboratory has been actively studying the structure and biochemistry of the 
RET (REarranged during Transfection) receptor tyrosine kinase. This project has 
arisen from a long standing interest in the cystine knot superfamily of growth factor 
ligands that include the glial cell-line derived neurotrophic factor (GDNF), and their 
interactions with partner proteins. RET has an unusual level of importance as an 
RTK, as it is essential for vertebrate development and contributes to multiple 
human diseases including several forms of cancer, Hirschsprung’s disease and 
congenital anomalies of kidney and urinary tract (CAKUT). The diseases 
associated with RET are discussed later in section 1.4.  
1.3.1 Biological functions of RET 
RET plays a crucial role in development, with RET function being required for 
spermatogenesis and the development of the kidneys and nervous system. RET is 
expressed in the cells of both the central and peripheral nervous systems, and its 
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inactivation has been shown to result in renal agenesis, due to a loss of ureteric 
bud development (Schuchardt et al., 1994a).  RET can display multiple alternative 
splicing variants, resulting in three different carboxyl termini: 9 terminal amino acids 
(RET9), 43 terminal amino acids (RET43) and 51 terminal amino acids (RET51) 
(Myers et al., 1995). It has been suggested that there are isoform-specific roles for 
splicing variants RET9 and RET51 during this development (Jain et al., 2006). 
Along with defects in kidney development, mice lacking RET were found to lack 
enteric neurons throughout the digestive tract (Schuchardt et al., 1994b). This lack 
of neural crest development also occurs in humans and was identified in the mid 
1900’s as Hirschsprung’s disease (HSCR) (Whitehouse and Kernohan, 1948).  
 
RET is also expressed in the motor neurons of the spinal cord, with GDNF found to 
be required for their survival during embryogenesis (Oppenheim et al., 2000). 
GDNF appears to be required for the survival of several types of neuron, with 
RET/GDNF signalling shown to protect midbrain dopaminergic neurons from 
chemically-induced cell death (Trupp et al., 1996). The beneficial effect of GDNF 
on neuronal survival results in the implication of the ligand in the treatment of 
Parkinson’s disease, and some loss-of-function studies have shown that RET or 
GDNF ablation results in defects within dopaminergic neurons (Kramer et al., 2007, 
Pascual et al., 2008).  RET, GDNF and GFRα have all been shown to be required 
for spermatogenesis: a process that is essential for reproduction (Naughton et al., 
2006, Jain et al., 2004).  
1.3.2 RET evolution 
Only one RET gene is known to exist in mammals, lower vertebrates and 
arthropods; the gene is absent from other phyla of the animal kingdom (Shiu and Li, 
2004). The RET gene can be found in Drosophila melanogaster, but the fly appears 
to lack genes encoding GDNF or GFRα and Drosophila RET cannot interact with 
the mammalian ligand or co-receptor (Abrescia et al., 2005). However, the RET 
expression pattern is similar to that of mammals, and a Drosophila model for RET-
associated multiple endocrine neoplasia type 2 (MEN2) has been developed for 
drug profiling (Hahn and Bishop, 2001, Dar et al., 2012, Das and Cagan, 2010).  
The zebrafish (Danio rerio) has been used as a model organism for studying RET, 
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in which it was shown that the function of RET and its bipartite ligand (defined as 
two GDNF and two GFRα1 molecules) is conserved in enteric nervous system 
development (Shepherd et al., 2004, Shepherd et al., 2001, Marcos-Gutierrez et al., 
1997).  
1.3.3 RET ligands and co-receptors 
RET binds to a GDNF family ligand (GFL) – GDNF, neurturin (NRTN), artemin 
(ARTN) or persephin (PSPN) – and a corresponding GDNF family receptor (GFR) 
co-receptor (1-4) that is GPI-linked to the plasma membrane (Figure 1.9) (Klein et 
al., 1997, Treanor et al., 1996). Assembly of the GDNF-GFRRET ternary 
complex leads to RET activation by transmembrane signalling. The current model 
for RET activation involves a disulphide-linked ligand homodimer, two membrane-
associated GFRs and two RET molecules. In the case of ARTN/GFR3, the order 
of assembly has been determined as: 1 GFR3 + ARTN dimer + 1 RET + 1 GFR3 
+ 1 RET (Schlee et al., 2006).  
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Figure 1.9 Schematic of RET/ligand/co-receptor interactions & downstream 
signalling pathways 
Disulphide-linked homodimer ligands and their corresponding GPI-anchored co-receptor bind to 
RET and induce kinase activation. Tyrosine residues within RET-ICD become auto-
phosphorylated and act as docking sites for scaffold and downstream signalling proteins. This 
recruitment leads to the activation of particular downstream signalling pathways.  
 
There are currently two distinct models of RET/GFL/GFR signalling. The first 
model involves RET and GFR expression in the same cell, with GFR localised to 
lipid rafts: signalling compartments within the membrane that have high levels of 
cholesterol and sphingolipids to accommodate for membrane-associated signalling 
molecules (Lingwood and Simons, 2010). Upon GFL/GFR binding, GFR recruits 
RET to the lipid raft, allowing for in cis RET activation (Sariola and Saarma, 2003). 
The second model is based on GFR1 being cleaved from the membrane by 
phospholipases, resulting in a soluble GFR1 that can bind to GDNF before 
binding to and activating RET (Paratcha and Ledda, 2008).  
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Alongside the canonical RET/GFL/GFR signalling mechanism, there are several 
other proposed RET ligands and co-receptors. Ephrin-A has been proposed as a 
novel RET co-receptor, competing with GFR1 to mediate the Ephrin-A signalling 
in motor axons (Bonanomi et al., 2012). It has also been shown that RET51 can be 
indirectly activated by nerve growth factor (NGF) in sympathetic neurons (Tsui-
Pierchala et al., 2002). RET has been found to bind to and phosphorylate 
protocadherins – cadherin-like TM proteins – along with GDNF, suggesting that 
they are components of a signalling complex (Schalm et al., 2010). Independent of 
RET, GDNF and GFR1 are thought to signal through the neural cell adhesion 
molecule (NCAM). NCAM interacts with a GDNF-GFRα dimer, leading to the 
activation of the Src-like kinase Fyn in the cytoplasm and Focal Adhesion Kinase 
(FAK) (Sariola and Saarma, 2003, Paratcha et al., 2003).  
1.3.4 RET-specific signalling pathways 
RET activation stimulates similar downstream signalling responses to those of 
other RTKs, such as the MAPK/Ras, PI3K/Akt and STAT3/JAK pathways. 
Activation of RET is defined by phosphorylation of its tyrosine residues within the 
ICD. Eight tyrosine residues (Y806, Y809, Y900, Y905, Y981, Y1062, Y1090 and 
Y1096) have been identified by mass spectrometry and found to be phosphorylated 
upon bipartite ligand binding (Kawamoto et al., 2004). Other auto-phosphorylation 
sites – Y687, Y752, Y928, Y1015 and Y1029 – have also been observed in 
separate studies (Liu et al., 1996, Salvatore et al., 2000, Schuringa et al., 2001). 
Y1090 and Y1096 are only found in the RET51 splice variant, due to its extended 
carboxy-terminus.  
 
RET activation leads to the activation of the mitogen-activated protein kinase 
(MAPK) pathways (rat sarcoma oncogene/extracellular signal-related kinase 
(RAS/ERK), p38 MAPK and ERK5), the janus kinase/signal transducer and 
activator of transcription (JAK/STAT) pathway, the phosphatidylinositol-3-kinase 
(PI3K)/Akt pathway, a protein kinase C (PKC) pathway and the c-Jun N-terminal 
kinase (JNK) pathway (see Figure 1.9) (Mulligan, 2014). The phospho-tyrosine 
residues mentioned above act as docking sites for a host of signalling molecules, 
with pathway activation specific to the tyrosine residue phosphorylated. 
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1.3.5 Ligand and co-receptor structures 
The crystal structures of GDNF from rat and human ARTN have been previously 
solved (Wang et al., 2006, Eigenbrot and Gerber, 1997). The structures reveal that 
each monomer contains a cystine knot fold between two β-sheet ‘fingers’ and an -
helix ‘heel’. Dimerisation of the ligand results in a two-fold symmetry with 
intertwined ‘fingers’ and projecting ‘heels’ towards the co-receptor. 
 
While GFL ligands are mostly specific to canonical GFR components (GDNF-
GFR1, NRTN-GFR2, ARTN-GFR3, PSPN-GFR4), there appears to be a 
degree of crosstalk (Airaksinen et al., 1999). GFR1-3 contain three domains (D1-
3), while GFR4 contains only D2 and D3 (Hatinen et al., 2007). The structures of 
the D2-D3 domains from GFR1 and GFR3 have been solved, revealing a five-
helix bundle constrained by disulphide bonds within each domain (Parkash et al., 
2008, Wang et al., 2006). D1 is predicted to share the same fold, but is not 
essential for RET binding (Leppanen et al., 2004, Scott and Ibanez, 2001).  
 
The crystal structures of GDNF-GFR1(D2D3) and ARTN-GFR3(D2D3) have 
been solved, revealing the D2 domain of GFR binds to each projecting ‘finger’ 
region at either end of the GFL dimer (Wang et al., 2006, Parkash et al., 2008).  
Domain D3 makes no contacts with the GFL. GFR1 D2-3 has been proposed as 
the primary RET-binding region, with several residues implicated in RET activation 
(Parkash et al., 2008, Scott and Ibanez, 2001). Differences in flexibility of GFL 
ligands when in complex with GFR have been proposed to influence RET 
signalling outputs (Parkash and Goldman, 2009).  
1.3.6 RET ectodomain structure 
RET is the only RTK to contain calcium-dependent adhesion like domains (CLDs) 
and has co-opted these domains to form a binding site for its cognate ligands. The 
receptor contains four CLDs (CLD1-4) with a calcium-binding site conserved only 
between CLD2 and 3 (Schneider, 1992, Anders et al., 2001a). Other sites have lost 
calcium-binding function. CLD1-4 is followed by a cysteine-rich domain (CRD) that 
precedes the transmembrane (TM) region of the receptor.  
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The CLDs share similarity with extracellular cadherin (EC) domains, which adopt a 
seven-stranded β-barrel fold. EC domains are arranged end-to-end, with conserved 
calcium-binding regions at the junctions (Boggon et al., 2002, Harrison et al., 2011). 
Calcium binding motifs are generally composed of acidic residues (motifs: E, EN, 
DRE, DXNDN, DXD, D) at the junction of two consecutive cadherin domains. 
Indeed, the junction of CLD2-3 contains almost all of these motifs, lacking only the 
D. It has therefore been proposed that these two CLDs will have a linear 
arrangement with a calcium-binding site at the junction (Anders et al., 2001a). 
 
The calcium-binding property of the RET-ECD is required for proper folding, 
processing, ligand recognition and signalling. In the absence of calcium, the 
receptor fails to be exported to the cell surface – potentially due to protein 
misfolding within the ER and subsequent degradation (van Weering et al., 1998). 
Further evidence for this can be found in HSCR mutations within the calcium-
binding region of RET that lead to defective RET export (Pelet et al., 1998). In 
terms of RET signalling, it has been shown that calcium is required for GDNF-RET 
binding, RET KD auto-phosphorylation and activation of the downstream MAPK 
signalling pathway (Anders et al., 2001a, Nozaki et al., 1998).  
 
In 2010, Dr Svend Kjaer solved the structure of human RET CLD1-2 (hRET CLD1-
2) in the McDonald Laboratory (Figure 1.10) (Kjaer et al., 2010).  The structure 
revealed a clamshell-like fold, stabilised by two disulphide bonds within CLD2 and 
one within CLD1. There is a hydrophobic interface between the two CLDs, with the 
N-terminal β-strand of CLD-1 buried within this interface. The similarity between EC 
domains and the RET CLDs was confirmed by the presence of a seven-stranded β-
barrel fold within CLD1 and 2. Several structural elements were identified that 
appear to be conserved only among higher vertebrates: an anti-parallel β-strand 
(βC’- βC’’), a short -helix (1) and a six-residue loop containing a cis-proline (cis-
Pro loop) constrained by a disulphide bond (Kjaer et al., 2010). The cis-Pro loop 
cannot form in lower vertebrates because one of the cysteine residues is absent 
and an alternative ‘swapped’ disulphide is formed, while both cysteine residues are 
absent in arthropods (Figure 1.10c). These mammal-specific structural elements 
have been implicated in RET ternary complex formation and were found to be 
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involved in the hRET CLD1-2 dimeric interface (Figure 1.10b) (Kjaer and Ibanez, 
2003, Kjaer et al., 2010). The implications of this evolution of RET cannot be fully 
understood until the structure of the human ECD is compared to that of a lower 
vertebrate.  
 
 
Figure 1.10 The human RET CLD1-2 crystal structure with mammal-specific 
structural elements and disulphide swapping 
 (A) Ribbon view of the hRET CLD1-2 crystal structure (PDB code 2X2U), revealing a 
clamshell-like arrangement of CLD1 (cyan) and CLD2 (dark blue). The N-terminal βA strand 
(red) is buried within the interface. Disulphide bonds are represented in orange and the C-tail is 
pink. (B) Side view of the CLD1-2 structure, revealing the crystallographic interface. The 
highlighted structural elements are not seen in classical cadherin structures. (C) Schematic 
representation of the disulphide bond swapping that occurs between mammalian, lower 
vertebrate and amphioxus/arthropod RET CLD1-2 (Kjaer et al., 2010).  
1.3.7 RET ternary complex formation 
As mentioned previously, RET activation requires the formation of a ternary 
complex comprised of a GFL homodimer, two GFRs and two RET monomers. 
Several studies – the latest of which was recently published by the McDonald 
Laboratory – have identified regions within the receptor, ligand and co-receptor that 
are believed to be required for this ternary complex formation.  
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A previous study proposed that CLD1, 2 and 3 were required for bipartite ligand 
interactions and identified regions within CLD1-2 that were necessary for 
GDNF/GFR1 binding. They used a loss-of-function human/Xenopus RET chimera 
to identify regions required for ligand-co-receptor binding (Kjaer and Ibanez, 2003). 
Three of the predicted regions within CLD1-2 were found to lie within the 
crystallographic dimer interface of hRET CLD1-2, consistent with the conclusion 
that this interface occurs within the context of GDNF-GFRα1 binding (Figure 1.10b) 
(Kjaer et al., 2010). A subsequent study – based on mass spectrometry of the 
cross-linked ternary complex – found three interactions between RET, GDNF and 
GFR1 that were not present between ligand and co-receptor alone (Amoresano et 
al., 2005). These interactions were all localised to the GFR1 domain D1, which 
cross-linked with RET CRD, the N-terminus of GDNF and the base of CLD4. 
Interestingly, the primary RET binding region within GFR1 D2-3 was not identified. 
They also showed that CLD4-CRD is important for ternary complex formation, as 
RET CLD1-3 could not compete with RET for GDNF-GFRα1 binding.  
 
A more recent structural analysis has led to the creation of an EM structural model 
of the RET ECD-GDNF-GFRα1 ternary complex, providing an insight into the basis 
of RET ligand recognition (Figure 1.11). Coordinates for the GFRα1D2-D3-GDNF 
dimeric ligand (PDB code 3FUB) were placed into the model by aligning the 
bipartite ligand symmetry axis with the 2-fold symmetry axis of the EM map. This 
resulted in the bipartite ligand being placed in the centre of the complex, with 
GDNF closest to the base of the electron density map. The position of RET CLD1-4 
could be identified from architectural knowledge obtained from the zebrafish SAXS-
derived model. The interdomain CLD angles observed in zebrafish RET CLD1-4 
SAXS data were preserved within the EM map, validating the SAXS-derived model 
and confirming the position of CLD1-4 within the map (Goodman et al., 2014 (In 
press)).  
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Figure 1.11 Model of RET/GDNF/GFRα1 ternary complex derived from EM map 
(A) Grid view of mammalian ternary complex reconstitution in figure-of-eight (left) and wing 
(right) positions. Structures of RET, GDNF and GFRα1 (surface view) are fitted into the map. 
(B) Surface view of the mammalian ternary complex reconstitution with structures of RET, 
GDNF and GFRα1 (ribbon view) fitted in.  
 
1.3.8 RET kinase domain structure and regulation 
The binding of GFL/GFRs to the RET ECD results in rapid auto-phosphorylation 
of the RET KD and subsequent activation RET-specific downstream signalling 
pathways. To understand the molecular mechanisms involved, I will first discuss 
what is currently known about the structure of the RET KD. The structures of the 
non- and phosphorylated forms of the RET KD were elucidated in 2006 by the 
McDonald Laboratory (Knowles et al., 2006). The bilobal domain comprised of the 
canonical protein kinase structural elements: an N-lobe consisting of five anti-
parallel β-strands and the C helix between strands β3 and β4, a flexible GRL 
above the nucleotide-binding pocket, and a predominantly helical C-lobe. 
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Figure 1.12 Two structural orientations of the RET KD 
(A) Ribbon view of non-phosphorylated RET (light grey) as two protomers within the asymmetric 
unit related by non-crystallographic symmetry, with 2’,3’-cAMP in the active site (PDB code 
2IVS) (B) Ribbon view of phosphorylated RET (gold) in a head-to-tail dimer containing a single 
monomer, with AMP in active site (PDB code 2IVT) (Knowles et al., 2006).  
 
Published crystal structures (Figure 1.12b) of the RET KD revealed a head-to-tail 
crystallographic dimer (or in some cases a non-crystallographic symmetry (NCS) 
dimer, Figure 1.12a ) (Knowles et al., 2006, Mologni et al., 2010). The appearance 
of this RET KD dimer  led to the hypothesis that the dimer interface could be 
relevant in vivo, as the formation would occlude the substrate binding region and 
prevent kinase activity through a trans-inhibitory mechanism (Knowles et al., 2006). 
This dimer has not yet been validated. 
1.4 The role of RET in human disease 
RET is a critically important RTK, due to its involvement in the development of a 
number of human diseases, as discussed earlier. The receptor appears to have 
several signalling thresholds that dictate the phenotypic outcome: excessive 
signalling through over-expression or constitutive activation results in the 
development of a number of cancers, while reduced RET signalling leads to 
Hirschsprung’s disease in humans. The absence of RET is embryonically lethal in 
knockout studies due to the lack of kidney development. 
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1.4.1 Loss-of-function mutations and Hirschsprung’s disease 
Harold Hirschsprung first described Hirschsprung’s disease (HSCR) in 1888, when 
two boys died of severe constipation resulting from congenital megacolon 
(abnormal dilation of the colon) (Hirschsprung, 1888). However, the absence of 
intramural ganglion cells in the colon was not identified as the cause of the disease 
until the mid-20
th
 century (Whitehouse and Kernohan, 1948). HSCR is now defined 
as a congenital malformation of the colon, caused by an absence of enteric ganglia 
within the length of the hindgut (Amiel et al., 2008). HSCR can be divided into three 
subtypes dependent on the severity of the phenotype: short-segment HSCR, where 
the rectum and anus are affected by aganglionosis; long-segment HSCR, where a 
larger proportion of the colon is affected; and total colonic aganglionosis, the most 
severe form lacking a functional enteric nervous system for the entire colon (N-Fek, 
1986, Neilson and Yazbeck, 1990).  
 
While the RET gene is most commonly mutated in HSCR – accounting for 
approximately half of familial cases and 15-20% of sporadic cases – there are 
several other genes implicated in HSCR development: GDNF, NRTN, endothelin 
receptor B (EDNRB), endothelin 3 (ET-3), endothelin-converting enzyme 1 (ECE1), 
SOX10, and ZFHX1/SIP1 (Asai et al., 2006, Heanue and Pachnis, 2007). A large 
number of loss-of-function RET mutations have been associated with the 
development of HSCR and can be separated into five classes (Figure 1.13) (Plaza-
Menacho et al., 2006, Carlomagno et al., 1996).  
 
Class one mutations are found within the RET ECD and affect the transport of the 
receptor to the cell surface. It is believed that this reduction in cell surface 
expression is caused by a lack of proper folding and processing within the ER, and 
some of the mutations have been shown to affect calcium-binding and N-linked 
glycosylation (Kjaer et al., 2010, Kjær and Ibanez, 2003b, Pelet et al., 1998). Kjaer 
et al. developed a mammalian RET ECD secretion assay to investigate the effect of 
a range of HSCR mutations (Kjaer et al., 2010). Mass spectrometry was used to 
identify unpaired cysteine residues in the recombinant protein that may be involved 
in the formation of aberrant disulphide bonds during protein folding. Two unpaired 
cysteine residues were subsequently mutated (C87R and C216S) in an effort to 
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improve protein folding and export. Their mutation led to the export of some HSCR 
mutant forms of the RET ECD that were usually exported unsuccessfully.  
 
The severity of the disease phenotype was found to correlate with the ability of the 
cysteine mutations to restore RET export: RET G93S (a mutant that causes total 
colonic aganglionosis, a very severe disease phenotype) could not be rescued 
through the elimination of the unpaired cysteines, while the export of RET S100M 
(a mutation resulting in a milder disease phenotype) could be completely restored. 
Point mutations associated with Hirschsprung’s disease can be divided into five classes, four of 
which can be localised to a region of the RET receptor. CLD – cadherin like domain; CRD – 
cysteine rich domain; TM – transmembrane domain; JM – juxtamembrane domain; KD – kinase 
domain; C-tail – carboxy-terminal tail. Figure adapted from (Plaza-Menacho et al., 2006). 
 
Class two mutations are located within the CRD and result in the presence of an 
unpaired cysteine residue. This unpaired cysteine can cause reduced folding 
efficiency, resulting in a loss of receptor export, but it can also cause covalent 
dimerisation. This dimerisation can lead to constitutive activation of the receptor, as 
seen in multiple endocrine neoplasia type 2A (MEN2A). These are more complex 
mutant phenotypes, as the families affected can demonstrate the occurrence of 
both HSCR and MEN2A (Kjær and Ibanez, 2003b, Pelet et al., 1998).  
 
Figure 1.13 RET mutations associated with Hirschsprung's disease 
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Class three mutations are found within the kinase domain of the receptor and 
disrupt the kinase activity. They tend to target essential catalytic residues, charged 
residues or bulky hydrophobic groups (Knowles et al., 2006). Class four mutations 
also affect the activity of the receptor by targeting docking sites within the C-
terminal tail, disrupting downstream signalling events (Geneste et al., 1999). Finally, 
class five mutations are located within the regulatory sequences within introns 
separating exons of the RET gene, reducing RET expression levels.  
1.4.2 RET gain-of-function mutations and MEN2 
Medullary thyroid carcinoma (MTC) is a malignant cancer that arises from 
calcitonin-producing thyroid parafollicular C cells, with around 25% of cases being 
familial. The carcinoma is a component of multiple endocrine neoplasia 2 (MEN2), 
a syndrome divided into three disorders: MEN2A, MEN2B and familial MTC 
(FMTC) (Santoro and Carlomagno, 2013, Donis-Keller et al., 1993, Hofstra et al., 
1994). FMTC is characterised by the presence of MTC itself, while MEN2A is 
characterised by MTC, pheochromocytoma, or parathyroid hyperplasia/adenoma. 
MEN2B is the most aggressive of the three subtypes, with an earlier MTC onset 
and pheochromocytoma. Other developmental problems can arise as well, 
including mucosal neuromas, intestinal ganglioneuromatosis, and ocular and 
skeletal abnormalities (Arighi et al., 2005). RET mutations that are associated with 
MEN2 have been schematically annotated in Figure 1.14.   
 
MEN2A mutations target the extracellular cysteine residues, with the most common 
being C634. These CRD-localised mutations result in disulphide-linked homo-
dimerisation of the receptor and subsequent constitutive activation (Santoro et al., 
1995). The ability of the RET TM regions to self-associate has been shown to 
underlie this oncogenic activity, as homo-dimerisation via the TM brings the 
unpaired cysteine residues within the CRD in close proximity with one another 
(Kjaer et al., 2006). There are suggestions that RTK signalling may not be as 
simple as the current dimerisation model, and could involve oligomerisation of 
many dimers at the cell surface (Wu, 2013). As such, the CRD-localised mutations 
may also increase the prevalence of this oligomerisation at the plasma membrane 
and lead to heightened activation. As mentioned above, the mutation of some 
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cysteine residues – C609, C611, C618 and C620 – cause constitutive activation 
and poor protein folding, resulting in both MEN2A and HSCR (Ito et al., 1997). 
 
In contrast, MEN2B arises from mutations within the RET KD: M918T (95% of 
cases) and A883F (5%) (Carlson et al., 1994, Smith et al., 1997). These mutations 
result in a monomeric onco-protein that can signal independently of ligand, 
although the mechanism by which this occurs is not well understood. The highly 
conserved M918 maps to the substrate binding P+1 loop of the RET KD and may 
therefore play a role in substrate selection. For example, the RET M918T mutation 
within this P+1 loop has been show to result in constitutively phosphorylated 
STAT3 (Yuan et al., 2004). Recent investigations suggest that the mutation 
destabilises RET, making it a better substrate for auto-phosphorylation (Plaza-
Menacho et al., 2014).   
 
 
RET schematic with point mutations associated with particular syndromes highlighted. Clinical 
mutations observed are reported in (Plaza-Menacho et al., 2006, Kodama et al., 2005). 
 
1.4.3 RET fusion mutations and thyroid cancer, lung cancer and leukaemia 
A further mechanism of RET deregulation causing disease is found in the case of 
RET fusion proteins that have been observed in papillary thyroid carcinoma (PTC). 
Figure 1.14 RET point mutations associated with cancer 
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PTC is the most common thyroid cancer and arises from follicular cell tumours that 
are both benign adenomas and metastatic carcinomas (Arighi et al., 2005). 
Somatic chromosomal rearrangement results in the fusion of the RET kinase region 
with several genes, creating fusion oncogenes known as RET/PTC. 11 RET/PTC 
oncogenes have been identified to date, with fusions to the coiled-coil domain 
containing gene 6 (CCDC6) or nuclear receptor co-activator gene 4 (NcoA4) 
accounting for over 90% of the rearrangements (Santoro et al., 2006). More 
recently, RET fusion proteins have also been implicated in the development of non-
small cell lung cancer (NSCLC) and chronic myelomonocytic leukaemia (CMML) 
(Ballerini et al., 2012, Takeuchi et al., 2012, Kohno et al., 2012, Lipson et al., 2012). 
The presumption is that forced dimerisation of the kinase domains results in 
activation.  
1.4.4 Over-expression of RET in breast and colorectal cancer  
RET overexpression has been reported in a number of different cancers, including 
prostate, pancreatic, bile duct, lung and breast cancer (Morandi et al., 2011, Zeng 
et al., 2008, Dawson et al., 1998). Aberrant RET expression has been investigated 
further in the case of breast cancer and was found to be specifically associated 
with oestrogen receptor (ER)-positive breast cancer (Plaza-Menacho et al., 2010, 
Boulay et al., 2008, Esseghir et al., 2007). RET activation was found to result in 
oestrogen-independent activation of the ERα, facilitating resistance to endocrine 
therapy (Plaza-Menacho et al., 2010).  
 
In contrast, RET is believed to play an opposite role as a tumour suppressor in 
colorectal cancer (Luo et al., 2012). Aberrant methylation of RET was found to 
occur in 27% of colon adenomas and 63% colorectal cancers, with the methylation 
correlating with reduced RET expression. Furthermore, inactivating RET mutations 
were found in primary colorectal cancer and RET overexpression resulted in 
apoptosis in colorectal cancer cell lines.  
1.5 Targeted therapy towards tyrosine kinases in cancer 
The crucial and highly regulated role protein tyrosine kinases play in cell signalling 
has resulted in their implication in almost every type of cancer. Tyrosine kinases 
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are therefore highly targeted for cancer therapy development, with a large 
proportion of that research and development focusing on small molecule ATP 
pocket inhibitors.  The development of Imatinib, a small molecule ATP-competitive 
inhibitor of the ABL kinase that was first used to treat chronic myeloid leukaemia, 
pioneered this area of therapy (Druker et al., 2001). Since this time, targeted 
therapy through the design of specific RTK inhibitors is becoming increasingly 
prevalent. While a great deal of effort has led to the development of ATP-
competitive inhibitors, the high level of sequence conservation within the 
nucleotide-binding region of tyrosine kinases makes specific inhibitor design 
extremely challenging. Allosteric inhibitors, RTK ECD-targeted antibodies, 
aptamers and protein substrate mimics are proving useful alternative strategies 
(Cowan-Jacob et al., 2009). 
 
RET is a validated cancer target and is a driver of MEN2A & B, FMTC, NSCLC and 
breast cancers. There were no approved treatments for inoperable MTC until the 
development of Vandetanib (ZD6474): a small molecule ATP-competitive RET and 
VEGFR2/3 inhibitor (Thornton et al., 2012, Carlomagno et al., 2002a). The success 
of Vandetanib as a treatment of MTC has validated RET as a cancer target, but the 
high number of adverse reactions and poor life expectancy extension of only 6 
months in advanced MTC survival suggest that better treatments need to be 
developed (Thornton et al., 2012).  
1.5.1 Chemical inhibition of kinases 
Small molecule inhibitors that target the nucleotide-binding pocket of tyrosine 
kinases can be divided into two groups: type I DFG-in inhibitors and type II DFG-
out inhibitors. Type I inhibitors target the hydrophobic region usually occupied by 
the adenine ring of ATP, forming multiple hydrogen bonds with the kinase hinge 
between the N and C lobes (Liu and Gray, 2006). In the presence of type I 
inhibitors, the conserved DFG motif located at the start of the activation loop is in 
the active DFG-in conformation (Figure 1.15). Several published structures of the 
RET KD bound to type I inhibitors are available (e.g. PP1 and Vandetanib), with 
novel structures presented in this thesis (Knowles et al., 2006, Mologni et al., 2010). 
Type II inhibitors (e.g. Sorafenib) also target the ATP pocket, but displace the DFG 
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motif into the catalytically incompetent DFG-out conformation, disrupting the 
formation of the hydrophobic R-spine (Liu and Gray, 2006). At present, attempts to 
crystallise the RET KD bound to a DGF-out inhibitor have been unsuccessful. 
Therefore, models for Sorafenib binding have been built from other RTK-Sorafenib 
structures, such as VEGFR-2 (McTigue et al., 2012).  
 
 
Figure 1.15 Arrangement of the DFG motif in kinases bound to type I and II 
inhibitors 
The left panel displays the DFG-out conformation of the VEGFR-2 kinase domain bound to the 
type II inhibitor Sorafenib (PDB code 4ASD). The right panel displays the DFG-in conformation 
of the RET kinase domain bound to the type I inhibitor PP1 (PDB code 2IVV). The gatekeeper 
residue is highlighted in purple, and the D (green) F (cyan) G (coral) motif is annotated – along 
with the GRL – for both kinases.  
1.5.2 Clinically approved RET inhibitors 
There are several small molecule inhibitors that were originally designed for other 
tyrosine kinases and have been found serendipitously to target RET. These 
include: Vandetanib (RET/VEGFR/EGFR), Sorafenib (RET/BRAF/VEGFR/FLT3), 
Sunitinib (RET/VEGFR/FLT3), Cabozantinib (RET/MET/VEGFR/KIT) and 
Motesanib (RET/VEGFR/KIT) (Borrello et al., 2013). Vandetanib is an 
aminoquinazoline compound that has been FDA approved for the treatment of 
MTC and has been found to be active against the wild-type and M918T mutant 
form of RET. The inhibitor cannot inhibit RET when the gatekeeper mutation 
V804M or V804L is present, presumably due to the fact that it binds into the back of 
RET’s ATP pocket behind the gatekeeper residue and would be blocked from 
binding in the case of a bulky gatekeeper mutation (Carlomagno et al., 2004, 
Knowles et al., 2006). Sorafenib is a bisarylurea compound that was originally 
developed against the serine/threonine kinase BRAF and has since been found to 
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be active against several tyrosine kinases, including RET (Wilhelm et al., 2006). 
The inhibitor has been FDA approved for the treatment of liver and kidney cancers, 
and has been found to be active against RET-V804M in vitro (Plaza-Menacho et al., 
2007). Sunitinib is an indolinone approved for the treatment of Imatinib-resistant 
GISTs (gastrointestinal stromal tumours), advanced pancreatic and renal cancer. 
Interestingly, the inhibitor has been found to bind to the KIT KD in the inactive 
DGF-out conformation, while targeting RET in the active DFG-in conformation 
(Goodman, unpublished) (Gajiwala et al., 2009).  
1.6 Project Aims 
A large number of RET mutations are associated with the development of 
Hirschsprung’s disease. Previous work has demonstrated that the HSCR RET 
mutations can result in a bottleneck in RET folding and a loss of RET export. 
Relatively little is known about why RET is so inefficiently folded, despite the 
obvious relevance to human disease. As such, this thesis aims to further 
understanding around how RET proceeds from a nascent polypeptide to a cell 
surface glycoprotein and identify how HSCR RET mutants are targeted by ER 
quality control mechanisms. A cell-based immunofluorescence assay that could be 
used to study RET folding, maturation and trafficking to the cell surface was 
developed. The assay was used to identify factors involved in RET folding, 
maturation and trafficking, with the aim to understand whether the factors identified 
could be involved in the development of Hirschsprung’s disease.  
 
Secondly, RET is recognised as a valid cancer target. While several FDA-approved 
RET inhibitors are available, their lack of specificity and potency suggests that the 
development of a new generation of RET inhibitors is required. This thesis aims to 
aid this development through the elucidation of the structure of the RET KD bound 
to several ATP-competitive inhibitors that can be separated into distinct chemical 
scaffolds. The high-resolution structures presented could be used to explain 
biochemical and cellular IC50 data and define key inhibitor-residue interactions, thus 
informing further rounds of scaffold modification with the aim of enhance potencies 
against RET.  
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Chapter 2. Materials & Methods 
2.1 Materials 
2.1.1 Reagents 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. All 
primers were obtained from Sigma-Aldrich and all restriction enzymes were from 
New England Biolabs (NEB).  
 
 
Table 2.1 Reagents & consumables 
 
 
Reagent Source
Agarose UltraPure, Invitrogen
dNTPs 100 mM stock, Invitrogen
Lullaby transfection reagent OZ Biosciences
Effectene transfection reagent Qiagen
FuGENE HD transfection ragent Promega
Full range rainbow marker Spectra Multicolor, Thermo Scientific
Filter paper 3M
Enhanced Chemiluminescence (ECL) solution Luminata Classico, Millipore
Nitrocellulose membrane Amersham HyBond, GE Healthcare
Chemiluminescence film Amersham Hyperfilm, GE Healthcare
KOD polymerase Novagen
NuPAGE 4-12% Bis-Tris Gels Life Technologies
Competent E.coli NovaBlue, prepared - Promega method - in house 
(original source: Novagen)
Crystallisation additive screen Hampton Research
MRC 2 drop 96 well trays SwissCi
Crystal loops MiTeGen
Polyperfluoroether oil Hapton Research
SYPRO Orange Dye Invitrogen molecular probes (Lot 980228)
rtPCR 96 well trays MicroAmp Fast Optical, Life Technologies
Glutathione sepharose 4B GE Healthcare
Vivaspin columns Sartorius stedium biotechnology
Protein G sepharose beads GE Healthcare
Express 35S Protein Labeling Mix PerkinElmer
Coomassie stain Phastgel Blue, GE Healthcare
PCR tubes Thermo Scientific
Bradford assay solution BioRad
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Table 2.2 Buffers & media 
 
 
Table 2.3 Pharmacological agents & recombinant reagents 
 
Buffer Preparation
LB medium 5 g Bacto yeast extract, 10 g Bacto-tryptone, 10 g NaCl, volume 
adjusted to 1 l with water, autoclaved
LB agar 6 g agar, 400 ml LB medium, autoclaved
SOC medium 20 g Bacto-tryptone, 5 g Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgSO4, 20 mM D-glucose, volume adjusted to 1 l with water, 
autoclaved
DNA 6x sample buffer 0.25% bromophenol blue, 30% (v/v) glycerol
TAE 40 mM Tris-acetate, 0.1 M EDTA
TBS 50 mM Tris HCl, 150 mM NaCl pH 7.5
TBST TBS and 0.1% (v/v) Tween-20
PBS
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, pH 7.4 (with 
HCl), volume adjusted to 1 l with water, autoclaved
MOPS SDS-PAGE 1x MOPS (NuPAGE, Invitrogen) in water
Transfer buffer 25 mM Tris base, 129 mM Glycine, 10% methanol
Mammalian cell lysis buffer 1% Triton-X100, 20mM Tris (pH 8), 130 mM NaCl, Protease Inhibitor 
(CoMplete, Roche), Phosphatase Inhibitor Cocktail 2 (SIGMA)
Insect cell lysis buffer 20 mM Tris (pH 8), 100 mM NaCl, 1 mM DTT, 10 mM Benzamidine, 0.2 
mM ABSF
RET KD purification buffer 20 mM Tris (pH 8), 100mM NaCl, 1 mM DTT
RET KD TSA purification buffer 20 mM HEPES (pH 8), 100 mM NaCl, 1 mM DTT
Poly-D-Lysine in PBS 10% (v/v) Poly-D-Lysine (SIGMA) in PBS
Immunofluorescence (IF) fixing buffer 3.65% Formaldehyde (SIGMA) in PBS
IF blocking buffer 3% Bovine Serum Albumin (BSA) in PBS
IF staining buffer 1% BSA in PBS
Western blot (WB) buffers 5% (w/v) dried skimmed milk powder (Marvel) in TBST
LDS sample buffer (4x) Novex®, Life technologies
Reagent Preparation Provided by
Inhibitor 1 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 3 3.3 mM in 100% DMSO Dr Allan Jordan, Paterson Institute for Cancer Research UK
Inhibitor 4 25 mM in 100% DMSO Professor Morten Grötli, University of Gothernburg
Inhibitor 5 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 6 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 7 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 8 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 9 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 10 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 11 10 mM in 100% DMSO Dr Nathanael Gray, Harvard Medical School
Inhibitor 18 (PP242) 20 mM in 100% DMSO Selleckchem
Inhibitor 19 (BMS-536924) 20 mM in 100% DMSO Selleckchem
PP1 10 mM in 100% DMSO Sigma-Aldrich
Vandetanib 10 mM in 100% DMSO Selleckchem
Sorafenib 100 mM in 100% DMSO AK Scientific Inc
Pz-1 100 mM 100% DMSO Dr Hong-Yu Li, University of Arizona
Sunitinib 37 mM in 100% DMSO Sigma-Aldrich
Epoximicin 1 μM in 100% DMSO Sigma-Aldrich
Pitstop2 10 μM in 100% DMSO Abcam
17-AAG 1 μM in 100% DMSO Sigma-Aldrich
TBK1 inhibitor (MRT67307) 1 μM in 100% DMSO Professor Sir Philip Cohen, University of Dundee
TBK1 control inhibitor (MRT199665) 1 μM in 100% DMSO Professor Sir Philip Cohen, University of Dundee
Recombinant human GDNF 100 μg/ml in sterile PBS + 0.1% BSA R&D System, 212-GD
Recombinant human GFRα1 100 μg/ml in sterile PBS + 0.1% BSA R&D Systems, 714-GR
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Table 2.4 Primary and secondary antibodies 
 
 
Table 2.5 Media and antibiotics 
Antibody target Subset Description Source & code Use Dilution
RET
mAb718
Mouse monoclonal 
(Clone 132507) R&D systems, MAB718 WB 1:500
C20 Goat polyclonal 
Santa Cruz Biotechnology, 
sc-1290 WB 1:1000
1D9 Mouse monoclonal
Massimo Santoro 
(Salvatore et al., 2002) IF/FACS 1:40
23C Mouse monoclonal In house, Dr Svend Kjaer IF
phospho-RET
pYpan
Mouse monoclonal 
(Clone 4G10) Millipore, 05-321 WB 1:1000 (WB)
pYpan Mouse monoclonal
Santa Cruz Biotechnology, 
sc-7020 IF 1:100
pY1062 Rabbit polyclonal
Santa Cruz Biotechnology, 
sc-20252-R WB/IF
1:1000 (WB) 
1:100 (IF)
phospho-ERK1 
(pThr202/pTyr204)/2(pThr185/pTyr187) Rabbit polyclonal Sigma-Aldrich, E7028 WB/IF
1:1000 (WB) 
1:100 (IF)
ERK1/2 Rabbit polyclonal Sigma-Aldrich, M5670 WB 1:10000
Actin Mouse monoclonal (Lot 
E0610)
Santa Cruz Biotechnology, 
sc-4778 WB 1:1000
phospho-Akt (Ser473) Rabbit monoclonal 
(193H12) Cell Signaling, 4058 WB 1:1000
Akt Rabbit polyclonal Cell Signaling, 9272 WB 1:1000
CHIP Mouse monoclonal 
(Clone ST21.55) Sigma-Aldrich, S1073 WB 1:500
Ube2D1 Rabbit polyclonal Boston Biochem, A-615 WB 1:500
BiP Rabbit monoclonal 
(C50B12) Cell Signaling, 3177 WB 1:1000
PERK Rabbit monoclonal 
(D11A8) Cell Signaling, 5683 WB 1:1000
Calnexin Rabbit monoclonal 
(C5C9) Cell Signaling, 2679 WB 1:1000
Secondary antibodies Description Source & code Use Dilution
Alexa® Fluor 488 (anti-mouse) Donkey polyclonal Abcam, ab150105 IF/FACS 1:2000
Alexa® Fluor 488 (anti-rabbit) Donkey polyclonal Abcam, ab150073 IF 1:2000
Anti-mouse HRP Goat anti-mouse IgG 
linked to HRP
Santa Cruz Biotechnology, 
sc-2031 WB 1:10000
Anti-rabbit HRP Goat anti-rabbit IgG 
linked to HRP
Santa Cruz Biotechnology, 
sc-2030 WB 1:10000
Anti-goat HRP Mouse anti-goat IgG 
linked to HRP
Santa Cruz Biotechnology, 
sc-2354 WB 1:10000
Item Preparation Source
SfIII insect cell media Invitrogen
Dulbecco's Modified 
Eagle Medium 1x 
(DMEM) Gibco, Life Technologies
Met/Cys-free DMEM Gibco, Life Technologies
Foetal Bovine Serum 
(FBS) Sigma-Aldrich
Penicillin/Streptomycin 
(PenStrep) 100x LRI laboratory services
Trypsin LRI laboratory services
Hygromycin B 50 mg/ml in water Sigma-Aldrich
Zeocin 100 mg/ml in water Invitrogen
Blasticidin 10 mg/ml in water Sigma-Aldrich
Doxycycline hyclate 50 mg/ml in water Sigma-Aldrich
Gentamicin 10 mg/ml Gibco, Life Technologies
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2.1.2 Plasticware 
All plasticware was purchased from Corning International unless otherwise stated. 
96 well plates used for immunofluorescence were obtained from Nunc, Thermo 
Scientific (96 well optical bottom, polymer base, black).  
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Mammalian cell lines 
The Flp-In system was utilised in order to create stably transfected mammalian 
cells that could express various RET species upon the addition of doxycycline 
(Figure 2.1). Hek293 FlpIn cell lines expressing WT, S100M and S100M* 
(S100M/C87R/C216S) RET were previously generated by Dr Svend Kjaer 
(McDonald Laboratory, London Research Institute), with methods detailed in 
section 2.2.1.3 (Kjaer et al., 2010). DLD-1 and HeLa FlpIn cells were kindly 
donated by Professor Stephen Taylor (University of Manchester).   
 
 
Table 2.6 Mammalian cell lines and antibiotic requirements 
2.2.1.2 Tissue culture 
All cells were grown in T25 flasks, passaged twice every week and were cultured at 
37 °C with 10% CO2. All cells were cultured in DMEM with 10% FBS and PenStrep. 
Individual antibiotic requirements for each cell line are outlined in the Table 2.6.  
Antibiotic requirments of each cell line (μl per 15 ml media)
Cell line Hygromycin (50mg/ml) Blasticidin (10 mg/ml) Zeocin (100 mg/ml) Created by
Hek293 FlpIn 3.75 30 Dr Svend Kjaer, London Research Institute
Hek293 WT RET 45 3.75 Dr Svend Kjaer, London Research Institute
Hek293 WT* RET 45 3.75 Dr Svend Kjaer, London Research Institute
Hek293 S100M RET 45 3.75 Dr Svend Kjaer, London Research Institute
Hek293 S100M* RET 45 3.75 Dr Svend Kjaer, London Research Institute
DLD-1 FlpIn 12 9 Professor Stephen Taylor, University of Manchester
DLD-1 WT RET 120 12 Emily Burns, London Research Institute
DLD-1 S100M RET 120 12 Emily Burns, London Research Institute
HeLa FlpIn 6 7.5 Professor Stephen Taylor, University of Manchester
HeLa WT RET 60 6 Emily Burns, London Research Institute
HeLa S100M RET 60 6 Emily Burns, London Research Institute
HeLa S100M* RET 60 6 Emily Burns, London Research Institute
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2.2.1.3 Establishing stable cell lines  
Stable DLD-1 and HeLa FlpIn cell lines expressing WT, S100M (HeLa) and 
S100M* (DLD-1) were generated as per the Flp-In™ T-Rex™ guidelines. Initially, 
the pFRT/lacZeo plasmid is randomly integrated into the genome to generate the 
zeocin-resistant host cell line. This is followed by co-transfection with the 
pcDNA5/FRT expression vector containing the gene of interest (GOI) and the 
pOG44 plasmid. Flp recombinase, found within the pOG44 vector, catalyses a 
homologous recombination event between the FRT sites in the pFRT/lacZeo and 
pcDNA5/FRT vectors, allowing integration of pcDNA5/FRT. The end result is a 
stable mammalian cell line that is hygromycin resistant, zeocin sensitive and 
expresses a gene of interest upon incubation with doxycycline. Successful clones 
were expanded and tested for zeocin sensitivity and gene expression prior to 
selection.  
 
Figure 2.1 Establishment of the Flp-In mammalian cell expression system 
The three separate vectors required during the establishment of an inducible mammalian cell 
line expressing a gene of interest (GOI). Figure adapted from Life Technologies. 
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Briefly, the Flp-In cell lines (courtesy of Professor S Taylor, University of 
Manchester) were plated on 10cm dishes and grown to 60% confluency before 
cotransfection with the vector pOG44 and the pcDNA5/FRT/TO vector containing 
the gene of interest (WT, S100M or S100M* RET). Ratios from 10:1 to 15:1 
(pOG44:pcDNA5) were used – 10:1 is equal to 5 μg pOG44 and 500 ng pcDNA5. 
24 hours after transfection, cells were washed and incubated in new DMEM 
(blasticidin only). 48 hours after transfection, the cells were split to 25% confluency 
and incubated for 2-3 hours before the media was replaced (hygromycin and 
blasticidin). The hygromycin concentration required for DLD-1 and HeLa cell lines 
was previously determined by Professor Stephen Taylor’s laboratory. Media was 
replaced every 3-4 days until visible colonies began to form. Colonies were 
selected and expanded (approximately 10 per cell line created), before testing for 
zeocin sensitivity and RET expression.  
 
The transfection was carried out using the Effectene transfection reagent (Qiagen) 
as per the instructions of the handbook. Briefly, 500 ng pcDNA5/FRT/TO(RET) 
vector and 5 μg pOG44 was mixed with EC buffer to 150 μl total. 44 μl enhancer (8 
μl for every μg DNA) was added and the mixture incubated at room temperature for 
5 min. 137.5 μl effectene (25 μl for every μg DNA) was added and the mixture 
pipetted up and down five times. This was incubated at room temperature for a 
further 10 min, during which time the cells were washed in PBS and the media 
replaced. 1 ml media was added to the transfection mixture, which was then added 
to the cells dropwise.  
2.2.2 Monitoring RET maturation 
2.2.2.1 Immunoblotting 
Cells were harvested and washed with ice cold PBS before resuspension in 1x 
NuPAGE Sample buffer (Invitrogen). The cells were incubated at 90 °C for 5 
minutes and then lysed by sonication for 2 seconds, followed by centrifugation 
(10,000 x g, 5 minutes). The supernatants were loaded onto SDS-PAGE NuPAGE 
4-12% Bis-Tris gels (Invitrogen) with a protein marker and 90 V were applied. 
Proteins were transferred onto nitrocellulose membranes that had been soaked 
(along with fibre pads and filter paper) in transfer buffer. The sequence of items, 
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starting on the side of the black cathode, were: 1) fibre pad, 2) filter paper, 3) the 
gel, 4) the nitrocellulose membrane, 5) filter paper, 6) fibre pad (at the side of the 
red anode). Wet transfer was carried out in the cold room at 100 V for 90 min.  
 
Membranes were blocked with 5% non-fat dry milk (in 1x TBST) for 1 hour, washed 
in 1x TBST and then probed with the relevant primary antibody diluted in 5% milk 
overnight. Membranes were washed three times in 1x TBST and probed with the 
corresponding HRP-conjugated secondary antibody for one hour, before washing 
three times once more in 1x TBST. For development, membranes were developed 
using the enhanced chemiluminescence (ECL) method. Membranes were 
incubated with ECL solution and exposed onto ECL film. Using this method, the 
horseradish peroxidase (HRP) conjugated to the secondary antibodies catalyses 
the oxidation of luminol, resulting in the emission of light.   
2.2.2.2  Pulse chase analysis 
Hek293 cells were plated onto 100mm dishes (Corning Costar) and grown in 
DMEM/10% FCS until they reached 60-80% confluency. Cells were washed three 
times with pre-warmed PBS and incubated with 5 ml Met-Cys-free DMEM (+ 10% 
FCS) at 37 °C for one hour. 2 ml of fresh Met-Cys-free DMEM was added to the 
cells (+ 10% FCS + 100 μCi S35-Met express label) for a further one-hour 
incubation. The cells were washed in pre-warmed PBS and incubated in 5ml 
standard DMEM (+ 10% FCS) at 37 °C for 0, 30, 60, 90, 120, 180, 300 min 24 
hours. One plate of cells (zero time point) was harvested by cell scraping into 1 ml 
ice cold PBS and centrifuged (14,000 x g, 45 seconds, 4 °C). The PBS was 
removed and each cell pellet stored at -80 °C.  
 
Protein G sepharose beads were washed in mammalian lysis buffer and incubated 
with anti-RET C20 antibody (5 μl per sample) for 1 hour at 4 °C. 0.8 ml mammalian 
lysis buffer was added to each thawed cell pellet and left for 15 minutes on ice, 
before centrifugation (10,000 x g, 10 min, 4 °C). The lysate was transferred to a 
new eppendorf containing the anti-RET antibody and Protein G sepharose bead 
mixture and incubated at 4 °C for 4 hours with constant rotation. The beads were 
washed with lysis buffer three times and harvested (centrifugation at 1000 x g, 5 
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min). The harvested beads were resuspended in 1x Sample Buffer (+ 10% β-
Mercaptoethanol), incubated at 90 °C for 5 minutes, and centrifuged (10,000 x g, 1 
min). The supernatants were then subjected to SDS-PAGE and nitrocellulose 
membrane transfer. Resulting membranes were exposed to a phosphor screen for 
24 hours, with individual bands quantified by a phosphoimager.  
2.2.3 Detecting RET cell surface expression levels 
2.2.3.1 FACS analysis 
Hek293 cells were plated on 10 cm plates at approximately 60% confluency and 
RET expression was induced with 2 μg/ml doxycycline for 24 hours. Cells were 
harvested in trypsin, washed in ice cold PBS and centrifuged at 400 xg for 5 min. 
Cells were resuspended at 5 x 10
6
 cells/ml in FACS buffer (ice cold PBS + 2% FBS 
+ 0.1% sodium azide) to prevent internalisation of surface antigens. 100 μl of the 
resuspended cells was added to each eppendorf with 2.5 μl 1D9 antibody (an anti-
RET antibody binding to the extracellular domain of RET ECD, (Salvatore et al., 
2002a)) and incubated for 30 min at 4°C. Cells were washed three times in ice cold 
PBS (400 xg, 5 min) before incubation with secondary Alexa488 antibody (1:2000 
in FACS buffer) for 30 min at 4°C in the dark. Cells were washed three times as 
before and resuspended in PBS + 2% FBS, in polystyrene round-bottom BD Falcon 
tubes for immediate analysis. 
 
Samples were analysed in the London Research Institute FACS facility by Marwa 
Jalal and Sukhveer Purewal using the FACSCalibur (Becton Dickinson). Data was 
analysed using FlowJo. Cells are initially sorted based on viability (using the DAPI 
staining at 450/50nm bandpass filter). Live cells were then gated away from 
doublets and debri, as defined by the side scatter (SSC) pulse width and intensity. 
Cell number was finally plotted in a histogram against fluorescence intensity at 
530/30nm.  
2.2.3.2 Immunofluorescence 
10,000 DLD-1, Hek293 or HeLa cells were plated in 200 μl DMEM in each well of 
the Poly-D-Lysine coated 96-well glass bottom plates. Once the cells were 
adherent, RET expression was induced by replacing the media with that containing 
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2 μg/ml doxycycline (non-induced controls were also present on the plate). After 24 
hours, cells were fixed for 15 minutes in 50 μl/well 3.65% PFA (diluted in PBS) and 
washed three times in PBS. A portion of each plate was permeabilised using 50 
μl/well 0.01% Triton-X100 for 5 min at room temperature. The plate was washed 
three times and blocked using 50 μl/well 3% BSA for 1 hour, before washing again 
three times and overnight staining in 50 μl/well 1D9 anti-RET primary antibody 
(1:40 in 1% BSA). The plate was washed three times and incubated for 1 hour (in 
darkness) in 50 μl/well Alexa488 secondary antibody (1:2000 in 1% BSA). The 
plate was washed a further three times and incubated for 1 hour (in darkness) in 50 
μl/well 4',6-diamidino-2-phenylindole (DAPI) (1:10,000 in 1% BSA). DAPI is a 
fluorescent dye that binds to the A-T rich regions of DNA, therefore staining the 
nucleus. The plate was washed a final three times before 100 μl/well PBS was 
added to all wells.  
 
Plates were processed by the HTS facility. Images of the cells were taken at 10x 
magnification of channel 1 (DAPI detection channel) and channel 2 (Alexa488 
detection channel) fluorescence, using the Cellomics Arrayscan VTI HCS (High 
Content Screening) automated microscope (Thermo Scientific). This fully 
automated and software controlled microscope is designed for high-throughput 
fluorescence imaging of fixed and live cells. Images were analysed using the 
Thermo Scientific HSC Studio software platform known as Cellomics iView. The 
software calculates the number of nuclei (defined as channel 1 fluorescence, 
stained with DAPI, known as the object count) and the average ring intensity 
(defined as channel 2 fluorescence surrounding the nuclei, stained with Alexa488 
secondary antibody and interpreted as RET staining). These values were used for 
interpretations of fluorescence levels, normalising against the number of cells in 
each field of view.  
2.2.4 Mammalian cell transfection 
2.2.4.1 Transient overexpression of cDNA constructs in DLD-1 cells 
Transient transfections of DLD-1 cells were performed using the transfection 
reagent FuGENE HD. FuGENE HD is a nonliposomal transfection agent; the lipid-
based reagent interacts with and forms micelles around the exogenous DNA. The 
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complex can interact with the cell membrane, allowing for delivery of the DNA into 
the cytoplasm via endocytosis (Medina-Kauwe et al., 2005).  
 
DNA and FuGENE HD at a ratio of 1:3 were mixed and incubated at room 
temperature for 15 min, and then added to the adherent cells. Media was replaced 
24 hours later, cells were lysed 48 hours post transfection.  
2.2.4.2 High-throughput siRNA transfection of 300-candidate siRNA library 
Gene expression can be silenced by the addition of double stranded RNA (dsRNA). 
dsRNA is cleaved by the RNAase enzyme Dicer into small interfering RNAs 
(siRNAs). These small oligomers are integrated into the multi-subunit complex 
called  RISC (RNAi-inducing silencing complex), which guides them to the target 
RNA sequence. The siRNA unwinds and the antisense strand remains attached to 
RISC and directs degradation of the mRNA sequence by endo- and exonucleases 
(Morris et al., 2004).   
 
The siRNA targets of the four library plates can be found in the appendix of chapter 
4. 10 μl of each siRNA (375 nM stock) was plated onto Poly-D-Lysine coated 96-
well glass bottom plates . Plates were frozen (-20°C) for storage. Prior to use, 
plates were thawed for 20 min at room temperature and centrifuged for 1 min at 
1000 rpm before removing the seal. 10 μl of Lullaby transfection reagent (pre-
diluted in serum-free media Opti-MEM (Life technologies), final concentration 0.2 
μl/well) was added to each well using the microplate dispenser Thermo Scientific 
Matrix WellMate™ and plates were incubated at room temperature for 20 min. 
10,000 DLD-1 cells were added to each well. Plates were incubated at 37°C, 10% 
CO2 for 48 hours. On the morning of day 3, media was aspirated by the plate 
washer and 100 μl media containing 2 μg/ml doxycycline was added. 8 hours later, 
media was aspirated again (from 4-PBA control wells) and replaced with 100 μl 
media containing doxycycline and 10 mM 4-PBA. On day 4, media was aspirated 
and 50 μl/well 3.65% PFA was added; plates were incubated at room temperature 
for 15 min. Plates were washed three times with PBS and 50 μl/well 3% BSA (in 
PBS) was added for 1 hour (incubated at room temperature). The blocking solution 
was aspirated and 50 μl/well primary 1D9 anti-RET antibody (diluted 1:40 in 1% 
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BSA) was added. Plates were incubated at 4°C overnight before washing three 
times in PBS. 50 μl/well secondary Alexa488 antibody (1:2000 in 1% BSA) was 
added for 1 hour (in darkness) before washing again and staining with 30 μl/well 
DAPI (10 mg/ml diluted 1:10,000) for 1 hour (in darkness). Plates were finally 
washed twice and left in 100 μl/well PBS.  
 
Plates were processed by the HTS facility at 10x magnification using the Cellomics 
Arrayscan VTI HCS automated microscope (Thermo Scientific). Images were 
analysed using Cellomics iView; the number of nuclei (channel 1 DAPI, object 
count) and the average ring intensity (channel 2 RET) were used for interpretations. 
All images are stored on the HTS server – barcodes in Table 2.7 can be used to 
access the images of each plate. 
 
 
Table 2.7 Barcodes for all siRNA screen plates 
2.2.4.3 siRNA transfection of DLD-1 cells 
siRNA transfections of DLD-1 cells were performed using the transfection reagent 
Lullaby. Lullaby is also a lipid-based transfection reagent; lipids form complexes 
HTS barcodes
Plate Repeat Barcode
WT RET 1 1 00022138
2 00022139
3 00022140
2 1 00022144
2 00022145
3 00022146
3 1 00022150
2 00022151
3 00022152
4 1 00022156
2 00022157
3 00022158
S100M RET 1 1 00022153
2 00022154
3 00022155
2 1 00022147
2 00022148
3 00022149
3 1 00022141
2 00022142
3 00022143
4 1 00022135
2 00022136
3 00022137
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with the nucleic acids,  resulting in the formation of micelles around the exogenous 
RNA. These micelles gain access to the cytoplasm via endocytosis, delivering the 
RNA to the cytoplasm (Medina-Kauwe et al., 2005).   
 
For a 96-well plate, 37 nM siRNA and 10 μl Lullaby (prediluted in Optimem, final 
concentration 0.2 μl/well) were mixed at room temperature for 20 min and added to 
5000 cells/well. RET expression was induced 24 hour later with 2 μg/ml 
doxycycline, with fixing and staining occurring 48 hours post transfection.  
 
 
Table 2.8 siRNA targets and serial numbers used in chapter 3 
2.2.5 Cloning 
2.2.5.1 Baculovirus transfer vectors 
The hRET KD construct was originally cloned into a pBacPAK-His3 derivative 
called pBacPAK-GST by Mr Phillip Knowles and was used in the production of 
hRET KD in the McDonald Laboratory (Knowles et al., 2006). Following this, a 
codon-optimised version of the hRET KD construct was obtained from Gentech to 
improve protein expression levels. Dr Kerry Goodman cloned this new construct 
into the pBacPAK-GST vector. The pBacPAK-GST vector encodes an N-terminal 
glutathione S-transferase (GST) tag, followed by a 3C cleavage site. Cleavage of 
this tag with 3C protease results in the residues GPLSL being left at the N-terminus 
of hRET KD. The recombinant hRET KD protein used spanned from residues 705-
1013, with the kinase insert (residues 827-840) removed.  
siGENOME SMARTpool siRNA
Target Serial number
RISC-free D-001220-01-05
OTP Control D-001810-10-05
RET M-003170-02-0005
RAB7A M-010388-00-0005
P4HB M-003690-01-0005
ATP6V0C M-017620-02-0005
ATP6V1C2 M-016263-01-0005
ERP44 M-026181-01-0002
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2.2.5.2  Site-directed mutagenesis 
Site-directed mutagenesis of plasmids was carried out using KOD Hot Start DNA 
polymerase (Novagen). Typically, the reaction mixture was composed of 0.3 μM 
forward and reverse primer, 100 ng template DNA and a 1x KOD mastermix 
composed of 1 unit KOD polymerase, 150 μM each dNTP, 8 mM MgCl2 and 20 mM 
Tris HCl pH 7.5. The KOD polymerase chain reactions (PCR) were carried out with 
an initial polymerase activation temperature of 94 °C for 2 minutes. Denaturation 
was carried out at 98 °C for 15 sec, annealing at the primer melting temperature for 
10 sec, extension at 70 °C for 4 min; 30 cycles were carried out before storage at 
4 °C. 
 
The template DNA was removed from the reaction by digestion using 20 units of 
Dpn1, with incubation at 37 °C overnight. 250 μl of competent NovaBlue cells were 
transformed with 5 μl of the reaction by incubating on ice for 30 minutes, followed 
by 42 °C for 45 seconds and 2 minutes on ice. Transformed cells were spread onto 
LB-agar plates containing 200 μg/ml carbenicillin and incubated at 37 °C overnight. 
Colonies were selected and grown in LB medium containing 200 μg/ml carbenicillin, 
ready for plasmid purification using the Qiagen mini-prep kit. This was carried out 
according to the manufacturer's instructions and the plasmid was subsequently 
sequenced to determine whether the mutagenesis had been successful.  
 
The Cancer Research UK London Research Institute equipment park staff carried 
out all DNA sequencing, using the BigDye™ Terminator Cycle Sequencing kit (PE 
Applied Biosystems) and capillary sequencing on an ABI Prism 3730.  
 
 
Table 2.9 DNA constructs used 
pBacPAK-GST = modified pBacPAK-His3 (Clontech) vector; 3C = 3C protease cleavage 
recognition site; GST = glutathione S-transferase; (B) - in bacteria, (M) - in mammalian cells.  
Construct Expression cassette details Antibiotic resistance Created by
pcDNA5/FRT/TO WT RET pCMV-2xTetOperator-WT RET Amp (B), Hygromycin (M) Dr Svend Kjaer, London Research Institute
pcDNA5/FRT/TO S100M RET pCMV-2xTetOperator-S100M RET Amp (B), Hygromycin (M) Dr Svend Kjaer, London Research Institute
pcDNA5/FRT/TO S100M* RET pCMV-2xTetOperator-S100M* RET Amp (B), Hygromycin (M) Emily Burns, London Research Institute
pOG44 pCMV-synthetic intron-FLP Amp (B) Life Technologies
pBacPAK-GST-RET KD GST-3C-hRET705-826;841-1013 (codon optimised) Amp (B) Dr Kerry Goodman, London Research Institute
pCMV5 CHIP FLAG CHIP-FLAG tag Amp (B) MRC Dundee
pCMV CHIP P269A FLAG CHIP P269A - FLAG tag Amp (B) MRC Dundee
pCMV5-HA UBE2D1 HA tag-UBE2D1 Amp (B) MRC Dundee
pCMV5-HA UBE2D1 C85A HA tag-UBE2D1 C85A Amp (B) MRC Dundee
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2.2.6 Protein expression  
2.2.6.1 Baculovirus production 
The production of baculoviruses from baculovirus transfer vector constructs, initial 
viral amplification and protein expression tests in insect cells were carried out by 
the Cancer Research UK London Research Institute Protein Production Facility. 
Baculoviruses were produced in Sf9 cells using the Clontech BacPAK system 
(BacPAK™ Expression System User Manual, Clontech). Briefly, this system uses 
the Autographa californica (AcMNPV) nuclear polyhedrosis virus to produce 
recombinant proteins in insect cells. The target gene is inserted into a shuttle 
vector and cotransfected into the insect cells with linearised BacPAK6 viral DNA; 
this forces recombination of the virus and shuttle vector. The isolated recombinant 
virus is then amplified and used for insect cell infection.   
2.2.6.2  Insect cell culture 
Sf9 cells were cultured in suspension in serum-free SfIII media (Invitrogen) 
containing 10 μg/ml gentamycin. They were grown at 27 °C with continuous 
shaking (140 rpm) in 100-500 ml aliquots in 2 l roller bottles, at a maintained 
density of 1.5-6 x 10
6
 cells/ml. Cell density was determined using a Vi-CELL cell 
counter (Beckman Coulter). The cell counter uses the trypan blue exclusion assay 
to determine the number of viable cells present, based on the principle that live 
cells have intact cell membranes that exclude trypan blue dye (Strober, 2001). 
Cells were only used for baculovirus amplification or protein expression if the 
viability was above 89% and the doubling time was above 24 hours.  
2.2.6.3  Baculovirus amplification 
Baculovirus amplification was carried out in Sf9 cells using a baculovirus multiplicity 
of infection (MOI) of 0.1-0.5 and 250 ml cell aliquots at a density of 1 x 10
6
 cells/ml. 
MOI refers to the ratio of virus particles to cells used, with low MOI used during 
virus amplification. The culture was incubated at 27 °C with shaking (140 rpm) for 6 
days before harvesting the baculovirus-containing media by centrifugation (3000 x 
g, 20 minutes, 4 °C). This process was often repeated, with baculoviruses used in 
protein expression being passaged in Sf9 cells 3-5 times.  
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2.2.6.4  Calculation of viral titre 
The High Pure Viral Nucleic Acid Large Volume Kit (Roche) was used to purify 
baculoviruses from media following the manufacturer's instructions. Briefly, the viral 
nucleic acids are isolated from the cells by lysing the cells and virus. Centrifugation 
in the presence of a glass-fibre purification column results in the final isolation of 
the viral nucleic acids separate from salts, proteins and impurities. The nucleic 
acids are eluted in nuclease-free water. Reverse Transcription PCR was performed 
by the Cancer Research UK London Research Institute Protein Production Facility 
in order to quantify the viral RNA.  
2.2.6.5  Protein expression 
Sf9 cells at 1 x 10
6
 cells/ml in 500 ml aliquots were infected with baculoviruses at 
an MOI of 2. The infected cells were incubated at 27 °C with shaking (140 rpm) for 
3 days before harvesting the pellet by centrifugation. Following purification, the 
expression yield for hRET KD was approximately 1.5 mg/l culture.  
2.2.7 Protein purification and analysis 
2.2.7.1  hRET KD protein purification and autophosphorylation 
hRET KD protein was purified using essentially the same protocol as was 
published in 2006 (Knowles et al., 2006). Harvested Sf9 cell pellets were harvested 
by centrifugation (3000 x g, 15 min, 4 °C), resuspended in cold KD lysis buffer 
(20ml per 1 l culture) and lysed by sonication for 90 seconds on ice. The lysate was 
then centrifuged (29220 x g, 30 min, 4 °C) and the supernatant taken forward for 
purification. Glutathione-sepharose resin (GE Healthcare) was washed in KD lysis 
buffer and added (0.5ml per 1 l culture) to the supernatant. This lysate-resin 
mixture was incubated overnight at 4 °C with constant rotation, before the resin 
was collected in a 10 ml syringe and washed with 20 ml KD buffer. The washed 
resin was resuspended in 10 ml KD buffer and hRET KD phosphorylation was 
carried out by adding 5 mM ATP (pH 8) and 10 mM MgCl2. This mixture was 
incubated on ice for 6 hours before thorough washing of the resin beads with 30 ml 
KD buffer, to remove excess ATP and magnesium.  
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The resin was resuspended again in 10 ml KD buffer and GST-tagged 3C-protease 
was added (100 μg per 1 ml resin). This mixture was incubated at 4 °C overnight 
with constant rotation, before the cleaved protein was separated from the resin 
using a 10 ml syringe and the resin washed with 2 volumes of KD buffer. The 
affinity-purified protein was concentrated in a Vivaspin column at 3000 x g (GE 
Healthcare). The theoretical protein parameters used in further analysis were 
calculated using the ProtParam tool in ExPASY (http://web.expasy.org/protparam). 
hRET KD: 300 amino acids, 34.3 kDa, pI of 9.04, extinction coefficient (*10
3
M
-1
cm
-
1
) of 49.39).  
2.2.7.2  Measuring protein concentration 
The concentration of purified protein was measured using the Bradford protein 
assay (Bradford, 1976). A standard assay was carried out using KD buffer with 
bovine serum albumin (BSA) concentrations of 0, 250, 500, 750 and 1500 μg/ml. 
25 μl of each sample was added to 1.3 ml Bradford solution (diluted 1:5 with water). 
The mixture was incubated at room temperature for 15 min before transfer to a 1.5 
ml cuvette for measurement in a spectrophotometer at 595 nm. The absorption 
reading of each standard was plotted against the concentration and used to 
calculate the concentration of unknown samples. 
2.2.7.3  SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to analyse the purity of protein samples. 4-12% NuPAGE gels were used with 
MOPS running buffer. Protein samples were prepared in 4x SDS loading buffer and 
incubated at 95°C for 5 minutes, before loading into the wells of the gel. A voltage 
of 120 V was applied until the SDS loading buffer dye had migrated into the bottom 
edge of the gel. Gels were stained with coomassie stain for 20 min and destained 
in water overnight.  
2.2.7.4  Differential Scanning Fluorimetry 
Differential scanning fluorimetry (thermal shift assay) was used to examine the 
thermal stability of the WT RET KD in the presence of a range of chemical 
inhibitors.  hRET KD protein was purified in HEPES buffer and diluted to 0.05 
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mg/ml. The protein was aliquoted (100 μl per tube) into PCR tubes and 1 μl of each 
inhibitor (100 μM stocks, 1 μM final concentration) was added. For the ATP/Mg2+ 
control, 200 μM ATP and 10 mM MgCl2 was added. The tubes were incubated at 
4°C for 2 hours. SYPRO orange dye was diluted 1:100 in HEPES buffer and 5 μl 
was added to each tube and incubated for a further 15 min. Samples were 
transferred into an rtPCR plate: 25 μl in each well (4 repeats of each sample). The 
plate also included a HEPES buffer only, a HEPES buffer + ATP/Mg
2+
 and a KD 
alone control.  
 
The thermal stability was assessed using the BioRad I-Cycler rtPCR machine, 
increasing the temperature from 4°C to 90°C over 2 hours. Relative fluorescence 
units (RFU) at each 0.5°C temperature point were exported and analysed as 
described in chapter 5. 
2.2.8 X-ray crystallography 
2.2.8.1  Co-crystallisation of hRET KD with inhibitors 
The hRET KD was co-crystallised with several inhibitors designed and produced by 
our collaborators. The purified and phosphorylated protein was incubated with each 
inhibitor at a molar ratio of 1:3 (protein:inhibitor) at 4 °C for 2 hours with constant 
rotation, followed by concentration to 3-4 mg/ml in a Vivaspin column for 
crystallisation.  
2.2.8.2  Crystallisation screening and optimisation 
Crystallisation conditions used in prior hRET KD crystallisation (2.2 M sodium 
formate and 0.1 M sodium acetate (pH 4.5)) were extended upon in 2-drop 96 well 
MRC plates (Knowles et al., 2006). Conditions were dispensed into the MRC plates 
(100 μl per well) using a Formulator robot (Formulatrix) and mixed using a Hydra 
robot (Thermo Scientific). Sitting drops of typically 100 nl of purified protein at 3-4 
mg/ml plus 100 or 200 nl of well solution were aliquoted using a Mosquito robot 
(TTP Labtech). Sealed plates were incubated at 20 °C in a robotic crystal hotel and 
imager (Rock Imager, Formulatrix).  
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Crystals were confirmed to be protein using UV absorption (Rock Imager) and a 
further round of screening was carried out around the most optimal condition, 
varying the pH, salt concentration and protein concentration for further refinement 
of the crystallisation conditions. The aim was to produce large three-dimensional 
single crystals. In the case of inhibitors 1, 7, 9 and ADP, the additive screen kit was 
also used in optimisation, as per Hampton Research instructions.  
2.2.8.3  Cryo-protection and crystal mounting 
Before X-ray data collection, crystals were cryoprotected in perfluoropolyether oil 
(Hampton Research), mounted in litholoops (Molecular Dimensions) and flash-
frozen in liquid nitrogen. This cryoprotectant was first tested with 5 min exposure 
time on the in-house X-ray system (Rigaku) and no ice rings were observed.  
2.2.8.4  Diffraction data collection 
X-ray data collection was carried out at Diamond Light Source or the European 
Synchrotron Radiation Facility (ESRF). Details of the beamline used for each 
dataset are listed in the results section with X-ray data. The loop was mounted onto 
the goniometer using beamline robotics and the crystal was centred in the X-ray 
beam. Data collection strategies for each dataset were determined using MOSFLM 
(Powell, 1999) or EDNA (Diamond Light Source) based on preliminary images at 
0 °, 45 ° and 90 ° rotation angles of the goniometer.  
2.2.8.5  Diffraction data processing 
Data were processed using XDS: diffraction spots were identified on each image, 
indexed and integrated based on refined unit cell parameters and crystal 
orientation, and the Laue and space group predicted (Kabsch, 2010). The process 
of indexing and integration converts 2D coordinates into 3D reciprocal lattice 
coordinates, providing the unit cell parameters and crystal orientation. The images 
are then integrated, predicting the position of Bragg reflections and estimating the 
intensity of each reflection (Leslie, 2006). The integrated spot intensity data were 
scaled and merged using Aimless and XSCALE (Kabsch, 2010, Evans and 
Murshudov, 2013).  These programs ensure that all of the data are processed on a 
common scale, with partial reflections and symmetry equivalents merged. The 
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Laue group (diffraction symmetry) and space group were chosen based on cell 
dimensions directly in XDS using POINTLESS (Evans, 2006). The output files 
generated by these programs detailed the data quality metrics against the 
resolution and image number. They were analysed to determine the resolution limit 
of each dataset, with poor images being discarded. The data were scaled and 
merged again to the determined resolution. Data quality details for each dataset 
are listed in the results section.  
2.2.8.6  Molecular replacement 
In order to create an electron density map, the phase problem must be solved. In 
the case of RET KD-inhibitor structures, this was carried out using molecular 
replacement. All pRET KD-inhibitor structures were solved by molecular 
replacement using the published pRET KD-adenosine structure (PDB code 4CKJ), 
with the GRL and αN helix removed as a standard model. The “Cell Content 
Analysis” tool within the CCP4 suite was used to determine the Matthew’s 
Coefficient and identify the number of molecules in the asymmetric unit 
(Collaborative Computational Project, 1994, Matthews, 1968). There was only one 
pRET KD molecule in the asymmetric unit for all pRET KD-inhibitor structures 
except for pRET KD-I-3, in which there were two. Molecular replacement was 
carried out using the maximum likelihood program PHASER, with the edited protein 
coordinates of the pRET KD-adenosine structure (McCoy et al., 2007). One good 
solution was found for each of the structures, which was taken forward for 
refinement and model building.  
2.2.8.7  Refinement and model building  
Refinement and model building were carried out alternately, using the molecular 
replacement solution electron density map and the protein coordinates. 
Modifications to the structures were made based on the composite 2Fo-Fc density 
map (Fo – observed structure factor, Fc – calculated structure factor), used to 
reduce model bias, and the Fo-Fc difference density map. This process of 
refinement gradually improves the phases of the data, resulting in an improved 
electron density map. The structures were refined in PHENIX (Adams et al., 2010), 
while model building was carried out in COOT (Emsley and Cowtan, 2004).  TLS 
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(translation, libration, screw rotation) groups were defined (N-terminal helix 700-
712; N-lobe 716-808; C-lobe 809-1013) in the fourth round of refinement, allowing 
individual rigid body refinement of the RET KD N- and C-lobes.  The Rfree and Rwork 
values were used to determine the quality of the refined model.  The Rwork (also 
known as R-factor) calculates the discrepancy between the simulated model and 
the original experimental diffraction data (Rupp, 2010). The Rfree value is calculated 
by comparing the simulated model to original experimental observations omitted 
from refinement, removing some of the bias associated with Rwork (Brunger, 1992). 
This process was continued until the Rfree ceased to improve and there was less 
than 7% difference between the Rfree and Rwork.  At this point, the electron density 
map should allow for good interpretation of the structural model.  
 
 
Chapter 3. Characterisation of the maturation of a 
RET S100M missense mutation causal in 
Hirschsprung’s disease 
3.1 Introduction 
This chapter describes the generation and characterisation of stable cell lines 
producing the mild RET S100M Hirschsprung’s disease mutant.  The aim was to 
investigate whether this mutant was transported to the cell surface and to compare 
its maturation kinetics to those of wild type RET and a potential folding rescue 
mutant (RET S100M/C87R/C616S, referred to as S100M*). Immunofluorescence, 
FACS analysis, western blot analysis and S
35
 pulse-labelling methods were used to 
characterise S100M RET. Chemical chaperones and a double cysteine mutation 
were each able to restore S100M RET maturation and cell surface localisation. 
Preliminary efforts to influence RET cell surface levels by siRNA (small interfering 
RNA) gene targeting are described. 
 
In 2010, the laboratory published the structure of human RET CLD1-2 obtained 
using x-ray crystallography (Kjaer et al., 2010), revealing a clamshell-like 
arrangement of the top two domains of the RET extracellular domain (ECD) (Figure 
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3.1). To produce the recombinant hRET CLD1-2 protein used in crystallisation, two 
unpaired cysteine residues, identified by mass spectrometry in disulphide swapping 
experiments, were mutated: C87R and C216S (Figure 3.1). It was reasoned that 
eliminating potentially problematic oxidised cysteines from the extracellular region 
of this glycoprotein would be beneficial to protein yields. Western blot analysis of 
cell lysates showed two species for wild type (WT) RET, corresponding to an 
immature partially glycosylated 150kDa form and a mature fully glycosylated 
170kDa form. Removal of the two unpaired cysteine residues resulted in the loss of 
the lower molecular weight immature form, suggesting the slow kinetics of WT RET 
protein folding could be accelerated. Recombinant S100M RET extracellular 
domain (ECD) was also not efficiently secreted into the media in a surrogate assay 
used to quantify protein yields (Kjaer et al., 2010), suggesting the presence of a 
bottleneck in HSCR RET folding. Upon the removal of the two unpaired cysteine 
residues from the HSCR mutant ECD (S100M*), the protein was found to be fully 
glycosylated and efficiently secreted. It was also shown to bind to GDNF and 
GFRα1 with equivalent affinity to WT RET ECD, suggesting the possibility that 
restoring cell surface expression of mild HSCR mutants could rescue ligand-
binding and potentially RET signalling. 
 
As the aim of this chapter was to investigate both WT and HSCR mutant S100M 
RET maturation and export in more detail, I exploited an inducible mammalian 
expression system (Flp-In System, Life Technologies) in which the export and 
signalling capabilities of various RET species could be investigated. Previous 
experiments with RET from the literature and within the McDonald laboratory have 
indicated that obtaining good ligand-induced RET activation in transiently 
transfected cell lines is problematic, due to the high level of basal RET auto-
phosphorylation. The inducible Flp-In system was explored as a potential way to 
alleviate these problems within the field.  
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Figure 3.1 Structure of hRET CLD1-2 and relevant HSCR mutations 
(A) The structure of hRET CLD1-2 (PDB code 2X2U) with key structural elements coloured and 
the positions of C87R and C216S highlighted. CLD1 – cyan; CLD2 – dark blue; N-terminal β-
strand buried in the interface – red; C-tail – pink; connecting loop – grey; disulphide bonds – 
orange. (B) The structure of hRET CLD1-2 (grey ribbon) with HSCR mutations within this region 
of RET annotated (Kjaer et al., 2010).  
 
3.2 Structure-based sequence alignments of RET CLD1-2 
The sequences of selected RET species are shown in Figure 3.2, highlighting the 
secondary structural elements of human RET CLD1-2, the location of unpaired 
cysteines, a glycosylation site mutation and the site of S100M (Figure 3.2).  
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Figure 3.2 ECD sequence alignment for selected RET species 
ECD domains from selected species of RET highlighting secondary structural elements from the 
human CLD1-2 structure. The location of two unpaired cysteines is shown by a grey star above 
the residue, along with a serine residue at an N-linked glycosylation site mutation. The domain 
boundaries are based on the alignment of the CLDs to cadherin EC domains (Anders et al., 
2001b). 
  
3.3 Generating inducible RET and RET mutant Flp-In stable 
mammalian cell lines responsive to GDNF-GFRα1 
The accumulation of an immature species within the ER in higher abundance than 
mature processed RET suggests that it has an inherently slow and complex folding 
trajectory. The rate-limiting step during RET folding and export is not known but 
could relate to achieving a “native” conformation and correct disulphides, 
glycosylation processing or the transit from Endoplasmic Reticulum (ER) exit sites. 
In addition, the ER organelle from different mammalian cell types is known to 
function with varying levels of efficiency and can be easily become stressed and 
blocked by misfolded proteins produced by overexpression (van Weering et al., 
1998) (Kjaer et al., 2010). We reasoned that transiently transfecting RET constructs 
into mammalian cells would therefore not be an optimal platform for examining RET 
Chapter 3 Results 
 
 78 
maturation and export, due to potential aggregation and ER stress. While 
endogenous RET expression can be examined in several neuronal cell lines (Trupp 
et al., 1999), preliminary investigations showed levels to be far lower than that 
achieved using an over-expression system. For these reasons, it was determined 
that an inducible stable cell line expressing RET was required.     
 
The Flp-In system (as seen in Figure 2.1) was utilised in order to create stably 
transfected mammalian cells that could express various RET species upon the 
addition of doxycycline. This involves transfecting a mammalian cell line with three 
separate vectors that will ultimately lead to the creation of a stable cell line 
expressing a gene of choice (methods are detailed in Chapter 2).  
 
Previously in the laboratory, Hek293 Flp-In stable cell lines expressing WT, WT*, 
S100M or S100M* RET had been created previously by Dr Svend Kjaer (London 
Research Institute). While these particular cell lines were sufficient for biochemical 
analysis of RET maturation, they were not optimal for immunofluorescence assays, 
due to the heterogeneous RET expression levels and the tendency of the cells to 
grow very close together, hindering the identification of separate cells during 
analysis. In order to overcome these issues, DLD-1 and HeLa Flp-In cells were 
kindly donated by Professor Stephen Taylor (University of Manchester), in order to 
create cell lines expressing the various RET species that could be used for imaging 
and future assay development.  
 
The mammalian cell lines used in this thesis are derived from human embryonic 
kidney cells (Hek293), cancer cells (HeLa) or colorectal adenocarcinoma cells 
(DLD-1). Human embryonic kidney (HEK) cells were originally exposed to sheared 
fragments of the human adenovirus type 5 (Ad5) DNA, which resulted in the 
incorporation of this DNA into the host genome and the creation of the subsequent 
cell line used today, known as Hek293 (Graham et al., 1977). The cancer cell line 
known as HeLa is named after Henrietta Lacks, from whom they were originally 
derived from in 1952. While originally reported as cervical cancer cells, they were 
later identified as a rare adenocarcinoma and were the first cancer cell line created 
in the laboratory (Masters, 2002). DLD-1 cells are epithelial cells originally derived 
from a colorectal adenocarcinoma and are positive for oncogenes myc, myb, ras, 
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fos, sis, and p53 (Trainer et al., 1988, Rodrigues et al., 1990). They also have a 
constitutively active PI3K-Akt pathway, but their ligand-responsive pERK1/2 
signalling pathway is intact. Hek293 cells were used for primary western blots, 
FACS and pulse chase analysis; DLD-1 cells were used for immunofluorescence 
staining and chemical or genetic manipulation experiments. HeLa cell lines stably 
expressing WT and S100M RET were created as an alternative to Hek293, but 
DLD-1 cells were selected for future experiments investigating the role of specific 
factors in RET cell surface expression levels. DLD-1 cells were chosen over HeLa 
cells due to their higher levels of RET expression.  
 
3.4 Examining RET maturation and cell surface expression 
levels 
In all mammalian cells examined, both the immature 150kDa and mature 170kDa 
species of WT RET are observed, while S100M RET is only present as the 
immature species (Figure 3.3a). The 120kDa nascent RET polypeptide is believed 
to be folded within the ER and partially glycosylated into its immature form. Once 
correctly folded, the protein can be exported from the ER to travel to the Golgi 
apparatus, where it is fully glycosylated (by the addition of more complex N-
glycans) into the mature 170kDa species that is expressed at the cell surface 
(Takahashi et al., 1991, Takahashi et al., 1993). Therefore, the existence of S100M 
RET as an immature form indicates that the mutant receptor may not reach the 
Golgi apparatus and is not therefore fully glycosylated.  
 
Live-cell FACS analysis was carried out using Hek293 cells stably expressing WT 
and S100M RET (herein referred to as WT RET or S100M RET Hek293 cells), in 
order to examine cell surface levels of these receptors. The cells were incubated 
with the anti-RET 1D9 antibody, before the addition of the Alexa488 fluorescent 
antibody. The 1D9 anti-RET antibody was kindly donated by Professor Massimo 
Santoro (Salvatore et al., 2002b). While no fluorescence intensity was found in 
non-induced WT RET Hek293 cells, a shift in intensity (Figure 3.3b, left and middle 
histograms) was observed once RET expression had been induced with 
doxycycline. Comparison of fluorescence intensities for WT and S100M RET 
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Hek293 cells (Figure 3.3b, right histogram) suggests significantly reduced levels of 
S100M RET at the cell surface.  
 
RET cell surface expression was also investigated via immunofluorescence in 
DLD-1 cells stably expressing WT and S100M RET (Figure 3.3c). In non-
permeabilised (minus Triton X-100) induced DLD-1 cells expressing either WT or 
S100M RET, only WT RET was visible at the cell surface. S100M RET staining 
could only be seen in permeabilised cells, confirming that S100M RET does not 
reach the cell surface and is trapped within the cell. The peri-nuclear staining 
observed suggested that S100M RET was localised to the ER. The combined 
observations from western blot, FACS and immunofluorescence analysis confirm 
that S100M RET is not fully glycosylated and the majority of the protein does not 
reach the cell surface. FACS analysis suggests that a very small proportion of the 
protein may reach the surface, but the levels are greatly reduced in comparison 
with the WT protein.  
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Figure 3.3 S100M RET is not fully glycosylated and is not exported to the cell 
surface 
(A) Western blot of immature and mature RET species in Flp-In, WT RET or S100M RET 
Hek293 cells. (B) (Far left) Histogram displaying fluorescence intensity for non-induced and 
induced Hek293 cells expressing WT RET obtained via FACS analysis; (middle) Histogram 
displaying fluorescence intensity for non-induced and induced Hek293 cells expressing S100M 
RET obtained via FACS analysis; (far right) histogram displaying fluorescence intensity for 
induced Hek293 cells expressing WT or S100M RET obtained via FACS analysis. The graphs 
are a representative of three separate experiments. (C) Detection of surface and intracellular (+ 
Triton-X100) RET levels in non-induced and induced DLD-1 cells expressing WT or S100M 
RET. Scale bar represents 50 μm. 
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3.5 Investigating the role of unpaired cysteine residues in RET 
maturation 
As mentioned previously, two unpaired cysteine residues (C87 & C216) found 
within hRET CLD1-2 were mutated to enhance expression yields and allow 
subsequent crystallisation of the protein (Kjaer et al., 2010). They were also shown 
to restore full glycosylation of the HSCR mutant S100M RET and allow export of 
the S100M ECD in a surrogate secretion assay. As seen in Figure 3.4a, S100M 
RET existed only as the immature 150kDa species, while the mutations C87R and 
C216S (S100M*) resulted in glycosylation of the receptor into its mature 170kDa 
form, similar to the WT RET protein.  
 
In order to examine maturation kinetics for each of the RET species, pulse chase 
analysis was carried out using WT, S100M and S100M* Hek293 cells and 
radioactive RET levels were examined over a period of six hours. Radioactive RET 
levels were detected using a phosphor screen (Figure 3.4b) and each band 
quantified with Image J (Schneider et al., 2012). WT RET maturation – i.e. export 
from the ER to the Golgi apparatus and glycosylation – appears to occur between 0 
and 90 minutes (Figure 3.4c). Since many proteins have been shown to fold and be 
exported in under a minute (Wiseman et al., 2007), the RET folding/export kinetics 
of up to 90 minutes highlight the fact that the RET receptor is a slow folding protein 
even in its non-pathogenic state. S100M RET does not mature over the six hours 
post radioactive pulse, further indicating that S100M RET does not reach the Golgi 
apparatus and is not fully glycosylated. In contrast, the S100M* RET is no longer 
blocked as an immature form but is fully glycosylated and we infer therefore 
exported to the Golgi apparatus. The kinetics of maturation were calculated by 
quantifying the band intensities using Image J and normalising the intensity of the 
lower or upper band against total RET levels at each individual time point. In the 
case of WT and S100M* RET, the levels of 150kDa RET fall as it is converted into 
the 170kDa form (Figure 3.4c). This does not occur for S100M RET. 
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Figure 3.4 Maturation kinetics of WT, S100M and S100M* RET 
(A) Cell lysates from Flp-In, WT RET, S100M RET and S100M* RET Hek293 cell lysates were 
immuno-blotted for RET expression. WT RET and S100M* RET exist as both immature and 
mature species, while S100M RET can only be found as the immature 150kDa species. (B) 
Phosphor screen detection of immuno-precipitated RET in WT, S100M or S100M* Hek293 cells 
pulse chased with S
35
-methionine. (C) Analysis of phosphor screen band intensities. The 
150kDa or 170kDa band was normalised against the sum of both bands for each time point. 
N=5 experiments have been performed and standard error of the mean (S.E.M) is displayed. 
 
The pulse chase experiments confirmed that the removal of two unpaired cysteine 
residues restored a wild type maturation pathway for the RET S100M mutant. A 
probable explanation is that protein disulphide isomerases within the ER promote 
the correct disulphide bonds and/or reshuffle incorrect disulphides formed through 
C87 and/or C216. Removal of two unpaired cysteines reduces the probability of 
incorrect non-native disulphide bond formation to effectively increase the efficiency 
and rate of RET folding. Considering this kinetic explanation, S100M RET may 
have an even slower folding trajectory within the ER, leading to incomplete 
glycosylation processing; triggering ER associated degradation (ERAD). The 
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C87R/C216S mutation may assist folding by reducing the number of 
inappropriately paired disulphide bond possibilities, allowing the protein to exit the 
ER before ERAD intervenes. This species of S100M can then be processed to a 
fully glycosylated form within Golgi apparatus (modelled in Figure 3.10 in the 
conclusion). An alternative explanation is that the mutation of the two RET cysteine 
residues removes a thiol-dependent ER retention signal as found for 
unpolymerised IgM molecules (Anelli et al., 2007). Thiol-retention chaperones – 
such as ERp44 – could interact with S100M RET via the unpaired cysteine 
residues, retaining the protein within the ER and preventing its export to the Golgi 
apparatus (Anelli et al., 2003).  
 
To examine the consequences of restoring a wild type maturation path to S100M 
RET, cell surface levels of S100M* RET were compared to that of WT and S100M 
RET via FACS analysis. Live cell FACS analysis of WT, S100M or S100M* RET 
Hek293 cells (Figure 3.5a) showed a fluorescence intensity for S100M* RET similar 
to that of WT RET, indicating that cell surface RET levels had been restored.  
Cell surface levels of S100M and S100M* RET was also investigated using 
immunofluorescence staining. This was carried out in Hek293 cells due to the fact 
that DLD-1 stable cell lines were only available for WT and S100M RET. Fixed cells 
were stained with the 1D9 anti-RET antibody, the Alexa488 secondary fluorescent 
antibody and DAPI. The average ring (the area of the cell surrounding the nucleus) 
fluorescence intensity values were calculated by the Cellomics iView (Thermo 
Scientific) and averaged over 12 individual wells of a 96-well plate. Both the 
surface and intracellular levels of S100M* RET were significantly higher than those 
of S100M RET (Figure 3.5b). This suggests that S100M RET is degraded at a 
much higher rate, which could be due to the protein trapped within the ER being 
targeted for ERAD. 
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(A) Histogram displaying fluorescence intensity for WT, S100M or S100M* RET Hek293 cells 
obtained via FACS analysis. This is a representative graph of three separate experiments. (B) 
Graph showing average ring intensity values (channel 2) for Hek293 cells expressing S100M or 
S100M* RET. S.E.M is calculated from n=12 and statistical significance was calculated using 
the unpaired t test (p<0.0001).  
3.6 Investigating RET signalling  
Ligand and co-receptor binding to the RET ECD at the cell surface leads to auto-
phosphorylation of the intracellular domain (ICD) and activation of its kinase activity. 
Several sites within the RET-ICD become phosphorylated, with these 
phosphorylated tyrosine residues serving as docking sites for intracellular signalling 
proteins (Kawamoto et al., 2004). In order to examine this process of RET 
activation, recombinant human GDNF and GFRα1 (R&D systems) were added to 
WT RET and S100M RET DLD-1 cells. Cell lysates were immuno-blotted with 
antibodies against RET, ERK1/2 and phosphorylated ERK1/2, as the MAPK 
signalling pathway is known to be stimulated upon RET activation (Besset et al., 
2000).  
 
Akt/PKB and MAPK pathway activation was examined to probe for the best marker 
of RET activation. We found that MAPK responded better to ligand/co-receptor and 
represented a better surrogate of RET activation (Figure 3.6b). Akt phosphorylation 
levels were persistently high, most likely due to a PI3K activating mutation in DLD-1 
cells (Figure 3.6a). Elevated ERK1/2 phosphorylation (pERK1/2 – upper band) was 
only detected under the conditions of induced WT RET expression in the presence 
of recombinant GDNF-GFRα1 (Figure 3.6b). In contrast, this pathway is not 
activated when S100M RET expression is induced in the presence of GDNF-
Figure 3.5 Cell surface expression of WT, S100M and S100M* RET 
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GFRα1, suggesting that S100M RET cannot activate downstream RET signalling 
pathways. This could either be because of its subcellular localisation or 
alternatively immature S100M RET cannot bind ligand and therefore cannot signal. 
We therefore wished to explore whether restoring cell surface expression of S100M 
RET could lead to a functional RET response through the MAPK pathway.   
 
 
Figure 3.6 Detecting downstream signalling for WT and S100M RET 
(A) Western blot analysis of WT or S100M RET DLD-1 cell lysates +/- doxycycline, immuno-
blotted for RET, Akt, phosphorylated Akt (pAkt) or Actin. (B) Western blot analysis of WT or 
S100M RET DLD-1 cell lysates +/- doxycycline and recombinant GDNF/GFRα1, immuno-
blotted for RET, ERK1/2 and pERK1/2. 
 
Initially, wild type RET, S100M and S100M* RET signalling was investigated in 
Hek293 cells, but our results were inconsistent and not reproducible. For this 
reason, experiments were continued in WT and S100M RET DLD-1 cells (as no 
S100M* DLD cell line was available), with results suggesting the pERK1/2 pathway 
was a robust indicator of RET activation in this cell line. In order to examine the 
S100M* RET signalling capabilities, S100M* RET DLD-1 and HeLa cell lines were 
being created at the time of writing. S100M* HeLa clones had been successfully 
expanded and were awaiting RET expression and zeocin sensitivity testing.  
 
As recombinantly expressed S100M and S100M* RET ECD were known to bind to 
recombinant GDNF and GFRα1 as efficiently as the WT RET ECD (Kjaer et al., 
2010), it was hypothesised that the restoration of cell surface expression could 
result in the restoration of downstream signalling activity. In order to investigate this 
further, both WT and S100M RET folding and export were manipulated using 
chemical chaperones and siRNA knockdown of a select number of targets, in an 
attempt to identify factors involved in RET export.  
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3.7 Efforts to manipulate S100M RET export using chemical 
chaperones 
Aberrant substrate folding within the ER can lead to a build-up of protein in an 
already crowded organelle and elevated stress levels. The unfolded protein 
response (UPR) is activated upon such ER stress, resulting in the transcriptional 
upregulation of folding chaperones and the attenuation of protein import into the ER 
(Ron and Harding, 2012).  It was assumed that the lack of S100M RET maturation 
(Figure 3.3a) and reduced protein levels compared to S100M* RET (Figure 3.5b) 
were due to a build-up of partially folded protein within the ER that was 
subsequently degraded via ERAD. In this instance, it was hypothesised that such 
an event would result in elevated ER stress levels.  
 
In order to test the effect of RET expression on ER stress levels, WT, S100M and 
S100M* RET Hek293 cells were immuno-blotted for the stress marker BiP, an ER 
chaperone that binds to unfolded proteins and regulates the activity of members of 
the UPR (Bertolotti et al., 2000). BiP levels were found to be elevated upon 
expression of S100M RET, suggesting that the protein was indeed trapped within 
the ER due to aberrant folding (Figure 3.7). Expression of WT or S100M* RET did 
not result in increased BiP levels, presumably due to the protein folding more 
efficiently and exiting the ER. This preliminary data needs to be built upon in order 
to confirm the result by investigating the levels of another ER stress marker – such 
as phosphorylated PERK (ER-localised PKR-like ER kinase). PERK is a mediator 
of the UPR that is responsible for translation inhibition when activated (Harding et 
al., 1999). 
 
There are several chemical chaperones known to aid protein folding or alleviate ER 
stress, including 4-Phenylbutyric acid (4-PBA) and glycerol. 4-PBA is a small 
molecular weight chemical chaperone that is known to inhibit histone deacetylase, 
in turn regulating gene transcription (Bolden et al., 2006). The chaperone has been 
shown to improve the trafficking and function of the ΔF508 mutant Cystic Fibrosis 
Transmembrane Regulator (CFTR), a protein known to misfold within the ER, but 
did not appear to have an effect on ΔF508-CFTR gene transcription (Rubenstein et 
al., 1997). 4-PBA was subsequently found to downregulate the expression of heat 
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shock cognate protein 70 (Hsc70), a molecular chaperone that belongs to the heat 
shock protein 70 (Hsp70) family and has been shown to target particular proteins 
for ubiquitin-dependent degradation (Rubenstein and Zeitlin, 2000). Glycerol has 
also been shown to rescue cell surface expression levels of ΔF508-CFTR, due to 
its ability to increase the thermodynamic stability of globular proteins (Sato et al., 
1996). 
 
Western blot analysis of Flp-In, WT, S100M and S100M* RET Hek293 cell lysates. Levels of the 
folding chaperone BiP were elevated in cells expressing S100M RET.  
 
The effect of 4-PBA and glycerol on S100M RET folding was examined in DLD-1 
cells. Cells were grown in a 96-well glass bottom plate (10,000 cells/well) in the 
presence of increasing concentrations of 4-PBA or glycerol for 24 hours, before 
fixing, staining and imaging. Both 4-PBA and glycerol resulted in increased S100M 
RET cell surface expression (Figure 3.8), indicating that HSCR RET cell surface 
expression could be restored using chemical chaperones.  
 
Figure 3.7 Elevated BiP levels in Hek394 cells expressing S100M RET 
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Figure 3.8 Cell surface expression of S100M RET in the presence of chemical 
chaperones 
(A) Images of non- and induced (-/+ doxy) DLD-1 Flp-In S100M RET cells grown in the 
presence of increasing concentrations of 4-PBA. Non-permeabilised cells (- triton-x100) show 
increasing levels of fluorescence intensity in the green channel. (B) Images of non- and induced 
DLD-1 Flp-In S100M RET cells grown in the presence of increasing concentrations of glycerol. 
Images were taken at 10x magnification using the Arrayscan automated microscope 
(Cellomics). Scale bar represents 50 µm. 
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WT and S100M RET maturation and phosphorylation (along with pERK1/2 levels) 
in the presence of 4-PBA must be examined in DLD-1 cells in order to gain insight 
into both the mechanism of action and the consequences of the chaperone. 
Preliminary western blot analysis (data not shown) suggests that the increased cell 
surface levels of S100M RET are not due to restored maturation and no 
phosphorylated ERK1/2 was observed upon ligand stimulation. 4-PBA may be 
forcing partially folded RET to the cell surface that is not capable of binding ligand 
and co-receptor. The experiment needs to be repeated, before subsequent 
investigation of the mechanism of action by examining RET transcription levels and 
possible downregulation of Hsc70.  
 
3.8 Manipulation of RET cell surface expression by siRNA 
knockdown of candidate targets involved in protein folding 
and export 
In order to gain a better understanding of RET’s transition through the cell, a 300-
candidate siRNA screen comprising of genes involved in protein folding, export and 
degradation was designed. While the design and implementation of this screen is 
described in the following chapter, the siRNA knockdown of a small number of 
potential targets was initially carried out, to test the viability of the design.  
 
Ras-related protein Rab7 (Rab7), Vacuolar-type H
+
-ATPase (V-ATPase), 
Endoplasmic Reticulum Protein 44 (ERp44) and the PDI portion of Prolyl 4-
Hydroxylase (P4HB) were chosen as initial knockdown targets. Rab7 is a small 
GTPase associated with the late endosome/lysosome pathway. Several Rab 
GTPases are involved in the endocytic process, with Rab5 found on early 
endosomes (involved in endosome biogenesis) and Rab7 marking matured late 
endosomes (involved in endolysosomal fusion) (Gautreau et al., 2014). It was 
hypothesised that the loss of a factor involved in lysosomal targeting may lead to 
increased RET cell surface levels, and Rab7 silencing has been shown to restore 
plasma membrane expression of the μ-opioid receptor in diabetic rats (Mousa et al., 
2013). V-ATPase is an enzyme found in the membrane of many organelles and is 
required for organelle acidification (Forgac, 1998). As the enzyme plays many roles 
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within the cell, there were several hypotheses as to the effect of its inhibition on 
RET cell surface levels. Firstly, V-ATPase knockdown could result in reduced cell 
surface levels of the receptor, as acidification of the Golgi apparatus is required for 
RET maturation, although previous data has shown that the chemical inhibition of 
V-ATPase does not result in reduced cell surface levels (Hirata et al., 2010). 
Alternatively, the knockdown could result in increased cell surface levels, due to its 
role in endocytosis and lysosomal acidification. Similar to Rab7, inhibition of 
lysosomal degradation of the receptor could result in increased plasma membrane 
levels. ERp44 is a thiol retention protein found within the ER that is known to 
interact with and prevent the export of cargo proteins with unpaired cysteines 
(Anelli et al., 2003). Therefore, the removal of this interaction via siRNA knockdown 
may increase the export efficiency and cell surface expression of RET. P4H is a 
multifunctional enzyme that acts as a prolyl hydroxylase and protein disulphide 
isomerase (PDI) (Kivirikko and Myllyharju, 1998). The knockdown of an important 
PDI could also affect RET export in two distinct ways: the prevention of efficient 
RET folding would have a negative impact, while the elimination of the PDI 
interactions with unpaired cysteine residues could have a positive impact. 
 
WT RET DLD-1 cells were incubated with siRNAs (ON-TARGETplus SMARTpool, 
Dharmacon) targeting each of these genes, with siRNA against two V-ATPase 
subunits – ATP6V0C and ATP6V1C (Figure 3.9). The silencing of the RET gene 
resulted in the loss of WT RET cell surface expression in induced cells (-72% 
compared to control), confirming the success of the siRNA experiment. ERp44 
silencing also resulted in a reduction in WT RET cell surface levels (-46%), which 
was surprising. The original hypothesis was that ERp44 may be acting as a thiol 
retention protein and holding RET within the ER, while this suggests that ERp44 
may actually be acting as a folding chaperone for RET. P4HB and ATP6V1C2 
silencing appeared to have little effect on the export of the receptor, while 
ATP6V0C silencing resulted in an increase in WT RET cell surface levels (+30%). 
The differences in effect between ATP6V1C2 and ATP6V0C may be indicative of 
siRNA inefficiency. The observation that V-ATPase knockdown causes an increase 
in WT RET cell surface levels suggests that the inhibition of endocytosis or 
lysosomal degradation has a positive effect, which is as expected. RAB7A silencing 
also had a modest positive effect on cell surface levels (+14%), which suggests 
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again that the inhibition of lysosomal degradation can increase RET targeting to the 
plasma membrane.  
 
 
Figure 3.9 Effect of specific target siRNA knockdown on the WT RET surface 
expression 
DLD-1 Flp-In S100M RET cells were grown in the presence of siRNAs (Risc free; RET; 
ATP6V0C; ATPV1C; ATP6V0C + ATPV1C; ERp44; P4HB; Rab7) for 48 h before the addition of 
doxycycline for a further 24 h. (A) Images taken of RET surface expression (anti-RET 1D9 
antibody + Alexa488 fluorescence antibody) at 10 x magnification using the Arrayscan 
automated microscope. (B) Percentage of control (POC) values for each target siRNA. Average 
channel-2 ring fluorescence intensity values were normalised against the mean control (Risc 
free). Mean value (n=2, 6 replicates in each experiment) with standard deviation (S.D) error 
bars displayed. Scale bar represents 50 µm. 
 
3.9 Chapter Conclusion 
The aim of the work described in this thesis chapter was to use a variety of 
methods to investigate RET maturation and export, and to attempt to restore 
S100M RET cell surface expression. I generated several inducible mammalian cell 
lines expressing WT and mutant RET to be utilised for this purpose, and have 
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presented FACS and immunofluorescence data confirming the absence of S100M 
RET at the cell surface of both Hek293 and DLD-1 cells. WT RET expression in 
DLD-1 cells in the presence of ligand and co-receptor leads to the activation of the 
MAPK signalling pathway, while S100M RET expression does not. This is a 
significant advancement, as these cells are responsive to GDNF-GFRa1 
specifically with low background and no apparent basal level of auto-
phosphorylation. In marked contrast, the equivalent Flp-In cell line producing 
S100M RET did not lead to ERK1/2 phosphorylation.  Previous data has shown 
that mature and secreted S100M RET ECD can bind to ligand and co-receptor as 
efficiently as WT RET, creating the hypothesis that restoring S100M RET to the cell 
surface may be sufficient to restore RET signalling capabilities.  
 
I describe how S100M RET cell surface levels can be increased via the deletion of 
two unpaired cysteine residues, potentially increasing the folding efficiency of the 
protein, and by the addition of chemical chaperones 4-PBA and glycerol. 
Preliminary investigations – that require further validation – into the maturation and 
signalling capabilities of S100M RET in the presence of 4-PBA suggest that 
chemical intervention is insufficient, and may be resulting in partially folded RET at 
the cell surface. Investigations therefore continued in the direction of gene silencing, 
identifying a small number of factors that may be involved in RET export and 
plasma membrane targeting. Gene silencing carried out in WT RET DLD-1 cells 
has shown that RET can be silenced, ERp44 appears to be required for optimal 
WT RET expression and inhibition of lysosomal degradation (via the knockdown of 
V-ATPase or Rab7) results in increased cell surface levels. These observations 
provide a basis for the next chapter: investigating the effect of silencing of a much 
larger group of targets. RET and ERp44 will be used as negative controls, and 
ATP6V0C and RAB7A will be used as positive controls.  
3.9.1 A hypothetical model of WT, S100M and S100M* RET folding and 
export 
Pulse chase data suggests that the WT RET protein is an intrinsically poor folding 
glycoprotein and therefore is a potential substrate for ERAD. A portion of the folded 
RET is exported from the ER and trafficked to the Golgi apparatus, where it is 
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glycosylated further (demonstrated by western blot analysis) and transported to the 
plasma membrane (as seen by FACS and immunofluorescence data). Here, the 
receptor can bind to ligand and co-receptor, resulting in dimerisation and trans-
phosphorylation of the kinase domain and subsequent activation of downstream 
signalling pathways (as seen by western blot analysis of the phosphorylation state 
of ERK1/2). Following activation, the receptor is subsequently internalised, with 
some recycling back to the plasma membrane and some lysosomal degradation. 
This final statement is based on the preliminary findings that V-ATPase knockdown 
results in increased WT RET cell surface levels.  
 
In the case of HSCR mutant S100M RET, western blot analysis and 
FACS/immunofluorescence data indicates that the receptor does not reach the 
Golgi apparatus (as it is not fully glycosylated) and is not exported to the cell 
surface. Instead, the receptor spends too long in the folding pathway, resulting in 
the activation of ERAD. This is indicated by the elevated levels of BiP (although 
further investigations could strengthen this) and has been previously observed 
(Kjær and Ibanez, 2003b). S100M* RET does not contain two unpaired cysteine 
residues, resulting in a lower number of possible disulphide bond formations. As 
such, the receptor folds in a shorter time period and is allowed to exit from the ER 
and continue its journey. This flow of RET export and subsequent degradation have 
been visualised in Figure 3.10. 
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Figure 3.10 A model of WT, S100M and S100M* RET transport through the cell 
RET is transformed from a nascent 120kDa polypeptide into a 150kDa folded immature receptor 
before transportation to the Golgi apparatus for further glycosylation. The mature 170kDa 
receptor can then be exported to the plasma membrane, ready for ligand/co-receptor binding 
and subsequent signalling. Receptor activation leads to internalisation and recycling or 
lysosomal degradation. S100M RET is targeted for ERAD within the ER and degraded via the 
proteasome. S100M* RET is exported to the Golgi apparatus and the plasma membrane, 
although signalling capabilities are currently unknown. 
 
3.9.2 Future investigations into RET signalling 
As mentioned previously, several clones of S100M* HeLa cell lines were created 
during the writing of this thesis. Future investigations should first involve the 
establishment of RET activity in WT, S100M and S100M* expressing HeLa cells; 
by examining the phosphorylation status of ERK1/2 or Akt in the presence and 
absence of ligand and co-receptor. While previous data has suggested that S100M 
and S100M* bind ligand and co-receptor as efficiently as WT, this should be 
established in a mammalian cell setting with the entire receptor present.  
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3.9.3 RET evolution: a role for unpaired cysteine residues 
Overexpression of RET at the plasma membrane has been observed in several 
cancer types, such as breast, pancreatic and lung (Morandi et al., 2011, Zeng et al., 
2008, Dawson et al., 1998). The observation that even WT RET protein folds at an 
unusually slow rate could be interpreted as a mechanism for preventing excess 
receptor expression at the cell surface. As discussed in the introduction, the RET 
receptor has several structural elements – such as the cis-Pro loop and disulphide 
bonds – that are only present in higher vertebrate species, indicating a level of RET 
evolution. The two unpaired cysteine residues Cys87 and Cys216 are also only 
present in higher vertebrates (Figure 3.12). It is plausible to hypothesise that RET 
acquired unpaired cysteines to control or influence cell surface levels and prevent 
oncogenic RET signalling.  
 
 
Figure 3.11 RET evolution in higher vertebrates 
The phylogenetic tree of RET with higher (group 1) and lower (group 2) vertebrates. Evolution of 
the cis-Pro loop (Gly69 and Cys142) and unpaired cysteine residues (Cys87 and Cys216) are 
shown for each corresponding species.  
 
To examine this possibility further, stable DLD-1 cell lines expressing oncogenic 
RET (such as M918T) and WT RET without the unpaired cysteine residues (WT*) 
could be produced. In doing so, the signalling properties and subsequent cellular 
phenotypes (such as differentiation, viability and growth patterns) could be 
compared.  
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Chapter 4. Implementation of a cell-based HTS 
screen to identify factors influencing WT and S100M 
RET maturation and export 
4.1 Introduction 
Pathways controlling the maturation and export of receptor tyrosine kinases are 
poorly understood. RET is unique among receptor tyrosine kinases for its slow and 
inefficient folding, making it sensitive to loss-of-function mutations causal in at least 
two human diseases. I have used the mild Hirschsprung’s disease mutation S100M 
as a model for understanding how to restore HSCR RET functionality and will 
improve knowledge of key components controlling RET maturation and export. The 
aim of this work was to develop a cell-based assay for monitoring cell surface 
expression levels of both wild-type (WT) RET and S100M RET. The assay was 
developed into a high throughput screen using an inducible S100M HSCR mutant 
cell line and a targeted small interfering RNA (siRNA) library to knock down 
candidates. In parallel, an siRNA screen was also carried out to investigate the 
effect of specific gene silencing on WT RET cell surface expression. Both screens 
targeted 300 candidate genes chosen based on their roles in protein folding, export, 
ER quality control and protein degradation. A primary hit rate of 10% was found 
which is high but unsurprising given the biased library used.  Positive hits 
influencing RET cell surface expression were connected to distinct cellular 
pathways, some expected and others quite unexpected, leading to current efforts 
into their validation as “true” positives. 
 
The largest effect on WT and S100M RET cell surface levels occurred when genes 
encoding components of three degradative pathways– proteasomal, lysosomal and 
autophagosomal – were silenced. Interestingly, optineurin (OPTN) – an autophagy 
receptor known to target aggregated proteins and Salmonella – was identified as a 
negative regulator of S100M RET (i.e. the knockdown of OPTN enhanced S100M 
RET surface expression). Furthermore, chemical inhibition of OPTN regulator 
TBK1 (courtesy of Professor P Cohen, Dundee) indeed boosted S100M levels at 
the cell surface. However, preliminary validation suggests that the cell surface 
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S100M RET rescued from these degradative pathways is not capable of restoring 
receptor maturation or downstream signalling. These findings provide indirect proof 
that immature S100M RET is not able to bind ligand and co-receptor even when 
present at the cell surface. The HTS screen also identified proteins involved in ER 
quality control and glycosylation. These candidate hits are likely to provide a better 
starting point for functional rescue of S100M RET signalling capabilities. Future 
directions are discussed, focussing on restoring S100M RET signalling by verifying 
hits involved in ER quality control and chaperone-assisted folding of WT RET cell 
surface expression.  
 
The development and implementation of both the siRNA and chemical screen was 
carried out in collaboration with the HTS facility at the London Research Institute. 
Mike Howell, Rachael Instrell and Ming Jiang were involved in the design, 
development and implementation, while Becky Saunders carried out the 
preliminary statistical analysis. 
4.2  Establishment of a cell-based assay to measure cell 
surface RET 
The overall aim was to establish a sensitive and reliable cell-based assay able to 
detect changes – whether by gene silencing or small molecule inhibition – in the 
cell surface levels of WT or S100M RET. Reduction, no effect or an enhancement 
in WT RET surface levels were considered plausible outcomes from the screen 
given the inducible functional RET present on the cell surface of the cell line used. 
In contrast, I anticipated either an enhanced cell surface level or no effect as 
outcomes from the HSCR S100M RET HTS screen.  As described in chapter 3, 
immuno-blotting and pulse chase analysis were sufficient to define the maturation 
state and kinetics of the receptor. Although the amount of mature RET observed is 
thought to correlate with cell surface levels, it remains a surrogate assay for cell 
surface location. To be certain of directly measuring RET surface expression levels, 
FACS analysis and/or immunofluorescence techniques were used. After successful 
pilot experiments, immunofluorescence was chosen as the cellular readout for the 
assay: cells would be plated and the fluorescence intensity in each well used as a 
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measurement for identifying conditions (gene silencing or chemical inhibition) that 
positively or negatively affected cell surface levels of the receptor.  
 
With many commercial and academic anti-RET antibodies available, preliminary 
experiments investigated the optimal antibody staining for the assay (Figure 4.1). 
Stable Hek293 cells expressing WT RET were plated in glass-bottomed 96 well 
plates, fixed and stained overnight with a panel of four anti-RET antibodies 
(including 23C, an in-house RET antibody produced by Dr S Kjaer), before 
continued staining with the Alexa488 fluorescent secondary antibody and DAPI. At 
this stage of assay development, inducible Hek293 cells were used because they 
were the only cell line available. The mAb718 antibody worked well in western blots, 
but – as seen in Figure 4.1 – a very high background was observed when used for 
immunofluorescence; high fluorescence intensity was seen in non-induced cells 
stained with the antibody. In uninduced Hek293 cells, no 1D9 immunofluorescence 
staining is apparent, whilst clear surface staining is evident on cells in which RET 
expression has been induced. This antibody was selected for future work and was 
found to work well in both HeLa and DLD-1 inducible cell lines that became 
available later in the project, and so optimisation was not repeated.   
 
Rachael Instrell, using siRNA against nuclear lamin A/C and RISC-free control, 
carried out the transfection optimisation. Fluorescence intensity, transfection 
efficiency and overall cell number was examined in both HeLa and DLD-1 cells. 
The most effective transfection reagents were then used to knockdown RET in 
HeLa and DLD-1 cells, identifying Lullaby® as the most effective transfection 
reagent (data not shown). As mentioned in the previous chapter, RET expression 
levels were far more heterogeneous in Hek293 cells than in HeLa and DLD-1 cells, 
an observation that has been confirmed by Professor Stephen Taylor (University of 
Manchester). HeLa and DLD-1 cells were therefore deemed optimal for the screen, 
with DLD-1 cells chosen as the cell line to take forward. This decision was based 
on a combination of satisfactory fluorescence intensity readouts, relatively 
homogeneous RET expression levels, high transfection efficiency and the 
robustness of the cell line during the screening procedure.   
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Figure 4.1 Optimising immunofluorescence with a panel of four anti-RET 
antibodies 
Hek293 cells (+/- doxycycline) were stained with four different anti-RET antibodies to examine 
their effectiveness when used for immunofluorescent studies. Cells were plated in 96-well plates 
before fixation and staining with each primary antibody, Alexa488 secondary antibody and DAPI 
nuclear stain. (Figure courtesy of Dr R Instrell, CRUK).  
 
Antibody concentrations and fixation times also required optimisation. DLD-1 cells 
were relatively sensitive to fixation, with a jump in fluorescence intensity at 30 
minutes suggesting cell permeabilisation. For this reason, cells were incubated in 
0.1% Triton-X100 for 20 minutes only. Primary antibody (1D9) concentrations of 
1:20 and 1:40 were tested, along with secondary antibody (Alexa488) 
concentrations of 1:1000 and 1:2000. No discernible difference was observed for 
the each condition, so the lower concentrations were used to conserve antibody.  
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4.3  Design and implementation of the cell-based 
immunofluorescence assay 
The screen was designed to take place over five days. A model for the assay can 
be seen in Figure 4.2. 
4.3.1 Selecting candidates for a biased siRNA screen 
The screen was developed to identify factors involved in RET maturation, folding 
and export and ER-associated degradation (ERAD). There are direct and indirect 
ways to accumulate RET at the cell surface; namely through the manipulation of 
protein glycosylation and folding, the perturbation of receptor internalisation and 
subsequent lysosomal degradation, or the bypass of the quality control-degradative 
pathway. As such, hits would be expected to arise from these three particular areas. 
However, the process of endocytosis is a post-maturation step linked to ligand-
dependent downregulation and desensitisation, while glycosylation/folding and 
ERAD are pre-maturation steps. As the intention of the screen was to identify 
maturation and export factors, the process of endocytosis was not a priority when 
selecting candidates.  
 
 
 
Figure 4.2 Design of the siRNA primary screen, analysis and validation 
After siRNA knockdown of 300 candidate genes in DLD-1 cells stably expressing WT or S100M 
RET (n=3), channel-2 fluorescence intensity would be analysed to identify hits. Validation of 
true positives would follow by functional rescue experiments to examine GDNF ligand-
stimulated auto-phosphorylation and MAPK pathway activation. 
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The initial candidates were identified via literature searches, selecting genes 
encoding proteins implicated in protein glycosylation, folding, export, degradation 
and ER-associated quality control (ERQC that includes ERAD). This preliminary list 
of approximately 50 genes was then inputted into the STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) database (string-db.org). The database 
identified proteins that were known or predicted to interact with the initial selection 
(an example STRING readout using MAN1B1 is shown in Figure 4.3), based on 
literature searches, and predicted and experimental interactions. This resulted in a 
pool of 300 final candidates; the list and plate layout can be found in the appendix 
at the end of this thesis.  
 
Figure 4.3 Identifying known or predicted protein-protein interactions networks 
by the use of multiple information sources 
Example of network diagram produced when using the STRING database (string-db.org) to 
identify protein-protein interactions. The database highlights known and predicted interactions 
with the primary candidate (in this case, MAN1B1), based on known experimental interactions, 
existing databases, text mining of published literature, interactions predicted de novo and 
interactions observed in one organism (Szklarczyk et al., 2014).  
 
4.3.2  Positive and negative controls 
As described in the previous chapter, a small number of siRNAs were tested to 
examine their effect on the cell surface expression of WT and S100M RET in DLD-
1 cells prior to screen development. Chapter 3 presented the effect of siRNA 
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against RET, V-ATPase, ERp44, the PDI subunit of P4H and Rab7 in WT RET 
DLD-1 cells. RET and ERp44 knockdown resulted in the reduction of cell surface 
WT RET levels, while V-ATPase (via the silencing of ATP6V0C) and Rab7 
knockdown resulted in increased cell surface levels. It was also identified that the 
chemical chaperone 4-PBA could restore S100M RET cell surface expression. As 
such, the positive controls used in the siRNA screen were 4-PBA and siRNA 
against ATP6V0C and Rab7; the negative controls used were siRNAs against RET 
and ERp44.  
4.4 siRNA screen execution and statistical analysis 
The expectation from the siRNA screen was that hits influencing cell surface levels 
of RET would be those involved in glycoprotein export, glycoprotein maturation by 
oligosaccharide-processing or ER-associated degradation (ERAD). I anticipated 
that all of the discrete processes within ERAD could potentially be involved. For 
example, components involved in the recognition of misfolded proteins; 
retrotranslocation of unfolded glycoproteins from the ER to the cytosol; or 
degradation in the cytosol via ubiquitin-proteasome system. The screen was 
carried out across 12 96-well plates (four plates required for one screen, in 
triplicate). After the screen was carried out with DLD-1 cells expressing WT or 
S100M RET, the mean channel-2 ring fluorescence intensity values were used for 
initial analysis (example immunofluorescence images are shown in Figure 4.5a). 
 
This value takes into account all channel-2 fluorescence of the cell excluding the 
nucleus, so to remove crossover from channel-1 DAPI staining. A reasonable level 
of reliability across and within the three replicates was observed and so the values 
were taken forward for statistical analysis (Figure 4.4).  This mean fluorescence 
intensity value was determined for each well from several field views before 
processing.  
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Figure 4.4 Correlation between WT RET plate 1 replicates 
The correlation of RET expression levels between replicates was examined using the 
correlation coefficient, with the example of WT RET plate 1 shown here. At the top, the 
correlation between WT RET replicates 1-3 is shown (grey), with correlation coefficient values 
between 0.6 and 0.8. On the bottom, the raw fluorescence intensity measurements for each 
plate (replicates 1, 2 and 3) are displayed; low fluorescence intensity is depicted as blue and 
high fluorescence intensity is depicted as red. The mean fluorescence intensity values for WT 
RET plate 1, calculated using all three replicates, is displayed on the green plate; low 
fluorescence intensity is depicted as pale green and high fluorescence intensity is depicted as 
dark green. N - the position of the negative control siRNA within the plate; P - the position of the 
positive control siRNA within the plate.  
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High throughput screen data can be pre-processed using three methods. The 
‘percentage of control’ (POC) method corrects for plate variability and normalises 
each measurement relative to the control; raw measurement values are normalised 
against the average control value. The ‘normalised percentage inhibition’ method 
instead uses the difference between individual measurements and the mean of the 
positive controls, dividing this value by the difference between the means of the 
positive and negative controls. The ‘Z score’ method rescales the plate values by 
subtracting the average of the entire plate from each measurement and dividing 
this by the standard deviation estimate of the plate (Malo et al., 2006).  
 
The Z score is commonly used when processing large data sets and the method 
does not normalise against specific controls, instead assuming that the majority of 
the siRNAs/compounds will have had no effect and that the whole plate can 
therefore be used as a control. This method could not be used for this particular 
screen, as the candidates were pre-selected, therefore introducing bias into the 
analysis. Instead, the POC scores were calculated by dividing the fluorescence 
intensity of each well by the mean control intensity (in our case, the ON-
TARGETplus non-targeting control pool (OTP) siRNA). Mean values are easily 
skewed by the presence of outliers, leading to the inclusion of putative hits. To 
prevent this, the median POC score from the three replicates was chosen to 
represent each candidate. 
 
Hits were defined as those siRNAs that induced a 25% increase or decrease in 
fluorescence intensity, as this particular threshold lead to the sectioning of 10% of 
the candidate targets (Figure 4.5). 300 candidate genes were tested with two 
species of the RET receptor (600 final measurements), resulting in the identification 
of 30 ‘hits’: 5% of the overall number of measurements. In Figure 4.6, those 
candidates above or below this 25% threshold have been annotated. The positive 
control knockdowns – ATP6V0C (V-ATPase) and RAB7A – were both above of this 
threshold, suggesting that the screen had been successful. The negative control 
knockdowns – Erp44 and RET – could also be observed below the 0.75 threshold 
for WT RET, with only the RET knockdown visible for S100M RET due to the much 
lower cell surface expression levels. The fact these controls behaved as expected 
from preliminary tests also suggested that the screen had been successful.  
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Figure 4.5 POC scores for all candidate genes in DLD-1 WT and S100M cells 
(A) Example immunofluorescence images of WT and S100M RET cell surface staining in DLD-1 
cells subject to siRNA knockdown of select targets: OTP (control), RET, CHIP and RAB7A. 
Scale bar represents 100 μm. (B) POC scores for all candidate genes are plotted for WT (blue) 
and S100M (pink) RET screens, with the majority lying between 1.25 (+25%) and 0.75 (-25%). 
Those each side of this threshold were considered hits. Over the screen, as expected, hits that 
reduced cell surface WT RET were detected (blue) but no targets reduced S100M RET as 
levels were already very low. 
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Figure 4.6 POC scores for candidate genes and potential hits for DLD-1 WT or 
S100M RET expressing cells 
POC scores for all candidate genes have been plotted for DLD-1 cells expressing WT (blue) or 
S100M (pink) RET. Candidates considered hits have been annotated, while control genes have 
been coded as follows: A6 – ATP6V0C; R7 – RAB7A; E4 – Erp44. RET has not been labelled; it 
accounts for every non-annotated point below the 0.75 threshold.  
 
The hits identified from the HTS screen can be divided into four groups: those that 
negatively regulate both WT and S100M RET surface expression (i.e. knockdown 
boosts cell surface levels), those that negatively regulate either WT or S100M RET 
surface expression and those that are required for WT RET surface expression (i.e. 
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knockdown reduces cell surface levels). The significance of the hits in this latter 
category (required for WT RET surface expression) cannot be determined for 
S100M RET due to the almost complete lack of the receptor at the cell surface.  
 
4.5 Dissection of factors involved in WT and S100M RET 
surface expression 
The siRNA targets and resulting POC scores for the identified 30 hits have been 
listed in Table 4.1 (a full list of all siRNA targets and resulting POC scores can be 
found in the appendix).  
 
 
Table 4.1 Hits from the HTS siRNA screen satisfying significance criteria 
A list of genes silenced that gave a POC value higher than 1.25 or lower than 0.75. Targets are 
divided into those that increase WT and S100M RET surface expression, those that increase 
either WT or S100M RET surface expression, and those that reduce WT RET surface 
expression. S.E = surface expression. 
 
To verify hits obtained from an HTS siRNA screen, it is often advised to 
deconvolute the SMARTpooled siRNAs and silence the selected genes with four 
individual siRNAs, rather than a pool. Only those genes whose knockdown elicits 
the same effect with three or more single siRNAs are then taken forward, 
eliminating those that may have off-target effects. This method is effective when 
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attempting to reduce the number of hits and only investigate those with a higher 
level on confidence. However, it may also result in the loss of genuine hits that 
have a less significant effect, which is especially undesirable when the hit list taken 
forward for validation is already relatively small or the definition of a hit (+/-25% 
POC) is not profoundly different from the norm. For these reasons, I have chosen 
not to deconvolute the siRNAs. Instead, I have pooled the targets into pathways, 
highlighting cellular mechanisms that appear to influence WT and S100M RET cell 
surface levels (Table 4.2).  
 
 
Table 4.2 Clustering of 30 hits identified from primary siRNA screen into cellular 
processes 
Hits identified as increasing or reducing WT or S100M RET levels (or both) have been divided 
into broad cellular processes for future validation and investigations.  
 
Preliminary validation would then be carried out with chemical inhibitors that target 
a particular pathway, or repeated siRNA experiments. Three key components of 
the eukaryotic degradation system (proteasomal, lysosomal and autophagosomal 
degradation) all appear to significantly influence both WT and S100M RET cell 
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surface levels. The control targets (RAB7A, V-ATPase, ERp44 and RET) all 
influenced WT and S100M RET surface levels as predicted, which allows a higher 
degree of confidence regarding the hits observed.   
4.5.1 siRNA targets negatively influencing both WT and S100M RET cell 
surface levels 
Analysis of hits from the siRNA screen suggested the targeting of two distinct 
pathways can increase cell surface levels of both WT and S100M RET protein: ER-
associated proteasomal degradation (ERAD) (defined by components STUB1 and 
SPFH2) and receptor internalisation and lysosomal degradation (defined by 
components RAB7A, ATP6V0C and ATP6V1A). These components are discussed 
in more detail below.   
4.5.1.1  ER-associated proteasomal degradation 
The quality control system of the ER targets misfolded proteins for degradation, a 
process commonly referred to as ERAD. The folding and chaperone systems of the 
ER will persist in protein folding for a finite time, before subsequent extraction from 
the pathway and disposal takes over (Hebert et al., 2010). The intrinsically slow 
folding nature of WT RET and the known misfolding properties of S100M HSCR 
RET make this pathway a predictable regulator of RET degradation.  
 
The STUB1 gene encodes Carboxyl terminus of Hsc70 Interacting Protein (CHIP), 
an E3 ligase that regulates protein quality control by targeting misfolded proteins 
for degradation (Matsumura et al., 2013). The protein contains three 
tetratricopeptide repeats (TPR), a structural motif that mediates protein-protein 
interactions, and a catalytic U-box domain required for ubiquitination (Ballinger et 
al., 1999, Jiang et al., 2001). CHIP binds to the C-terminus of Hsp/c70 (70kDa heat 
shock protein/70kDa heat shock cognate) and facilitates the polyubiquitination of 
misfolded client proteins, resulting in their degradation via the proteasome (Jiang et 
al., 2001, Matsumura et al., 2013).  
 
Heat shock proteins Hsp70 and Hsp90 have been found to regulate protein folding 
and degradation by binding to proteins – such as folding chaperone HOP and E3 
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ligase CHIP – that contain TPR motifs (Liu et al., 1999, Russell et al., 1999). 
Binding occurs via their highly conserved C-terminal EEVD sequence and is 
regulated by phosphorylation of this region (Muller et al., 2013). Several papers 
demonstrate that antagonising the client protein-Hsp90 interaction – and thus 
inhibiting assisted protein folding – results in CHIP-dependent degradation of 
Hsp90 client proteins (Krishnamoorthy et al., 2013, Connell et al., 2001, Zhou et al., 
2003). RET was recently shown to be an Hsp90 client protein, so the involvement 
of CHIP in receptor degradation is very possible (Alfano et al., 2010). CHIP has 
also been implicated as a tumour suppressor due to its role in the degradation of 
several oncogenic proteins, including p53, the Met receptor and SRC-3 (Muller et 
al., 2008, Jang et al., 2011, Kajiro et al., 2009b). The role of CHIP in RET 
degradation could be very interesting, as it could regulate the levels of oncogenic 
RET and target misfolded HSCR RET for degradation.  
 
CHIP knockdown resulted in an increase in both WT and S100M RET cell surface 
levels, suggesting that both forms of the receptor are targeted for ERAD via CHIP 
polyubiquitination (Murata et al., 2001). Notably, Hsp70 (HSPA1A) and Hsc70 
(HSPA8) were both included in the screen and although they were not identified as 
hits, their knockdown did result in increased RET levels (HSPA1A: WT +15%, 
S100M +14%; HSPA8: WT 24%, S100M +17%) of WT and S100M RET surface 
expression. This further implicates CHIP in RET degradation, as the loss of 
Hsp/c70 would result in impaired CHIP ubiquitination and a decrease in RET 
degradation. However, the knockdown of both Hsp90 (HSP90AA1/HSPCA) and 
Hsp90’s ER-localised paralog HSP90B1 had no effect on WT or S100M RET 
surface levels. Firstly, the efficiency of these particular knockdowns should be 
checked to confirm the effect of each and check for any disparities between the 
siRNAs. Also, the genes HSP90AA2 and HSP90AB1, coding for Hsp90-α2 and 
Hsp90-β were not included in the screen and should be examined.  
 
SPFH2 (also known as Erlin-2) is an ER-membrane protein residing within the ER 
lumen that contains the stomatin/prohibitin/flotillin/HflK/C (SPFH) domain. This 
domain anchors proteins to lipid membranes through associations with N-terminal 
hydrophobic regions (Matsumura et al., 2013). SPFH2 is a prohibitin family 
member that defines lipid raft regions within the ER membrane and has been 
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shown to mediate the ERAD of inositol 1,4,5-triphosphate (IP3) receptors (Xu et al., 
2008, Scheffner et al., 1995). Other substrates are likely and if this hit is correct, it 
would suggests that SPFH2 plays a key role in the ERAD of RET and may act as a 
degradation target recognition receptor.  
4.5.1.2  Endocytosis & lysosomal degradation 
Receptor internalisation by endocytosis can engage different intracellular sorting 
pathways, leading to the cargo being recycled back to the plasma membrane or 
degraded via the lysosome. A number of protein components operating within the 
lysosome have been identified. ATP6V0C and ATP6V1A both encode components 
of the ATP-dependent protein pump vacuolar (H
+
)-ATPase (V-ATPase), an enzyme 
that mediates the organelle acidification required for processes such as receptor-
mediated endocytosis and protein sorting (Jiang et al., 2001). ATP6V0C is one of 
six subunits that make up the membrane bound V0 domain required for protein 
translocation, while ATP6V1A is one of the eight subunits that compose the V1 
domain responsible for the ATPase activity. ATP6V1A has been proposed to be 
responsible for directing assembly of the complex and targeting the enzyme to the 
correct cellular location (Ballinger et al., 1999). Genes coding for other subunits 
were included in the screen (ATP6V0A1, ATP6V0B, ATP6V0D1, ATP6V1B1, 
ATP6V1B2, ATP6V1D, ATP6V1F) but their siRNA knockdowns did not result in a 
significant increase in WT or S100M RET knockdown. It is worth noting that this 
could be due to the efficiency of the siRNA.  
 
Due to the role of V-ATPase in Golgi acidification, it was originally hypothesised (as 
mentioned in chapter 3) that a loss of V-ATPase activity would result in lower 
surface expression levels of WT RET through the prevention of RET maturation. As 
the siRNA knockdown resulted in increased levels of both WT and S100M RET, it 
is thought that this has been caused by one of the other many roles V-ATPase 
plays within the cell. As well as facilitating endocytosis, V-ATPases are found within 
the acidified sorting endosomes that are required for receptor recycling; within 
multivesicular bodies (MVBs) required for endosomal transport; and within the 
lysosomes to allow degradation to occur (Muller et al., 2013, Liu et al., 1999, 
Russell et al., 1999). Therefore the observed increase in cell surface levels could 
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be due to an inhibition of endocytosis or lysosomal degradation. This could be 
examined in the future using chemical inhibitors against both pathways and 
preliminary investigations into the inhibition of endocytosis itself are discussed later 
on.  
 
RAB7A encodes the Rab7 protein: a small GTPase associated with the late 
endosomes and lysosomes. Several Rab GTPases are involved in this pathway, 
with Rab5 found on the early endosomes before being replaced by Rab7 on 
matured late endosomes. This Rab family member plays important roles in both 
endosomal maturation and transport from the late endosome to the lysosome 
(Gautreau et al., 2014). Rab7 has been shown to regulate the lysosomal 
degradation of the EGF:EGFR complex, therefore suggesting a possible role in the 
regulation of RTK degradation that could encompass RET (Connell et al., 2001).  
4.5.2  siRNA targets negatively influencing WT RET cell surface levels only 
Components of two main cellular pathways were identified from the siRNA screen 
as possible negative regulators of WT RET surface expression: protein folding and 
ER quality control (defined by components MAN1B1, PPIB), and proteasomal 
degradation (defined by the component COPS6). MAN1B1, also known as ERManI, 
is a class 1 mannosyl-oligosaccharide α-1,2-mannosidase. Like other class 1 α-
mannosidases, MAN1B1 is a member of the glycosyl hydrolase family 47 (GH47) 
and has an (αα)7 barrel structure. Other members of the GH47 also appear as hits 
in the screen and are discussed later. MAN1B1 is involved in both the maturation of 
N-glycans in protein folding and secretion as well as contributing to the disposal of 
misfolded glycoproteins by ERAD. Specifically, MAN1B1 removes the α-1,2-linked 
mannose groups from Asp-linked oligosaccharides such as Man9GlcNAC2 on 
glycoproteins in the ER. Glycoproteins that fail to fold have an increased amount of 
α-1,2-linked mannose groups removed, targeting these proteins for ERAD (Avezov 
et al., 2008). MAN1B1 represents a crucial point in the protein-folding pathway: 
glycoproteins targeted by MAN1B1 are subsequently targeted for ERAD, while 
those that are not trimmed can continue within the folding/export process. It has 
also been identified that MAN1B1 can reside within the Golgi apparatus, facilitating 
the retrieval of ERAD substrates back to the ER (Pan et al., 2013).  
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PPIB encodes the protein Cyclophilin B (CypB), a member of the cyclophilin 
chaperone family that increase the rate at which proteins fold through their peptidyl-
prolyl cis-trans isomerase (PPIase) activity. The protein is thought to protect cells 
from ER stress and has been shown to interact with the ER stress regulator BiP 
(also known as GRP78) (Kim et al., 2008). As the purpose of this chaperone is to 
increase the speed at which client proteins fold, it is interesting that it appears to 
negatively regulate the export of WT RET. It may therefore work indirectly to assist 
the folding of an intermediary RET component. It has been previously reported that 
CypB influences the activity of PDI, and it is thought that the two chaperones 
cooperate with each other to promote protein folding (Horibe et al., 2002). 
Therefore, the silencing of PPIB may negatively affect PDI activity.  
4.5.3 siRNA targets that negatively influence S100M RET cell surface levels 
only 
There are two cellular pathways that appear to selectively impact on the cell 
surface levels of S100M RET alone: ERAD (defined by the component EDEM2) 
and aggresome-based autophagy (OPTN, GABARAPL1). ER degradation-
enhancing α-mannosidase-like protein (EDEM)2 is one of three (EDEM1-3) lectins 
involved in the targeting of glycoproteins for ERAD (Mast et al., 2005, Hosokawa et 
al., 2001, Olivari et al., 2005). The exact role of these ER-localised glycosyl 
hydrolase 47 (GH47) family proteins is unclear, but their transcription is activated 
under conditions of ER stress and their overexpression accelerates the targeting of 
misfolded glycoproteins for ERAD (Hosokawa et al., 2001, Mast et al., 2005). 
Unlike the related MAN1B1, EDEMs were first believed to have no catalytic activity, 
but they retained a carbohydrate-recognition function involved in recognition of 
misfolded glycoproteins (Aebi et al., 2010). However, more recent data show that 
EDEM overexpression enhances de-mannosylation of misfolded proteins and that 
EDEMs possess all catalytic residues required for enzymatic activity in 1,2-
mannosidases (Hosokawa et al., 2010, Hirao et al., 2006). The activation of EDEM 
proteins is thought to accelerate N-glycan removal and promote ERAD. They may 
have distinct functions and specific client proteins, as the knockdown of EDEM1 
and EDEM3 had no effect on WT or S100M RET cell surface levels. The finding 
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that different GH47 family members appear as hits for WT (MAN1B1) and S100M 
(EDEM2) RET appears to implicate differential glycosylation between the two 
species, which may be of potential importance for restoring maturation of HSCR 
RET mutations. 
 
The second pathway implicated in negatively influencing S100M RET levels is the 
aggresome-autophagy pathway. This recently discovered pathway selectively 
targets protein aggregates or damaged organelles for clearance in cells (Lamark 
and Johansen, 2012). Two key components within the pathway are striking hits in 
the siRNA screen. One is an LC3-like homologue, GABARAPL1 (GABA(A)-
receptor associated protein like 1), an autophagy modifier that is located on the 
autophagosomal membrane. The second is Optineurin (OPTN), an autophagy 
receptor that binds to both the cargo protein and an autophagy modifier such as 
GABARAPL1 (Chakrama et al., 2010, Wild et al., 2011). The five GABARAP family 
members – GABARAP, GABARAPL1, MAP-LC3 (light chain 3 of microtubule 
associated protein), GATE-16 (golgi-associated ATPase enhancer of 16 kDa or 
GABARAPL2) and Atg8 – are implicated in protein and vesicle transport, as well as 
the formation of the autophagosome (Longatti and Tooze, 2009). These Atg8 family 
proteins are involved in the final step of autophagy: the formation of the 
autophagosome itself, through lipidation of the cytosolic proteins. OPTN is a 
ubiquitin-binding autophagy receptor localised in LC3-positive (an Atg 8 family 
member) vesicles. The receptor is phosphorylated by Tank-binding kinase 1 
(TBK1), a modification that is required for OPTN to be able to bind to autophagy 
modifiers (Wild et al., 2011, Korac et al., 2013). TBK1 is activated by Gram-
negative bacteria and OPTN has been shown to target Salmonella enterica for 
degradation via the autophagosome (Wild et al., 2011). Aside from this role in 
innate immunity, OPTN has been found to bind to aggregated proteins – through its 
C-terminal coiled-coil domain – and target them to the autophagy-lysosome 
pathway (Korac et al., 2013).  Thus, the siRNA screen has identified a potentially 
surprising link between S100M RET and an aggresome-autophagy pathway not 
previously connected.  
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4.5.4  siRNA targets that positively influence WT RET cell surface levels 
Unsurprisingly, the knockdown factors involved in ER to Golgi transport (RNP24, 
SEC23B, SEC24C) resulted in a reduction in WT RET cell surface levels. Perhaps 
also unsurprising is the important role a number of folding chaperones and ER 
quality control factors (HSPA5 (BiP), SEL1L, DDOST, MESDC2, ATF6, HYOU1, 
GRP58, CALR, ERN1) play in successful WT RET export. These initial findings do 
however start to build a detailed picture of the specific factors required for RET 
export. Not only would it be interesting to investigate whether these factors are 
RET or general RTK specific, but it could also be used in the development of future 
treatments of cancers caused by RET overexpression. 
 
It is notable that a number of genes included in the screen did not have the 
expected effect on WT or S100M RET surface expression. For example, ERGIC-53 
(Endoplasmic Reticulum-Golgi Intermediate Compartment Protein-53, also known 
as LMAN1), a mannose-specific lectin responsible for the transport of glycoproteins 
from the ER to the ERGIC (Hauri et al., 2000). There are other lectins involved in 
the process, which indicates a level of specificity within the pathway (Aebi et al., 
2010). A future experiment examining the effect of each of these lectins on WT 
RET cell surface levels could give an indication of the particular protein involved. 
Silencing of the EDEM1-associated disulphide reductase ERdj5 (gene name 
DNAJC10) also elicited no effect, despite the protein being a member of the ERAD 
complex that recognises and unfolds ERAD substrates (Ushioda et al., 2008). 
Again, this gives an indication of substrate specificity within the pathway.  
 
4.6  Preliminary validation of factors identified to be involved 
in RET surface expression 
4.6.1  Validation of hits involved in RET degradation using 
immunofluorescence 
To confirm that hits identified in the immunofluorescence-based assay were true 
positives, a subset – or pathways containing those chosen – that could be directly 
targeted by small molecule chemical inhibitors were investigated. These included 
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chemical inhibition of endocytosis (involving hits such as V-ATPase and Rab7), 
proteasomal degradation (COPS6, SPFH2, CHIP), and TBK1 activity (OPTN). For 
TBK1 inhibition, Professor Philip Cohen kindly donated a highly selective TBK1 
inhibitor with a control inhibitor known to inhibit the same off-targets (Clark et al., 
2011, Clark et al., 2012). Pitstop2 was used to inhibit endocytosis (von Kleist et al., 
2011), while epoxomicin was used to inhibit proteasomal degradation (Sin et al., 
1999).  
 
To confirm that these chemical inhibitors were restoring S100M RET cell surface 
expression, cell surface levels were examined using immunofluorescence. The 
experiment was also carried out in a 96-well plate format and the cells fixed and 
stained with the 1D9 anti-RET antibody. DLD-1 cell surface levels of WT and 
S100M RET were stained for immunofluorescence. 4-PBA was used as a control, 
as it was already known that this chemical chaperone can increase RET cell 
surface levels. The mean channel 2 intensity values were normalised against the 
control (i.e. no inhibitor), with each condition tested in triplicate wells, to obtain a 
POC value (Figure 4.7). Ordinary two-way ANOVA statistical analysis was carried 
out on the data. This test was chosen because there were two variables: a group of 
chemical inhibitors and two different forms of RET (WT and S100M). Statistical 
significance has been displayed on the graphs, between the non-induced (N) and 
induced (I) samples or the induced and the inhibitor samples. Non-significant 
results have a P value of >0.05, while significant results are as follows: * P<0.05; ** 
P<0.01; *** P<0.001; **** P<0.0001.  
 
The results show that the chemical inhibitors chosen all increase S100M RET 
surface expression (and that of WT RET), excepting the control TBK1 off-target 
inhibitor. This confirms that the increased surface expression caused by the TBK1 
inhibitor is not due to the known off target effects. All inhibitors (excepting the off-
target TBK1 control inhibitor) also caused an increase in intracellular (+ Triton-
X100) RET levels. This is understandable in the cases of 4-PBA (increased RET 
folding and export), epoxomicin (reduced proteasomal RET degradation) and the 
TBK1 inhibitor (reduced autophagosomal RET degradation). Inhibition of 
endocytosis with Pitstop2 also resulted in increased intracellular levels, which may 
be due to a reduction in lysosomal degradation of the cell surface receptor.  
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Figure 4.7 POC values for WT and S100M RET surface expression in the 
presence of selected chemical inhibitors 
DLD-1 cells stably expressing WT or S100M RET were incubated with chemical inhibitors for 24 
h before fixing and staining. Mean channel 2 fluorescence intensity values were normalised 
against control (I) to obtain a POC value. Standard deviation error bars are calculated from 
triplicate values. Two-way ANOVA statistical analysis was carried out, with statistical 
significance indicated between control (I) and each condition. Key: N – no RET expression; I – 
no inhibitor control; epo – epoxomicin; 4PBA – 4-phenylbutyrate; Pitstop – Pitstop2; TBK1 – 
TBK1 inhibitor; TBK1con – TBK1 control inhibitor. 
 
4.6.2 Investigation of hits involved in RET degradation by immuno-blotting 
Having confirmed that the chemical inhibitors could increase WT and S100M RET 
surface levels, it was necessary to determine whether they could restore S100M 
RET signalling. This was determined by western blot analysis of DLD-1 WT and 
S100M RET expressing cell lysates for phosphorylated tyrosine (referred to as 
pTyr-pan) and ERK1/2 (pERK1/2). As discussed in chapter 3, these are known 
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reliable surrogates for RET activation and signalling. Pilot experiments have 
investigated the effect of three inhibitors: the TBK1 inhibitor, the TBK1 off-target 
control inhibitor and 17-AAG. 17-AAG was used as a known potent Hsp90 inhibitor, 
in order to potentially upregulate CHIP activity. Further work is required to 
determine the effect of endocytosis or proteasomal inhibition on S100M RET 
activity.  
 
DLD-1 cells stably expressing WT or S100M RET were incubated with the 
inhibitors overnight, before lysis and sonication in sample buffer. Activation of TBK1 
leads to direct phosphorylation of the autophagy receptor OPTN. This modification 
leads to enhanced interaction of OPTN with the family of mammalian Atg8 proteins, 
which are ubiquitin-like and essential for autophagy. Inhibition of TBK1, which has 
been shown to block OPTN function, resulted in an overall increase in RET levels 
(Figure 4.8a&b). This increase was more prominent in the case of S100M RET and 
was not observed when the cells were incubated with the TBK1 off-target control 
inhibitor. While cell surface levels of S100M RET are seen to increase, there is no 
general increase in mature RET levels. Overall pTyr-pan and pERK1/2 levels were 
seen to increase for WT RET in the presence of GDNF and GFRα1. Again, this 
increase was not visible for S100M RET in the presence the TBK1 inhibitor – while 
a pTyr-pan band is observed when cells were incubated with TBK1 inhibitor, this 
background may be due to the much higher RET expression levels.  
 
 
Figure 4.8 WT and S100M RET levels and activation in the presence of chemical 
inhibitors 
(A) Western blot analysis of DLD-1 cells stably expressing WT RET in the presence of the 
TBK1 inhibitor, TBK1 control inhibitor or 17-AAG for 24 h. Cells are incubated with recombinant 
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GDNF and GFRα for 30 minutes before lysis. (B) Repeated western blot analysis of DLD-1 cells 
stably expressing S100M RET. (C) Western blot analysis of DLD-1 cells stably expressing 
S100M RET in the presence of epoxomicin or Pitstop2 for 24 h.  
 
Incubation with 17-AAG appears to result in a reduction in overall RET levels for 
both WT and S100M RET as was hypothesised (Figure 4.8a&b). 17-AAG inhibits 
Hsp90, thus potentially resulting in an increase in CHIP activity, so a greater 
amount of RET would be targeted for proteasomal degradation. This result 
provides preliminary validation of the implication of CHIP in RET degradation. None 
of the inhibitors (TBK1, TBK1 control, 17-AAG, epoxomicin or Pitstop2) resulted in 
S100M RET maturation (Figure 4.8), despite restoring surface expression (Figure 
4.7).  
 
While there is a degree of separation between the chemical inhibitors used and the 
hits identified in the screen, this result does further implicate the involvement of 
both autophagy and ERAD in the degradation of the RET receptor. These data also 
suggest that some pathways identified by the screen do indeed increase levels of 
WT and S100M RET at the cell surface but, for S100M RET, this does not result in 
the restoration of RET signalling. This may be because the increased RET levels 
are mostly immature forms that are not functional and cannot bind ligand. It points 
toward the need to implement a secondary screen to test for the restoration of 
ERK1/2 phosphorylation using hits from the primary immunofluorescence screen. 
 
The inhibition of Hsp90 using 17-AAG has partially validated the role of ERAD in 
RET degradation, but a more specific experiment is required to look closer at the 
role of CHIP itself. In order to further examine this, DLD-1 cells were transiently 
transfected with WT and dominant negative CHIP and Ube2D1 (UbcH5α). A 
mutation within the U-box of CHIP (P269A) has been reported to result in a 
dominant negative version of the protein, by eliminating the E3 ligase activity 
(Matsumura et al., 2013). Ube2D1 is an E2 enzyme that has been shown to 
specifically interact with CHIP, while the dominant negative mutation (C85A) 
eliminates the enzyme’s ability to form the thioester complex required for protein 
ubiquitination (Scheffner et al., 1995, Xu et al., 2008).  
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All constructs appear to express, with an optimal transfection reagent:DNA 
construct ratio of 2:1 for CHIP WT and P269A (Figure 4.14). The antibody used to 
detect Ube2D1 also detects Ube2D2 and Ube2D3, which are of almost identical 
molecular weights (16.6kDa, 16.7kDa and 16.7kDa respectively). As there are two 
bands present at approximately 17kDa (Figure 4.9), it can only be assumed at this 
point that the upper band is Ube2D1 as it appears with increasing transfection 
ratios. This needs to be repeated with a different Ube2D1 antibody, or analysed by 
mass spectrometry to be sure of the band identity. Future experiments are required 
to investigate the consequence of this overexpression on both WT and S100M RET 
maturation and signalling. 
 
 
Figure 4.9 Transient overexpression of CHIP and Ube2D1 in DLD-1 cells 
(A) DLD-1 cells were transiently transfected with WT or P269A CHIP cDNA using the FuGENE 
transfection reagent, before lysis and immuno-blotting with anti-CHIP and anti-β-Actin 
antibodies. (B) DLD-1 cells were transiently transfected with WT or C85A Ube2D1 cDNA using 
the FuGENE transfection reagent, before lysis and immuno-blotting with anti-Ube2D1 and anti-
β-Actin antibodies. 
 
In conclusion, inhibition of proteasomal, lysosomal and autophagosomal 
degradation appears to result in restored S100M RET cell surface expression. 
Preliminary investigations show that the inhibition of autophagosomal degradation 
using a TBK1 inhibitor does not restore S100M RET signalling capabilities or 
maturation. While this needs to be investigated further in the other pathways, it 
suggests that protein that has already been targeted for degradation is no longer 
functional.  
 
It has previously been shown that the recombinant S100M RET ectodomain, as a 
result of the double cysteine mutation facilitating its secretion into the cell medium, 
can bind to ligand and co-receptor as efficiently as WT RET (Kjaer et al., 2010). 
However, here we show that immature S100M RET in a full-length context at the 
cell membrane is not functional at the cell surface. This may be for two reasons. 
Firstly, protein that has been targeted for degradation may have been modified in 
Chapter 4 Results 
 
 122 
some way that makes it unable to bind to its bipartite ligand or signal. Secondly, the 
fact that the ‘rescued’ S100M RET is not fully mature implies that it has not 
travelled through the Golgi apparatus. This could suggest that the complex N-linked 
glycosylation received in the Golgi may be necessary for either bipartite ligand 
recognition or signal transduction. It has been previously shown that inhibition of 
RET maturation – via inhibition of Golgi acidification – does not prevent surface 
expression, but it was not examined as to whether that protein could function at the 
cell surface (Hirata et al., 2010). Work carried out in the laboratory has identified 
hotspots on the RET ectodomain that potentially implicate glycosylation sites in 
bipartite ligand binding (Goodman et al., 2014, in press). Therefore, future efforts 
into the restoration of S100M RET signalling should investigate the requirement for 
complex N-linked glycosylation in RET signalling and the possibility of ‘rescuing’ 
S100M RET before it is targeted for degradation. Alternatively, a greater emphasis 
should be placed on increasing mature RET levels by investigating components 
influencing proper glycosylation and disulphide formation of full-length RET. 
4.7  Future efforts: monitoring RET activation 
It is now clear that restored S100M RET cell surface expression does not correlate 
with restored signalling. Therefore, a secondary signalling screen is required to 
analyse the positive hits from the primary immunofluorescence screen.  The 
signalling screen could use the RET activation surrogates such as RET auto-
phosphorylation or ERK1/2 phosphorylation, which can be readily monitored by 
immuno-blotting. However, this method is only suited at present for low to medium-
throughput screening. 
 
For this reason, I investigated the possibility of monitoring RET activation via 
immunofluorescence. DLD-1 cells stably expressing WT or S100M RET were 
incubated with recombinant GDNF and GFRα1 for 30 minutes before fixing and 
staining with anti-RET, -phospho-RET (pTyr1062), -pTyr-pan and -pERK1/2. The 
average channel-2 fluorescence intensity values were normalised against the 
average fluorescence intensity of the non-induced control; WT and S100M RET 
values were normalised separately, as were those from separate antibodies. As 
seen in Figure 4.10, both intracellular and surface WT RET levels increase upon 
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induction of RET expression as expected, followed by a drop when activated by the 
recombinant ligand and co-receptor. This drop is most likely a direct consequence 
of ligand-induced receptor internalisation. To confirm this, repeated experiments in 
the presence of the endocytosis inhibitor Pitstop2 are needed. The increase in 
S100M RET surface and intracellular levels was far less prominent, as expected. 
 
A large increase in pTyr1062 intensity was observed when WT RET expression 
was induced and once again when activated. This increase may be due to 
background RET staining, as pTyr1062 intensity also increased for S100M RET 
when incubated with ligand and co-receptor. However, WT RET levels drop 
following RET activation while pTyr1062 levels rise, suggesting that it is specific to 
RET activation and could potentially be used as a method for monitoring RET 
activation.  
 
 
Figure 4.10 Using immunofluorescence to monitor WT and S100M RET levels and 
activation status 
DLD-1 cells stably expressing WT or S100M RET were activated with bipartite ligand for 30 min 
before fixing (PFA), permeabilisation (Triton-X100) and staining. Average channel 2 
fluorescence intensity values were normalised against non-induced controls for separate cell 
lines and primary antibodies. Key: N – non-induced; NG – non-induced + GDNF/GFRα; I – 
induced (+doxycycline); IG – induced + GDNF/GFRα.   
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While the intensity increase for pTyr-pan and pERK1/2 is much less obvious, the 
rise appears more specific to activated WT RET rather than induced WT RET 
expression. This rise in pTyr-pan and pERK1/2 intensity is also not observed in 
DLD-1 S100M RET cells that have been incubated with ligand and co-receptor. 
With optimisation, it is possible that this method could be used to monitor RET 
phosphorylation and identify either siRNA knockdowns or compounds that restore 
S100M RET signalling capabilities.  
 
pERK1/2 levels can increase when the ER is under stress (Arai et al., 2004), which 
could be the case when S100M RET expression is induced at the same time as 
other conditions within the DLD-1 cell are altered. It is therefore crucial that the 
pERK1/2 intensity increase is specific for induced + GDNF/GFRα, rather than the 
induced expression alone. Using either pTyr-pan or pTyr1062 as an alternative 
antibody alongside pERK1/2 could control for this. Future optimisation could 
involve the testing of other phospho-RET antibodies, such as pTyr905.  
4.8 Conclusion 
The aim of this chapter was to develop an immunofluorescence cell-based assay 
that could be used to study RET folding, maturation and trafficking to the cell 
surface.  I hoped to identify factors involved in these processes and investigate 
their contribution towards the development of Hirschsprung’s disease or their role 
as potential tumour suppressors. I successfully set up and carried out a high 
throughput biased siRNA screen that has identified novel factors and pathways that 
potentially regulate both WT and S100M RET cell surface expression levels. 
S100M RET cell surface expression can be restored via the siRNA knockdown of 
factors involved in folding, export and degradation. Aggrephagy, lysosomal 
degradation and ERAD all appear to play a role in RET degradation, but 
preliminary validation of a small number of positive hits from the primary screen 
suggest that protein rescued from degradation is no longer functional, underlining 
the need for a secondary screen on all positive primary screen hits to identify those 
that restore a GDNF-GFR1 mediated RET signalling response. 
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4.8.1 Optineurin & macroautophagy 
Optineurin and GABARAPL1 were both identified as negative regulators of S100M 
RET surface expression. The observation that both knockdowns were specific to 
S100M RET suggests that the mutated receptors are misfolded or improperly 
glycosylated and targeted to the autophagosome. It is important to note that the 
autophagy pathway assembles within the cytosol (Wong and Cuervo, 2010), 
arguing that misfolded S100M must be translocated from the ER back into the 
cytosol in order to engage the aggresome-autophagy pathway. This process may 
occur in a similar sequence to E3 ligase ubiquitination and subsequent 
proteasomal degradation. The inhibition of TBK1 results in both increased cell 
surface expression and increased overall protein levels, but does not restore 
S100M RET maturation or downstream signalling (measured by pTyr-pan and 
pERK1/2 levels). This needs to be repeated with OPTN siRNA to be sure of the 
effect, but suggests that the inhibition of OPTN-related autophagy will not restore 
S100M RET signalling.  
 
While the inhibition of aggrephagy may not be sufficient in rescuing S100M RET 
function, the identification of OPTN as a hit suggests a novel role for this pathway. 
Future investigations are required to elucidate whether this degradative mechanism 
is specific to RET – due to the misfolding nature of the protein – or to RTKs in 
general. So far, optineurin has been implicated in the autophagy of Salmonella and 
aggregated proteins (Wild et al., 2011, Korac et al., 2013). It would therefore be 
interesting to see whether all HSCR mutant forms of RET are targeted, or even a 
portion of the WT protein (as TBK1 inhibition did increase cell surface levels of WT 
RET when tested via immunofluorescence). It would be interesting to examine the 
difference between the targeting of kinetically compromised HSCR mutants 
(represented by S100M RET) and the more severe thermodynamically 
compromised HSCR mutants (such as G93S RET). To test this, a DLD-1 cell line 
stably expressing G93S RET would need to be created, with total cell levels of 
S100M or G93S measured via immuno-blotting before and after OPTN siRNA 
knockdown.  
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4.8.2 Possible ER exit routes for misfolded RET 
While the possible role of aggrephagy in RET degradation has been discussed, 
one potential obstacle is the subcellular location of RET when it is targeted for 
degradation. Aggrephagy operates within the cytosol, whereas ERAD pathways – 
whose inhibition leads to increased cell surface export of WT and S100M RET – 
function within the ER, using retrotranslocation to membrane-bound or cytosolic 
ubiquitin ligases (Olzmann et al., 2013). Retrotranslocation of RET for proteasomal 
degradation could potentially expose its transmembrane (TM) domain. Little is 
known about how such membrane proteins are exported out of the ER for 
degradation. Considering that cell surface RET will require an intact TM region, 
there are currently two models by which this could occur: ER associated autophagy 
(ERAA) and autophagy-independent EDEMosomes (Bernales et al., 2007, Zuber et 
al., 2007). 
 
Several misfolded proteins are known to be degraded by macroautophagy, such as 
the androgen receptor and α–synuclein (Webb et al., Pandey et al.). ERAA has 
been shown to involve the engulfment of the ER (as ERAA autophagosomes are 
derived in part from the ER membrane), which could in turn result in the 
degradation of damaged proteins within that portion of the ER (Bernales et al., 
2007). ERAA can be activated by the UPR, with specific emphasis on the Ire1 
branch (Ogata et al., 2006). Interestingly, the knockdown of Ire1 (a.k.a ERN1) in 
the siRNA screen resulted in reduced cell surface levels of WT RET. This suggests 
that Ire1 may have an alternative role in the case of RET.  
 
Separate to ERAA, ERAD regulators – such as the EDEM proteins – are cleared 
from the ER to prevent excessive protein degradation and allow protein folding to 
occur. They are released via COPII-independent vesicles that travel to the 
lysosome to target the chaperones for degradation (Zuber et al., 2007). These 
vesicles – termed EDEMosomes – are distinct from the autophagosome: ERAD-
associated vesicle membranes contain the noncovalently bound LC3-I (Cali et al., 
2008), while autophagosome membranes contain covalently bound (lipidated) LC3-
II (Kabeya et al., 2000). The transmembrane protein SEL1L (involved in the 
dislocation of misfolded proteins) has been implicated as the ERAD tuning receptor, 
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interacting with both cytosolic LC3-I and ER-localised EDEM1 and OS-9 
(Bernasconi et al., 2012). These interactions ensure that the GH47 family members 
are sequestered into EDEMosomes and transported for degradation. The 
identification of this process brings about the possibility that misfolded EDEM 
substrates could also be carried within the EDEMosomes and targeted for 
degradation. While EDEM1 and OS-9 were two GH47 family members that were 
not identified as hits within the siRNA screen, MAN1B1 has also been implicated in 
the process (Bernasconi et al., 2012). MAN1B1 appears to negatively regulate cell 
surface levels of WT RET, and this possible mechanism behind that regulation 
should be investigated in future experiments. EDEM2 (identified in this thesis as a 
negative regulator of S100M RET export) has not yet been found to localise to the 
EDEMosome, and this could also be examined in future studies. 
4.8.3 CHIP & ER-associated degradation 
Data presented in this chapter suggests both WT and S100M RET are targeted for 
ERAD via the E3 ligase CHIP. Overexpression of CHIP, Ube2D1 and dominant 
negative versions of both in DLD-1 cells stably expressing WT or S100M RET will 
help to confirm this. At that point, S100M RET maturation and signalling capabilities 
can also be tested, although it appears unlikely that CHIP inhibition will be sufficient 
to restore function. At the point of CHIP recognition, the protein has already been 
extradited from the ER and may have been unfolded in the process. CHIP has 
been implicated as a regulator of oncogenic pathways and has been found to target 
several kinases – including Akt, ErbB2 and EGFR – for degradation (Zhou et al., 
2003, Kajiro et al., 2009a, Su et al., 2011). Therefore, RET may be targeted for 
degradation by CHIP due to the intrinsically slow folding trajectory of WT RET 
activating ERAD. This point comes back to the question of RET evolution raised in 
chapter 3: have unpaired cysteine residues been introduced into the receptor to 
slow down folding and prevent oncogenic levels at the cell surface? Once CHIP’s 
involvement in RET degradation has been confirmed using the overexpression 
constructs, it would be interesting to examine the effect of CHIP knockdown on the 
growth of RET-dependent cancer cells – such as luminal breast cancer cells.  
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4.8.4 Future efforts: validation of hits involved in RET folding & 
glycosylation 
MAN1B1 and EDEM2 were identified as factors that negatively regulate cell 
surface expression levels of WT and S100M RET, respectively (Table 4.3). Firstly, 
validation of these hits via siRNA knockdown and chemical inhibition (using 
Kifunensine (Weng and Spiro, 1996)) is required to confirm their involvement in 
RET quality control. It is interesting that WT and S100M RET appear to be 
selectively targeted for ERAD by different ER-mannosidases. EDEM1/2/3 gene 
transcription is upregulated during ER stress (Olivari et al., 2005, Molinari et al., 
2003), which could explain why EDEM2 is only associated with S100M RET: 
EDEM2 levels are not high during WT RET expression and so the knockdown does 
not elicit a noticeable effect.  
 
It appears that S100M RET protein that has already been targeted for degradation 
cannot signal, even if it is directed to the cell surface. This observation is coupled 
with the fact that the ‘rescued’ protein is also not fully mature. Therefore, the 
receptor is reaching the cell surface without travelling through the Golgi to become 
fully glycosylated. Analysis of the human RET amino acid sequence using 
ExPASY’s NetNGlyc prediction server results in the high-confidence prediction of 
nine N-linked glycosylation sites (Gupta et al., 2004). While N-glycans are first 
added to the glycoprotein in the ER, processing often occurs in the Golgi (Stanley, 
2011). It may be that the complex N-linked glycosylation received in the Golgi is 
required for ligand and co-receptor binding. The NetOGlyc prediction server also 
finds four possible O-linked glycosylation sites within the sequence (although 
information on O-linked glycosylation consensus sequences is far less established). 
O-linked carbohydrates are attached to the amino acids serine or threonine. O-
linked glycosylation is carried out by the enzyme N-acetylgalactosamine (GalNAc) 
transferase, while N-linked glycosylation requires a host of enzymes that are 
localised to different portions of the Golgi. Mannosidases found within the cis 
cisterna first remove mannose residues; GlcNAc (N-acetylglucosamine) transferase 
I and Mannosidase II are found in the medial cisterna, mediating the process of 
complex N-glycan synthesis; Gal (galactose) transferase is found in the trans Golgi 
network and add galactose to the carbohydrate complexes (Stanley, 2011). 
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Future studies involving the knockdown of enzymes mentioned above could build a 
more elaborate picture of the glycosylation process the RET receptor goes through 
when in the Golgi. The existence of WT RET as two species detectable via western 
blot analysis allows us to identify those involved in the creation of the mature form. 
Once the enzymes involved have been established, investigations into WT RET 
cell surface expression and signalling capabilities should give an indications of 
whether the Golgi-localised complex glycosylation is necessary for ligand and co-
receptor binding or signal transduction. While previous studies have suggested that 
glycosylation is not necessary (Kjær and Ibanez, 2003a), recent work has identified 
several glycosylation sites within the RET ECD as ‘hot-spots’ for ligand and co-
receptor binding (Goodman et al., 2014, In press).  
 
Inhibition of ERAD could help to determine how much of both WT and S100M RET 
are targeted by members of the GH74 family within the quality control pathway. 
Kifunensine, an alkaloid compound, is used to suppress ERAD by inhibiting ER-
associated mannosidase activity (Tokunaga et al., 2000). This experiment would 
also assist in the validation of the EDEM2 and MAN1B1 members of GH74 family.   
4.8.5 WT RET folding 
Several chaperones have been identified as being required for optimal WT RET 
export, with crucial players such as calreticulin and BiP in the list adding confidence 
to others identified. As the screen was comprised of a large number of chaperones, 
some of which do not appear to be involved in RET folding, a more specific picture 
of RET export can be created through validation of these hits. Following on from 
repeated siRNA experiments, it would then be interesting to investigate whether the 
chaperones identified are also involved in the folding of another RTK, such as 
EGFR. It would also be possible to overexpress the chaperones in a RET-
dependent cancer cell line and investigate their effect on cell growth and 
differentiation. Identifying ways to control oncogenic RET cell surface expression 
could have implications in future cancer treatments.   
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4.8.6 Hypothetical model for future validation 
 
Figure 4.11 Model of RET trafficking for future validation and investigations 
Schematic model of WT and S100M trafficking through the cell, with implicated pathways and 
factors highlighted.  
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Chapter 5. Structural analysis of distinct ATP-
competitive chemical inhibitor scaffolds bound to the 
RET tyrosine kinase 
5.1 Introduction 
This chapter describes the preparation, crystallisation and structure determination 
of nine distinct chemical inhibitors bound to the RET tyrosine kinase domain (RET 
KD). All compounds are ATP-competitive and bind within the RET nucleotide-
binding pocket. Also presented is the structure of ADP bound to RET KD. Several 
related crystal forms were identified during this study. Solution IC50 data from 
collaborators is presented for the chemical inhibitors together with thermodynamic 
analysis using differential scanning fluorimetry. Comparisons between the solution 
and crystal data suggest ways to improve the inhibitors and rationalise their 
potencies leading to an improved 3D pharmacophore for the RET tyrosine kinase 
ATP-binding cleft. Key components of the kinase nucleotide-binding pocket are 
highlighted in Figure 5.1.  
 
 
Figure 5.1 Schematic of ATP within the kinase nucleotide-binding pocket 
The structure of ATP (N – blue, C – green, O – red, P – magenta) annotated, with key areas 
within the pocket annotated.  
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Published data from laboratory has presented the structures of the RET KD bound 
to AMP and AMPPNP (with only the adenosine visible). In the AMP structure, the 
gly-rich loop (GRL) is in a ‘closed’ conformation, and this was thought to preclude 
ATP binding. The AMPPNP structure contains the GRL in two alternative 
conformations, with an ‘open’ as well as closed arrangement. I present the 
structure of the RET KD bound to ADP. The predicted position of the gamma 
phosphate differs from that seen in related RTKs, such as the FGFR or Src.  
 
Current FDA-approved drugs, for RET-dependent metastatic thyroid cancer, suffer 
from off-target dose-dependent toxicity and a lack of specificity. I therefore hoped 
that the characterisation of the binding modes of several different scaffolds would 
provide further insight into their molecular interactions and contribute to the design 
of a second generation of more RET-specific chemical inhibitors. The structures 
solved identify five binding modes that have similarities and differences that are 
defined by specific interactions between the inhibitor and residues within the 
nucleotide-binding pocket (annotated in Figure 5.2). These observations have been 
combined with biochemical data investigating the binding and thermal stabilising 
properties of each inhibitor towards the RET KD, in order to design an improved 
RET pharmacophore. 
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Figure 5.2 The RET nucleotide-binding pocket 
(A) View of the RET nucleotide-binding pocket with the side chains of  residues with the pocket 
shown (Hinge – light blue, interior pocket - purple, catalytic region - yellow, roof - green, floor - 
pink.) (B) ADP bound within the pocket, with residues within 4 Å of the ligand highlighted. 
Among those annotated are the catalytic residue D874 and gatekeeper residue V804. 
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The McDonald laboratory has previously determined structures for the RET 
tyrosine kinase domain bound to a variety of chemical inhibitors including 
Vandetanib, as well as adenosine (Knowles et al., 2006, Mologni et al., 2010, 
Plaza-Menacho et al., 2014). A structure of the M918T oncogenic RET mutant has 
also recently been determined. The crystal form used in these studies is amenable 
to co-crystallisation or soaking of a variety of ATP-competitive inhibitors. Academic 
collaborations with several different medicinal chemistry groups at the Paterson 
Institute (UK), Arizona (USA), Uppsala (Sweden) and Harvard (USA) have provided 
us with various different compound scaffolds that all potently inhibit RET kinase 
activity. These compounds can be broadly classified into type I inhibitors (DFG-in) 
and type II (DFG-out). I therefore initiated experiments to structurally characterise 
several different scaffolds to define their contacts with RET, their mode of action, 
potency and structure-activity relationships (SAR). Our goal was to understand the 
available inhibitor SAR, provide ideas for new improved inhibitors, define a better 
pharmacophore for RET inhibition and link this to solution-based kinase stability 
and cellular data on RET inhibition. Previous structural studies on other enzyme-
inhibitor targets have found novel inhibitor binding modes that were subsequently 
exploited chemically (Walker et al., 2000, Hutton et al., 2014). Also, the crystal 
structure of the heterocyclic scaffolds within the kinase nucleotide cleft is still 
required to define the inhibitor orientation.  
5.2 RET chemical inhibitors: identifying distinct scaffolds 
The inhibitors used in this chapter were provided by several groups, with details of 
each inhibitor and its origin in Table 5.1. Prior to this thesis, the RET KD had been 
crystallised with the inhibitors Sunitinib (Sutent®), PP1, Vandetanib and three 
indolin-2-one compounds (referred to as X2K, X2L and X2M). This chapter 
presents the structure of the RET KD bound to a further nine. Within this set of 
inhibitors, there are five distinct chemical scaffolds that have been detailed below.  
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Table 5.1 Inhibitors and collaborators 
 
The nine RET KD-inhibitor structures described in this chapter cluster into five 
distinct chemical scaffolds. I-1, I-7, I-8, I-9 and I-10 contain the pyrimido [4,5-
b][1,4]-benzodiazepine scaffold, referred to as scaffold 1 (S1) (Figure 5.3), were 
received from Professor Gray’s laboratory at Harvard (Miduturu et al., 2011). The 
scaffold was identified as an inhibitor of several kinases during the high-throughput 
kinase profiling of 353 kinases. The core benzodiazepine heterocycle (a benzene 
ring fused to a diazepine ring) has been used to target the central nervous system, 
producing an array of anti-anxiety drugs (Olkkola and Ahonen, 2008). The 
benzodiazepine scaffold has also been used in the inhibition of p38 MAPK and the 
Parkinson’s disease kinase LRRK2 (Ghori et al., 2010, Deng et al., 2011).  
 
Scaffold Chemical name Inhibitor Collaborator Reference
1 Pyrimido [4,5-b][1,4]-benzodiazepine I-1 Dr. Nathanael Gray, Harvard Medical School Miduturu et al., 2011
I-5 Dr. Nathanael Gray, Harvard Medical School
I-6 Dr. Nathanael Gray, Harvard Medical School
I-7 Dr. Nathanael Gray, Harvard Medical School
I-8 Dr. Nathanael Gray, Harvard Medical School
I-9 Dr. Nathanael Gray, Harvard Medical School
I-10 Dr. Nathanael Gray, Harvard Medical School
2 Pyrazolopyrimidine I-4 Professor Morten Grötli, University of Gothenberg Diner et al., 2012
PP242 Commercially available - Selleck Feldman et al., 2009
4 4-anilinoquinazoline I-3 Dr. Allan Jordan, Patterson Institute for Cancer Research
5 Phenyl-benzimidazole BMS-536924 Commercially available - Selleck Wittman et al., 2005
Pz-1 Dr. Hong-Yu Li, University of Arizona
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Figure 5.3 S1 inhibitors based on pyrimido [4,5-b][1,4]-benzodiazepine 
The chemical structure of S1 is shown, along with each of the inhibitors in this thesis (I-1,I- 7,I- 
8,I- 9 and I-10) that are based on this scaffold.  
 
As seen in Figure 5.3, these related inhibitors differ, with all of them containing the 
core heterocyclic ring structure – that is reportedly ‘boat’ conformer – followed by 
an additional benzene ring. IC50 data from our collaborators defines the main off-
targets of these particular inhibitors as ERK5, AURKA and AURKB, LRRK2 and 
NUAK1. As AURKA (Aurora kinase A) inhibition leads to mitotic arrest in a large 
number of cases (Gorgun et al., 2010, Zhou et al., 2013), it would be important to 
attempt to “dial out” this effect if possible using the structural data to steer a further 
round of scaffold modification. Our main focus was therefore to compare the S1 
type inhibitors bound to RET KD with IC50 data from our collaborators and thermal 
shift assay data detailed below, to identify key substituents required for RET 
specificity. 
 
PP1, I-4 and PP242 were based on scaffold 2 (S2): pyrazolopyrimidine, a 
heterocyclic compound with a molecular formula of C6H5N3 (Figure 5.4). 
Pyrazolopyrimidines are also a class of sedative drugs, with many examples of 
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their use targeting kinases (Antonelli et al., 2011, Peat et al., 2004, Carlomagno et 
al., 2002b).  
 
5.4 S2 inhibitors are based on the pyrazolopyrimidine scaffold 
Chemical structures of S2, PP1, I-4 and PP242 are shown. 
 
PP1 was originally identified as a Src inhibitor (Hanke et al., 1996), and was then 
shown to inhibit the growth of human papillary thyroid carcinoma cell lines 
containing the RET/PTC fusion oncogene, and target MEN2A and B oncogenic 
forms of the receptor (Carlomagno et al., 2002b). The structure of RET KD bound 
to PP1 has already been elucidated (PDB code 2IVV) and has shown that this S2 
ring system mimics the adenosine position of ATP, forming hydrogen bonds with 
the main chain atoms of Glu805 and Ala807 of the RET KD hinge region. PP242 
was originally identified as an inhibitor of mTOR (mammalian Target Of 
Rapamycin), which resulted in the inhibition of Akt phosphorylation (Feldman et al., 
2009). Further investigation found that PP242 displayed potent cellular activity 
against RET and JAK family kinases (Liu et al., 2012). The benzene ring is 
predicted to extend into the interior pocket (defined in Figure 5.1). I-4 is one of a 
series of pyrazolopyrimidine compounds designed specifically to target RET kinase 
activity (Diner et al., 2012). I-4 was found to inhibit GFNF-induced RET activation of 
ERK1/2 in MC-7 breast cancer cells at a concentration of 100 nM. I-4 and PP242 
were anticipated to bind in a similar way to PP1, but the longer linker and added 
substituents on each compound could push further into the back of the RET ATP 
pocket up to and including residue Glu775.  
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Sunitinib and the compounds X2K, X2L and X2M all contain a 2-oxo-1H-indolinone 
core scaffold (S3) (Figure 5.5). Indolinones are a popular scaffold for kinase 
inhibition, with a number of inhibitors designed for kinases such as VEGFR, FGFR, 
PGFR and RET (Prakash and Raja, 2012). Sunitinib itself is marketed as Sutent® 
and is FDA-approved for the treatment of kidney cancer, pancreatic 
neuroendocrine tumours and gastrointestinal stromal tumours (GIST). Interestingly, 
Sunitinib was found to preferentially inhibit the non-phosphorylated DFG-out 
conformation of the RTK c-KIT (Gajiwala et al., 2009), while there appeared to be 
no preference between non- and phosphorylated RET KD (Dr Kerry Goodman, 
unpublished). The crystal structures of RET KD bound to each of these compounds 
has been elucidated: Sunitinib:RET KD was solved by Kerry Goodman and is 
currently unpublished; X2K, X2L and X2M structures can be found under the PDB 
codes 2X2K, 2X2L and 2X2M respectively (Mologni et al., 2010).  
 
 
Figure 5.5 S3 inhibitors are based on 2-oxo-1H-indolinone scaffold 
Chemical structures of  S3, sunitinib, X2K, X2L and X2M are shown 
 
Vandetanib (marketed under its trade name Caprelsa) and I-3 are based on the 4-
anilinoquinazoline compound, referred to as scaffold 4 (S4) (Figure 5.6). This 
scaffold has been successfully used to inhibit several kinases, and has been 
reported to inhibit EGFR (Zhao et al., 2013). Vandetanib is FDA approved to treat 
medullary thyroid carcinoma and inhibits RET, but also targets the EGFR and 
VEGFR kinases (Carlomagno et al., 2002a, Thornton et al., 2012). I-3 was 
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synthesised by our collaborator at the Paterson Institute (Table 5.1) and was 
predicted to bind in a similar mode to Vandetanib, but could use the additional 
hydroxyl group to reach into the back pocket towards Glu775.  
 
 
Figure 5.6 S4 inhibitors are based on the 4-anilinoquinazoline scaffold 
Chemical structures of the scaffold, Vandetanib and I-3 are shown 
 
Pz-1 and BMS-536924 are known in this thesis as scaffold 5 (S5) inhibitors, due to 
the presence of a phenyl-benzimidazole ring in both (Figure 5.7). BMS-536924 is a 
commercially available IGFR inhibitor (Wittman et al., 2005), while Pz-1 has been 
designed by collaborators in Arizona to target RET as a DFG-out inhibitor (the 
structure of Pz-1 is currently confidential). As mentioned in the thesis introduction, 
the conserved DFG motif must be in the active DFG-in conformation in order for the 
aspartate to coordinate magnesium binding. Type II inhibitors force this motif into a 
catalytically incompetent DFG-out conformation (Liu and Gray, 2006). The 
scaffolds are presented together in Figure 5.8.  
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Figure 5.7 S5 inhibitor based on the phenyl-benzimidazole scaffold 
Chemical structures of S5 and BMS-536924 are shown. The chemical structure of Pz-1 is 
currently confidential. 
 
 
 
 
Figure 5.8 Scaffolds 1-5 
 
5.3 RET KD production 
5.3.1 Sequence alignment of RET intracellular domains 
Alignment of the RET intracellular domain (RET-ICD) amino acid sequences from 
mammalian and lower vertebrate species (Figure 5.9) shows very high sequence 
conservation throughout. The most divergence is observed within the glycine and 
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serine rich kinase insert of the KD, which has been removed from the RET KD 
used for structural studies.  
 
 
Figure 5.9 Alignment of vertebrate RET-ICD amino acid sequences 
Jalview alignment of three higher (human, rat and mouse) and three lower (Xenopus, chicken 
and zebrafish) vertebrate RET-ICDs. Completely conserved residues are purple, with similarity 
correlating to the shade of purple. Secondary structural elements and domain boundaries are 
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annotated above the sequence, as observed in the RET KD crystal structure. Key structural 
elements are highlighted. Alignment carried out using TCoffee.  
 
5.3.2 RET KD protein expression and purification 
A detailed protocol had been previously developed in the laboratory for the 
expression of human recombinant RET KD in insect cells using baculovirus 
technology. Yields of approximately 1-2 mg/litre from Hi5 or Sf9 cells were routinely 
obtained. The baculovirus construct used throughout made use of a codon-
optimised (for insect cell expression) synthetic gene for hRET KD, spanning 
residues 705-1013, removing the highly flexible kinase insert (residues 827-840). 
The protein was produced with an N-terminal glutathione S-transferase (GST) 
affinity tag and a 3C protease site within a connecting linker. Purified RET KD 
produced in insect cells is not phosphorylated, so generating a fully active 
phosphorylated RET (pRET) required the addition of ATP and magnesium to 
trigger trans-phosphorylation. Trans-phosphorylation was performed while RET KD 
was still attached to the glutathione resin upon addition of 5 mM ATP and 10 mM 
MgCl2 for 6 hours at 4°C. The ATP and MgCl2 were then removed by washing of 
the resin, before adding 3C protease.  The protein eluate was judged pure by SDS-
PAGE (Figure 5.10a), and was known to crystallise without further purification. To 
readily visualise whether the RET KD was phosphorylated, the molecular weight of 
RET KD was compared to of pRET KD using SDS-PAGE (Figure 5.10b), with the 
more acidic pRET KD migrating slower. Previous work in the lab using Western blot 
analysis with anti-phospho-Tyrosine antibodies has shown RET to be fully 
phosphorylated under these conditions.  
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Figure 5.10 RET KD expression, purification and phosphorylation 
(A) SDS-PAGE analysis of RET KD expression and purification. (B) SDS-PAGE analysis of 
RET KD phosphorylation, indicated by a slight upwards shift in protein band location.  
 
5.4 Biochemical analysis of inhibitor potency 
5.4.1 Examining RET inhibitor potency using differential scanning 
fluorimetry 
Monitoring the thermal stability of a protein kinase in the presence of a range of 
chemical inhibitors is becoming a facile method for examining inhibitor potency. 
The process, known as differential scanning fluorimetry (DSF), utilises a 
fluorescent dye to track the thermal unfolding of a protein. The dyes used are more 
fluorescent in nonpolar environments, such as those accessible in the hydrophobic 
regions of unfolded proteins, when compared to the aqueous solution of stable 
protein. SYPRO orange is the fluorescent dye used in this thesis to examine RET 
KD stability, and was chosen because of its high signal-to-noise ratio and high 
excitation wavelength. A high excitation wavelength reduces the risk of the 
aromatic inhibitors interfering with the fluorescent signal and distorting the unfolding 
curve detected. This method identifies shifts in protein thermal stability and is 
known as the thermal shift assay (TSA) (Niesen et al., 2007, Vedadi et al., 2006).  
 
In order to determine the melting temperature of a protein (Tm), the fluorescence 
intensity is plotted as a function of temperature. This generates a two-state 
transition sigmoidal curve, from which the inflection point (Tm) can be calculated 
using the Boltzmann equation in GraphPad Prism (R
2
 values of > 0.99). In order to 
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examine the influences different inhibitors have on RET KD stability, the shift in Tm 
(ΔTm) has been plotted and examined (Niesen et al., 2007).  
 
A pilot TSA trial was carried out with RET KD protein at increasing concentrations 
in the absence of any inhibitor (Figure 5.11a). A prominent increase in fluorescence 
intensity could be observed as the temperature was increased from 25°C to 90°C. 
While the fluorescence intensity signal was amplified at a higher protein 
concentration of 0.4 mg/ml, 0.05 mg/ml was chosen for future assays, due to the 
feasibility of testing a large array of inhibitors at a sufficient (n=3) number of 
replicates and concentrations. As seen in Figure 5.11b, a large increase in 
fluorescence intensity – with a clear curve that could be used for calculating the Tm 
– can be observed at 0.05 mg/ml when the data is isolated.  
 
 
Figure 5.11 Pilot TSA analysis of RET KD protein alone 
(A) The fluorescent properties of SYPRO Orange dye binding to RET KD protein was recorded 
at increasing concentrations of protein. (B) Example of raw and trimmed data curves with a 
protein concentration of 0.05 mg/ml. Data presented in (A) and (B) are from separate 
experiments.  
 
Pilot experiments showed that RET KD thermal stability could be examined using 
the TSA. Therefore, the protein stability was probed by TSA after addition of the 
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inhibitor at a concentration of 1 μM. Although the protein was prepared and purified 
in a phosphorylated state, ATP and MgCl2 (at 5 mM and 10 mM respectively) were 
added to RET KD as a separate control.  After an incubation of 2 hours at 4°C, the 
SYPRO Orange dye was diluted 1:100 in purification buffer and added to each 
protein sample at a ratio of 1:20. The TSA was then carried out using a Real-Time 
PCR instrument, increasing the temperature of the rtPCR plate containing the 
protein from 25°C to 90°C over a period of 2 hours. For these particular 
experiments, RET KD was purified in HEPES buffer rather than Tris, as HEPES 
buffer can remain at a stable pH over the range of temperature involved.  
 
The Relative Fluorescence Units (RFU) were plotted against the temperature, with 
the sigmoidal curve truncated at the bottom and top of the 1
st
 slope in the two-state 
transition, defining the minimum and maximum intensities (Figure 5.11b). The Tm of 
RET KD in the presence of ATP or inhibitor was calculated using the Boltzmann 
equation and subtracted from the Tm of the RET KD alone, creating a ΔTm (Figure 
5.12a). In order to visualise these data, the RET KD ΔTm values have also been 
plotted as individual scaffolds (Figure 5.12b).  
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Figure 5.12 TSA analysis of the RET KD in the presence of ATP or inhibitors 
(A) The shift in thermal stability (ΔTm) of RET KD when incubated with ATP or each inhibitor. 
ΔTm is calculated by subtracting the Tm of the RET KD alone (KD con) from each individual Tm. 
Standard deviation (S.D) bars are shown from n=3 experiments. Each experiment contained 
four repeats of each condition. Data was analysed in Prism. (B) ΔTm of RET KD in the presence 
of each additive divided into scaffolds 1, 2, 4 and 5. Conditions with ΔTm values that are 
significantly higher than ATP (one-way ANOVA, P<0.005) are highlighted. All inhibitors 
excepting 1, 7, 9 and 10 gave ΔTm values significantly higher than the KD alone control (one-
way ANOVA, P<0.005).  
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Surprisingly, adding ATP and magnesium to RET KD caused a large shift in 
thermal stability (Figure 5.12a). As the ATP within the active site will have been 
hydrolysed to ADP or AMP during protein purification, this suggests that the RET 
KD has a higher affinity for ATP than ADP or AMP, resulting in an exchange of 
ligand and an increase in thermal stability. Future investigations should include 
ADP and AMP in the assay. Thermal stability is significantly higher in the presence 
of ATP than with cyclic AMP (cAMP) (Figure 5.12b); cAMP was tested in the assay 
due to its reported presence within the RET nucleotide-binding pocket in 
unsuccessful RET KD-compound crystallisation trials. The higher stability induced 
by ATP may be due to a higher affinity towards RET KD or the fact that ATP bound 
within the pocket will stabilise the C-spine. A lack of thermal shift can suggest one 
of two things: the inhibitor has not bound to the kinase, or the inhibitor has not 
affected the stability of the protein.   
 
S1 inhibitors all induced a thermal shift less than that of ATP and only I-8 gave an 
increase in thermal stability significantly higher than the KD alone control (Figure 
5.12). Statistical analysis was carried out using the ordinary one-way ANOVA 
statistical test, in order to make multiple comparisons between the datasets. The 
observation that most S1 inhibitors do not induce a significant ΔTm contradicts the 
assumption that a lack of positive ΔTm indicates a lack of binding, as I-7, I-9 and I-
10 were also captured in crystal forms bound to the RET KD. It does however give 
some indication of whether a complex should be taken forward for crystallisation 
trials, as I-5, I-6 and I-11 have the lowest ΔTm and could not be captured within the 
active site and were unable to displace the cAMP that is presumed endogenous, 
co-purifying with the RET KD from insect cells. Reasons behind the lack of binding 
of I-5, I-6 and I-11 will be discussed later in this chapter when RET KD-Inhibitor 
structures have been presented. As the S1 inhibitor giving the largest effect, I-8 is 
also the only compound from those tested that does not contain a trifluoromethyl 
group at the end, suggesting that its presence may hinder binding. I-10 was the 
least effective at inducing a thermal shift from those captured within the active site, 
which may be due to the extra five-membered ring within the heterocyclic core.  
 
S2 inhibitors appear more effective at inducing a shift in thermal stability than S1, 
with ΔTm values closer to that of ATP and all compounds found to be significantly 
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different to the KD alone (Figure 5.12). This may be due to the fact that the 
pyrazolopyrimidine scaffold is very similar to the core adenosine structure of ATP, 
but with bulky substituents extending from the N1 position. I-4 induces a higher 
thermal shift than PP1, with the main difference between the two inhibitors being 
the extended triple bond between the pyrazolopyrimidine scaffold and the benzene 
ring in I-4, which should extend further back into the interior pocket. PP242 appears 
to be the most effective out of the S2 inhibitors, inducing the highest ΔTm. Again, 
based on the structure of this compound, it may extend further into the interior 
pocket. This may be causing an increase in RET KD stability and also may be – if 
interacting with residues in the αC-helix – inducing a slight change in the 
conformation of the αN helix.  
 
Attempts to monitor the ΔTm of RET KD in the presence of Sunitinib were 
unsuccessful, despite using the protocol (identical to that of the other inhibitors) for 
incubating RET KD with sunitinib defined by Dr Kerry Goodman during 
crystallisation. This may be due to the auto-fluorescent properties of Sunitinib 
interfering with the measurements. X2K, X2L and X2M were not included in the 
assay as they were not available at the time of the experiment. Future 
investigations should include these inhibitors.  
 
S4 inhibitors, I-3 and Vandetanib, had a substantial effect on the thermal stability 
compared to the KD alone (Figure 5.12). The higher ΔTm of RET KD-I-3 could be 
due to several key differences between the two inhibitors. Firstly, I-3 contains a 
phenol group that could potentially push into the back of the ATP pocket and 
interact with Glu775 or the water molecule that is often seen close to this key αC-
helix residue; as opposed to the benzene ring with a fluoride and bromine attached. 
Alternatively, this higher stability could be due to the lack of a hydrogenated 
pyridine group at the other end of the compound. Within the RET KD-Vandetanib 
structure (PDB code 2IVU), this substituent – often added to improve solubility – 
forms hydrogen bonds with a water molecule and sits slightly outside of the pocket 
– as seen for the trifluoromethyl groups of the less effective S1 inhibitors.  
 
Sorafenib was included in the S5 inhibitors, along with Pz-1 and BMS-536924. 
Sorafenib is a DFG-out compound and has a rather similar structure to the S5 
Chapter 5. Results 
 
 149 
inhibitors (Figure 5.13). All three compounds have an extended shape and are 
composed of multiple ring systems. The RET KD thermal stability was increased by 
a remarkable amount when incubated with Sorafenib, which is indicative of a 
conformational change within the protein (Figure 5.12). Pz-1 induced a thermal shift 
of almost 20°C, suggesting that it too induces a conformational change similar – if 
not equal – to Sorafenib and is also likely to be a type II inhibitor stabilising a DFG-
out conformer. These two inhibitors were the only compounds to induce a ΔTm 
significantly higher than that of RET KD-ATP. This suggests that TSA is a facile 
and quick method to distinguish between DFG-in and DFG-out inhibitors in solution.  
 
 
Figure 5.13 Comparisons of the BMS-536924 (S5) and Sorafenib chemical 
structures 
5.4.2 Inhibitory effects of each compound on RET tyrosine kinase activity 
The inhibitory activity of each compound is measured using the maximal inhibitory 
concentration (IC50) value against a particular target. I have collated data both from 
published work and collaborators for each of the inhibitors in S1, 2, 4 and 5. Table 
5.2 shows IC50 values for each S1 compound against RET, V804L RET (oncogenic 
gatekeeper mutant) and known off-target kinases, along with data on PP242 and 
BMS-536924. These data are displayed together as the same collaborator 
contributed them: Dr. Nathanael Gray, Harvard Medical School. Table 5.3 shows 
IC50 values for I-4 and PP1 (S2), Vandetanib (S3), and Sorafenib and Pz-1 (S5) 
against RET and the V804M mutant. These data are collated from published work, 
with references provided.  
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Table 5.2 In vitro IC50 data for S1 compounds, PP242 and BMS-536924 against 
RET and off target kinase 
IC50 data obtained from our collaborators (Dr Nathanael Gray, Harvard Medical School) 
investigating the ability of each S1 compound to inhibit RET, the gatekeeper mutant of RET 
(V804L), and their main off targets: AURKA, AURKB, LRRK2 (G2019S) and NUAK1. 
 
In the case of S1 compounds, the ΔTm of the RET KD bound to each correlates 
with the inhibitory activity (Table 5.2). The most effective inhibitor (I-8) also has the 
lowest IC50 value of 36.4 nM against RET, while the ineffective inhibitors (I-5, I-6 
and I-11) had IC50 values of over 10 μM. One of the current problems with this 
group of inhibitors is that RET potency tracks AURKA activity: reducing off-target 
potency also results in a loss of potency towards RET. PP242 is very potent 
against RET (2.84 nM, Table 5.2), with much lower potencies for the AURKA/B off-
target kinases. Interestingly, PP242 and I-4 have very similar potencies toward 
RET, while PP1 is approximately 10-fold less effective (80 nM, Table 5.3). This also 
correlates with TSA data (Figure 5.12b), as I-4 induces the lowest shift in thermal 
stability. This may be due to the fact that both PP242 and I-4 are chemically 
extended and should push further into the interior pocket of the nucleotide-binding 
region towards Glu775. It is worth noting that all S2 inhibitors lose potency towards 
the gatekeeper mutant forms of RET (V804L/M), as the mutation at this position 
into a bulky residue will occlude access to the interior pocket. Vandetanib also 
loses potency against the gatekeeper mutant.  
Harvard collaborators
Target IC50 (nM)
Inhibitor RET RET (V804L) AURKA AURKB LRRK2 (G2019S) NUAK1
1 107 47.1 10.3 231 15.3 96.3
5 >10000 >10000 >10000 >10000
6 >10000 >10000 >10000 >10000
7 207 127 28.1 378 5.47
8 36.4 10.1 7.17 25.9 14 27.2
9 239 159 34.1 806
10 668 382 12 182
11 >10000 >10000 >10000 >10000
PP242 2.84 394 3540 3150
BMS-536924 6.77 2.24 312 639
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Table 5.3 In vitro IC50 data for inhibitors against WT and V804M RET 
Inhibitory activity of I-4, PP1, Vandetanib, Sorafenib and Pz-1 against wild type RET and the 
gatekeeper mutant V804M. References for the original data are shown.  
 
Interestingly, all S5 compounds (BMS-536924, Pz-1 and Sorafenib) are very potent 
against both WT and V804L/M RET – again, correlating with TSA data for WT RET. 
Pz-1 induced the largest shift in thermal stability, and is the most potent inhibitor 
against RET yet described (data obtained from our collaborator, Dr Hong Yu-Li, 
University of Arizona). While IC50 data collated from different sources should be 
validated within the laboratory in near future investigations, there is a clear 
correlation between inhibitor activity against RET and elicited effect on protein 
thermal stability (Figure 5.14). This correlation has been previously reported in the 
literature and could prove useful in future high throughput investigations (Fedorov 
et al., 2007, Slaymaker et al., 2008).  
 
Published IC50 data 
Target IC50 (nM)
Inhibitor RET RET (V804M) Reference
I-4 8 - Diner et al., 2014
PP1 80 5000 Carlomagno et al., 2002a & 2004
Vandetanib 100 5000 Carlomagno et al., 2002b & 2004
Sorafenib 5.9 7.9 Plaza-Menacho et al., 2007
Pz-1 <1 <1 Unpublished
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Figure 5.14 Correlation between RET KD IC50 values and ΔTm enhancement after 
incubation with each inhibitor 
Log-transformed IC50 values (from nM to μM concentrations) for each inhibitor against RET (x) 
are plotted against the shift in thermal stability of the RET KD in the presence of each 
compound (y). There is clear correlation between induced thermal stability and the inhibitor 
potency. (Correlation coefficient of -0.8995).  
 
5.5 RET KD crystallisation with inhibitors 
In order to structurally characterise the binding of each inhibitor to the RET KD, co-
crystallisation experiments were carried out. Each inhibitor was dissolved in DMSO 
and added to purified pRET KD at a 3:1 inhibitor:protein molar ratio in solution. The 
inhibitor:protein solution was incubated at 4°C for 2 hours to allow binding, before 
concentrating to 3-5 mg/ml for crystallisation.  
 
RET KD was previously crystallised in the presence of sodium acetate buffer and 
formate (Knowles et al., 2006), so this condition was used as a starting point for 
crystallisation by vapour diffusion. The protein-inhibitor complex was plated in 96 
well trays with a range of formate concentrations and with MES or acetate buffer at 
varying pH to identify the optimal crystallisation condition for each compound. The 
exact crystallisation condition for each inhibitor is detailed in Table 5.4. The crystals 
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obtained took the form of stacked square plates, with further optimisation leading to 
thicker single plates (Figure 5.15a). 
 
 
Table 5.4 Crystallisation conditions for each RET KD:ligand structure 
5.5.1 RET KD-inhibitor structure determination 
Crystals for each inhibitor ranged between 30 and 120 μm in size and were cryo-
protected in perfluoropolyether (PFPE) oil (Hampton Research) before flash-
freezing in liquid nitrogen. The crystals were screened at either the Diamond Light 
Source (DLS) or the European Synchrotron Radiation Facility (ESRF) and data was 
collected on crystals diffracting to at least 2.6 Å (example diffraction shown in 
Figure 5.15b). Data collection statistics for each inhibitor can be found in Table 5.5.  
 
 
Scaffold Ligand Buffer Sodium formate (M) Additive
- ADP 0.1 M Sodium acetate pH 4.8 3.3 3% (v/v) Ethanol
1 I1 0.1 M MES pH 5.1 3.1 0.2 M Lithium chloride
I7 0.1 M MES pH 5.8 2.7 3% (w/v) Trimethylamine N-oxide
I8 0.1 M MES pH 5.9 3.2
I9 0.1 M MES pH 5.9 3 0.01 M Cobalt (II) chloride
I10 0.1 M MES pH 5.9 2.8
2 I4 0.1 M MES pH 5.2 3
I18 0.1 M MES pH 5.5 3.3
4 I3 0.1M Sodium acetate pH 4.4 3.4
5 I19 0.1 M MES pH 6.0 3.8
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(A) Stacked crystal plates were grown in acetate/formate conditions (top), before optimisation 
into single plates grown in formate with MES or acetate buffer (bottom). (B) Example of 
diffraction images collected at a resolution of 2.15 Å that were used in structure determination.  
 
 
 
Table 5.5 Data collection statistics for each RET KD-ligand dataset 
RETKD:ADP RETKD:I1 RETKD:I7 RETKD:I8 RETKD:I9
X-ray source DLS DLS DLS DLS DLS
Wavelength / Å 0.97 0.92 0.98 0.92 0.98
Space group C2(C121) C2(C121) C2(C121) C2(C121) C2(C121)
Unit cell dimensions
a, b, c / Å 72.85, 69.43, 78.92 73.19, 69.89, 79.42 73.09, 69.76, 79.20 72.97, 70.68, 79.26 72.7, 69.73, 79.28
α, β, γ / ° 90.00, 102.13, 90.00 90.00, 102.89, 90.00 90.00, 103.14, 90.00 90.00, 102.24, 90.00 90.00, 103.18, 90.00
Resolution / Å 35.28 - 2.21 77.42 - 2.00 49.82 - 1.95 16.88 - 2.65 39.03 - 1.70
(Outer resolution shell) /  Å (2.27 - 2.21) (2.05 - 2.00) (2.00 - 1.95) (2.72 - 2.65) (1.74 - 1.70)
No. of unique reflections 19032 25956 27785 11338 40841
Redundancy 2.9 (2.6) 3.0 (3.0) 2.5 (2.5) 3.5 (3.6) 3.0 (2.0)
Completeness / % 98.2 (95.9) 98.2 (97.8) 98.1 (97.5) 98.4 (99.2) 96.3 (73.5)
CC(1/2) (outer shell) 0.596 0.558 0.573 0.493 0.52
I/σ 1.8 1.1 1.4 1.2 1.1
Rmerge / % 8.6 (66.6) 12.4 (87.1) 5.5 (68.1) 17 (89.7) 4.2 (75.4)
Rp.i.m / % 5.9 (50.1) 8.3 (58.2) 4.2 (51.2) 10.7 (64.9) 2.8 (60.9)
RETKD:I10 RETKD:I4 RETKD:PP242 RETKD:I3 RETKD:BMS-536924
X-ray source DLS DLS DLS DLS DLS
Wavelength / Å 0.98 0.92 0.92 0.98 0.98
Space group C2(C121) C2(C121) C2(C121) C2(C121) P4(P41212)
Unit cell dimensions
a, b, c / Å 72.87, 69.56, 79.28 73.2, 70.28, 79.53 72.75, 71.31, 79.85 73.85, 70.22, 158.78 50.23, 50.23, 236.81
α, β, γ / ° 90.00, 102.92, 90.00 90.00, 102.86, 90.00 90.00, 102.71, 90.00 90.00, 102.91, 90.00 90.00, 90.00, 90.00
Resolution / Å 49.70 - 1.80 39.36 - 2.60 50.30 - 2.26 51.56 - 2.45 50.23 - 2.3
(Outer resolution shell) /  Å (1.85 - 1.80) (2.67 - 2.6) (2.32 - 2.26) (2.51 - 2.45) (2.36 - 2.30)
No. of unique reflections 35417 48525 17865 15057 14470
Redundancy 3.0 (.2.6) 4.0 (4.1) 2.9 (3.0) 6.8 (6.7) 7.5 (7.6)
Completeness / % 98.9 (93.8) 99.0 (96.3) 95.5 (91.0) 99.7 (98.6) 100.0 (100.0)
CC(1/2) 0.581 0.641 0.712 0.551 0.619
I/σ 1.5 1.3 2 0.9 1.9
Rmerge / % 5.4 (67.9) 10.5 (91.3) 8.6 (54.1) 12.7 (72.3) 9.5 (112.1)
Rp.i.m / % 3.7 (49.6) 5.8 (66.3) 6.1 (37.3) 14.8 (65.5) 3.7 (43.0)
Figure 5.15 Crystallisation and structural determination of RET KD-inhibitor 
complexes 
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5.5.2 Data processing, structure solution and refinement 
I processed the data and refined the structures for all inhibitors except 9 and 10, 
which were processed by Dr Andrew Purkiss. The datasets were processed using 
the program Xia2 (Winter et al., 2013), using option “3daii” which utilises software 
programs XDS for indexing and integration (Kabsch, 2010), XSCALE for scaling 
and Aimless for merging (Evans and Murshudov, 2013).  The datasets with the 
same cell dimensions (all except I-3 and BMS-536924) were processed with a 
consistent Rfree set copied from the first dataset (I-1). Xia2 confirmed the 
spacegroup for each inhibitor using the program POINTLESS (Evans, 2006), with 
the majority being monoclinic C2, but a tetragonal cell space group P43212 was 
found for BMS-536924. Cell content analysis using the Matthews coefficient 
program in CCP4 indicated the number of molecules in the asymmetric unit (one 
molecule for all inhibitor structures except I-3, in which there were two molecules) 
(Matthews, 1968, Kantardjieff and Rupp, 2003). Each structure was solved by 
molecular replacement with PHASER (McCoy et al., 2007), using the pRET KD-
adenosine structure with the GRL and vector-derived N-terminal helix removed, to 
reduce initial model bias.  Each structure was refined using Phenix.refine and 
model building was carried out in COOT (Emsley and Cowtan, 2004). Initial 
refinement was carried out for approximately four rounds, before TLS (translation, 
libration, screw rotation) groups were added (N-terminal helix 700-712; N-lobe 716-
808; C-lobe 809-1013) to refinement. These groups allowed separate correlated 
motions of each defined subdomain, within the RET KD, to be modelled via 
temperature factors. The inhibitors were fitted into positive density after several 
rounds of refinement, to ensure optimal positive density within the active site after 
the kinase domain structure itself had been modelled. Final refinement statistics for 
each inhibitor can be found in Tables 5.6, with the electron density surrounding 
each ligand shown later.  
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Table 5.6 Refinement statistics for each of the RET KD-ligand datasets 
 
 
 
 
 
RETK:ADP RETKD:I1 RETKD:I7 RETKD:I8 RETKD:I9
Resolution / Å 35.277 - 2.21 77.42 - 2.00 49.82 - 1.95 16.88 - 2.65 39.03 - 1.70
(Outer resolution shell) /  Å (2.27 - 2.21) (2.05 - 2.00) (2.00 - 1.95) (2.72 - 2.65) (1.74 - 1.70)
Completeness / % 98.2 (95.9) 98.2 (97.8) 98.1 (97.5) 98.4 (99.2) 96.3 (73.5)
No. of unique reflections 19032 25956 27785 11338 40841
Rwork / % 17.23 (33.67) 18.76 (27.4) 17.07 (26.26) 20.39 (30.06) 18.67 (35.49)
Rfree / % 23.11 (40.97) 22.96(34.03) 21.06 (28.07) 23.31 (33.00) 21.42 (40.92)
Total protein atoms 2204 2276 2274 2241 2232
Total ligand atoms 39 39 29 32 36
Total solvent atoms 93 153 110 74 25
Wilson B factor 36.00 29.52 33.52 37.94 28.66
B-factor (Å2)
Protein 35.87 34.04 38.87 43.02 34.17
Ligand 88.6 41.87 36.62 36.95 36.44
Water 46.25 44.13 50.45 38.55 43.54
Ramachandran Plot / %
Favoured 97.57 98.64 98.32 97.91 98.29
Allowed 2.43 1.36 1.68 2.09 1.37
Outliers 0 0 0 0 0.34
RMSD from ideal values
Bonds /  Å 0.013 0.006 0.014 0.002 0.007
Angles / ° 1.326 0.913 1.528 0.625 1.183
No. of TLS groups 3 3 3 3 3
RETKD:I10 RETKD:I4 RETKD:PP242 RETKD:I3 RETKD:BMS-536924
Resolution / Å 49.70 - 1.80 39.36 - 2.60 50.30 - 2.26 51.56 - 2.45 50.23 - 2.3
(Outer resolution shell) /  Å (1.85 - 1.80) (2.67 - 2.6) (2.32 - 2.26) (2.51 - 2.45) (2.36 - 2.30)
Completeness / % 98.9 (93.8) 99.0 (96.3) 95.5 (91.0) 99.7 (98.6) 100.0 (100.0)
No. of unique reflections 35417 48525 17865 15057 14470
Rwork / % 19.15 (26.14) 22.36 (37.36) 18.23 (26.22) 25.09 (31.27) 19.76 (25.28)
Rfree / % 21.62 (30.35) 24.08 (37.47) 23.56 (32.29) 28.49 (40.68) 24.46 (32.71)
Total protein atoms 2193 2129 2206 2156 (mol A) 2135
Total ligand atoms 59 (2 conformations) 21 23 24 34
Total solvent atoms 36 43 128 28 49
Wilson B factor 26.43 55.35 36.06 38.39 44.04
B-factor (Å2)
Protein 31.46 60.42 39.2 45.7 (mol A) 48.59
Ligand 44.9 53.05 34.18 35.47 (mol A) 84.78
Water 30.27 57.75 44.41 29.95 55.23
Ramachandran Plot / %
Favoured 98.23 94.74 97.21 96.36 98.6
Allowed 1.41 4.91 2.79 3.1 1.4
Outliers 0.35 0.35 0 0.55 0
RMSD from ideal values
Bonds / Å 0.008 0.002 0.003 0.003 0.002
Angles /  ° 1.213 0.73 0.927 0.732 0.624
No. of TLS groups 3 3 3 3 3
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5.6 Overall description of the RET kinase-inhibitor structures 
All of the structures presented in this thesis show the same overall arrangement of 
N- and C-lobes: the smaller N-lobe consisting of a β–sheet comprised of five anti-
parallel β-strands (β1-5) with the αC helix between strands β3 and β4 (within the 
amino acid sequence), the flexible GRL lining the top of the active site, and a larger 
helical C-lobe (Figure 5.16).  
 
RET KD also has an N-terminal helix called αN, which contains five vector-derived 
residues (GPLSL) and 6 de novo residues (SVDAFK). The vector derived residues 
are not similar to those found in full-length RET, so it is unclear as to whether this 
helix is present in full-length RET. The linker (I711 to P715) connecting the αN-helix 
to the KD is often disordered.  
 
 
Figure 5.16 Superposition of KD structures solved in this thesis 
 (A) Ribbon view of aligned RET KD structures solved in this thesis. I-1 – ice blue; I-3 – light 
brown; I-4 – sea green; I-7 – gold; I-8 – coral; I-9 – grey; I-10 – pink; PP242 – lilac; BMS-
536924 – lemon; ADP – lawn green. (B) Side view of the RET KD, highlighting the positions of 
the αN-helix, αC-helix, the Gly-loop and the ATP pocket (surface view of PP1 inhibitor (PDB 
code 2IVV)).   
 
The main difference between the structures maps to the GRL, already known to be 
highly flexible and found on top of the nucleotide-binding pocket. While the majority 
of the structures contained a “closed” GRL conformation (including RET KD-ADP), 
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RET KD-I-3 had a more open conformer (approximately 1.25 Å above RET KD-
ADP, as measured between the backbones of Glu734 in each structure) and the 
RET KD-PP242 GRL was found to be even further open (approximately 4 Å at the 
widest point, again between the backbones of Glu734) (Figure 5.17a). The loop 
preceding the αC helix also has a different conformer depending on the inhibitor 
bound (Figure 5.17c). In the RET KD-PP242 structure, the Phe735 in the GRL has 
a different side chain rotamer, pointing away from the nucleotide-binding pocket, 
while all other structures show this residue pointing towards the pocket. This shift in 
rotamer may be due to the relative position of Lys758, which has also shifted to 
point towards the GRL, thus breaking the conserved salt bridge between itself and 
Glu775. While not as notable, the position of Lys758 appears to be coupled to the 
position of Phe735 for all structures. A change in the rotation along the Cα-Cβ axis 
of Lys758 (either towards or away from the GRL) induces a relative shift in the 
position of Phe735 (Figure 5.17b). It is also possible that the Phe735 is positioning 
Lys758 into an active conformer, rather than the opposite. 
 
 
Figure 5.17 Comparisons of Phe735 and Lys758 side chain positions 
(A) Close-up view of aligned RET KD structures solved in this thesis, with side chain positions 
of Phe735 and Lys758 highlighted. I-1 – ice blue; I-3 – light brown; I-4 – sea green; I7 – gold; I-8 
– coral; I-9 – grey; I-10 – pink; PP242 – lilac; BMS-536924 – lemon; ADP – lawn green. (B) 
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Alternate view of aligned structures with side chain positions of Phe735 and Lys758 highlighted. 
(C) Differences in the loop formation preceding the αC helix. 
 
5.7 Overall description of the RET kinase-ADP complex 
During protein purification and crystallisation, I attempted to crystallise the RET KD 
with Sorafenib, as the DFG-out form of RET has not been captured thus far. The 
process was identical to that with other inhibitors, in that the KD was incubated with 
ATP and magnesium before washing and cleavage from the GST resin. After 
incubation with Sorafenib at 3:1 molar excess and concentration to approximately 3 
mg/ml, crystallisation trays were set up with the original formate/acetate conditions. 
Crystals were produced (Figure 5.18a), cryo-protected in PFPE oil and flash frozen. 
Data was collected at Diamond Light Source, in the usual C2 space group and 
diffraction to 2.1 Å was observed (Figure 5.18b).  
 
 
Figure 5.18 Crystallisation and data collection of the RET KD-ADP complex 
(A) Crystal plates obtained in formate/acetate condition, believed at this point to be the RET 
KD-Sorafenib complex. (B) Example of diffraction images collected at a resolution of 2.1 Å that 
were used in structure determination. 
 
However, after processing and initial refinement, the density within the nucleotide-
binding pocket clearly did not correspond with the structure of Sorafenib. ATP was 
placed within the density, before being replaced with ADP due to poorly defined 
density surrounding the γ-phosphate. It is possible that the crystal contains multiple 
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occupancies of ATP and ADP, as the ATP is hydrolysed to ADP. Crystals from the 
same drop were taken to the synchrotron again after one month, resulting in the 
collection of a 2.1 Å dataset. In this particular crystal, only adenosine was found 
within the nucleotide-binding pocket, which validated the presence of ADP within 
the original crystal and confirmed its susceptibility to hydrolysis.  
 
ADP extends across the right side of the pocket, with the GRL in the closed 
position (Figure 5.19a). This is surprising, as the closed conformation has been 
suggested to sterically block ATP from accessing the pocket and binding within it. 
This was based on comparisons to the related FGFR kinase structure bound to 
ATP/Mg
2+
, where the phosphates interact with residues within the GRL (Figure 
5.20a). It is notable that no magnesium is present with ADP in the pocket. However, 
not all solvent will be visible at a resolution of 2.1 Å, so the presence – or lack of – 
a magnesium ion within the pocket could only be confirmed with a higher resolution 
dataset or a potential substitution with manganese. The nucleotide extends across 
the catalytic region of the pocket towards the catalytic residue Asp874 (Figure 
5.19d), and the γ-phosphate would be positioned close to where the incoming 
tyrosine nucleophile would be expected. The adenosine forms hydrogen bond with 
the main chain of both Glu805 and Ala807 in the KD hinge.  
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Figure 5.19 Structural characterisation of the RET KD-ADP complex 
(A) Ribbon view of RET KD (light grey) with ADP bound to the nucleotide-binding pocket. (B) 
Difference (blue), positive (green) and negative (red) density maps surrounding ADP. (C) 
Electrostatic surface view of the ATP pocket with ADP sat within it. (D) Close-up of ADP within 
the nucleotide-binding pocket of RET (light grey). Key residues within the pocket have side 
chains visible (grey), with dotted lines indicating hydrogen bonds between ADP and side chains 
(dark grey) or solvent (red). ADP key: carbon – lawn green; nitrogen – blue; oxygen – red; 
phosphorus – purple.  
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It is possible that two distinct ATP binding modes exist: that captured in this 
particular RET KD-ADP complex and that of the canonical RTK GRL + ATP. 
Further validation of this RET KD-ADP structure is required. It was previously 
reported that the closed GRL conformation of RET involves the tethering of three 
residues – Glu734, Arg912 and Asp771 – through hydrogen bonds (Plaza-
Menacho et al., 2014). Therefore, future investigations could examine the affinity of 
ATP towards both the wild type and mutant RET KD, or crystallisation of ATP (or a 
non-hydrolysable analogue) within the mutant RET KD could be attempted.  
 
As seen in Table 5.6, the B-factor for ADP is currently much higher than the protein 
or solvent. When examining the individual atom B-factors, it became apparent that 
the α- and β-phosphates had B-factors double that of the rest of the molecule, with 
the ribose slightly higher than the adenine ring. This may be due to low occupancy 
of the α- and β-phosphates. Further refinement is required, reducing the occupancy 
of the phosphates, to determine the optimal ligand and position. This RET KD:ADP 
conformation may contain a collapsed GRL, influenced by the presence of the N 
helix. Importantly, there are currently no main chain hydrogen bonds to the ADP 
phosphates, and Lys758 and Asp892 are too far away to contribute to the 
alignment of the ligand. Given their invariance in all RTKs, it would seem they 
should have a similar role in the binding of ADP to RET. A major difference when 
compared to other RTK:ATP structures is the current C4’-C5’ torsion angle of the 
ribose (Figure 5.20a). Structures of ADP (or ACP) within EphrinB2, ALK (anaplastic 
lymphoma kinase) or FGFR display a distinctly different torsion angle that directs 
the phosphates back under the GRL towards the catalytically conserved Lysine 
residue. In the case of EphrinB2 and FGFR, the phosphates are interacting with 
both the Lysine and the GRL, and magnesium ions are present - elements thought 
to be required for the catalytic mechanism of a kinase (Hubbard, 1997).  
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Figure 5.20 Comparisons of nucleotide binding and DFG conformation 
(A) Comparisons of RTK-ADP binding. Key hydrogen bonds between ADP or ACP (Carbon - 
green; nitrogen - blue; oxygen - red; phosphorous - purple) and relevant regions of amino acids 
in RET KD, EphrinB2 (PDB code 2HEN), ALK (PDB code 3LCT) and FGFR (PDB code 2PVF). 
Magnesium ions are represented as grey spheres and solvent is represented as red spheres. 
Residues in the GRL are annotated as such. Hydrogen bonds not annotated: EphrinB2 
magnesium forms hydrogen bonds with R758; FGFR magnesium forms hydrogen bonds with 
N631 and secondary phosphate. (B) The DFG-out conformation of VEGFR-2 bound to type II 
inhibitor Sorafenib (PDB code 4ASD) and the DFG-in conformation of RET (PDB code 2IVV) 
with Sorafenib from 4ASD modelled into the structure. The DFG motif (coral) is annotated. 
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It is unclear as to how ATP (hydrolysed to ADP) came to be present within the 
pocket, since the protein was washed after phosphorylation. It is possible that 
some residual ATP was still in the solution at the time of crystallisation. This crystal 
form has proved very useful in crystallising DFG-in type I compounds. However, 
despite many efforts it appears DFG-out type II inhibitors cannot be captured in the 
current crystal lattice. One explanation may be the presence of the vector-derived 
αN-helix (required for crystallisation of a DFG-in structure). Based on the structure 
of VEGFR2 bound to Sorafenib (Figure 5.20b), it is highly probable that the inhibitor 
will extend far into the back pocket in order to push out the DFG motif. As the 
vector-derived helix can be found behind the αC helix, its position may prevent the 
required conformational change from occurring - in RET's DFG-in conformation, 
Sorafenib would clash with Phe893. In solution, Sorafenib can bind (hence the 
large RET KD ΔTm), but the position of the vector-derived helix within the crystal 
lattice may force the protein into its original conformation. This could eject 
Sorafenib from the nucleotide pocket, allowing ATP to re-bind in its place.  
 
5.8 Structural characterisation of RET KD with S1 inhibitors 
The RET KD was crystallised with five S1 inhibitors (as seen in Figure 5.1): I-1 
(2.00 Å), I-7 (1.95 Å), I-8 (2.65 Å), I-9 (1.70 Å) and I-10 (1.80 Å). Crystals were also 
generated in the presence of Inhibitors I-6 and I-11, but compounds were not found 
within the active site (the monophospho-nucleotide cAMP was present in its place) 
and Tyr905 was phosphorylated. This is consistent with TSA data (Figure 5.12) 
data and will be discussed further in the next section.  
 
All S1 inhibitor-bound structures have a closed GRL, with Phe735 folding back 
towards I-7, I-9 and I-10 (Figure 5.21). This may be the case for I-1 and I-8 also, 
but unfortunately the electron density for these two structures does not define the 
complete GRL. The scaffold occupies the one side of the nucleotide pocket 
towards the KD hinge, forming a hydrogen bond with the main chain of Ala807, with 
none of the inhibitors extending into the interior pocket (as seen for S2, S4 and 
DFG-out inhibitors). The non-planar 3D shape of the benzodiazepine scaffold can 
be seen to fold over the floor (Leu881 and Gly810) of the nucleotide cleft, forming 
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hydrophobic contacts with those residues and those in the ceiling – Val738, Ala756 
and Leu730 (Figure 5.21d). I-10 is the only S1 inhibitor to contain an additional five-
membered ring underneath the benzodiazepine scaffold. This ring appears to 
induce strain within the central ring system and shift the position of the benzyl ring. 
This appears to have no positive effect on inhibitor-residue interactions and results 
in a slightly lower RET KD thermal stability (seen earlier in Figure 5.12). Therefore, 
S1 may be more effective as a RET inhibitor without this five-membered ring. 
 
The trifluoromethyl group found at the end of all S1 inhibitors – except for I-8 – 
appears to be flexible, as this portion of each inhibitor appears in different positions 
(Figure 5.21). I-8 induced the largest increase in RET KD thermal stability and 
lacks this group, suggesting that it hinders inhibitor binding. As an alternative, this 
portion of the S1 inhibitors could have a hydrogen bond acceptor – such as a 
carboxyl (COH) group – to interact with the Lys808 carbonyl group.  
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Figure 5.21 Structural characterisation of RET KD bound to S1 inhibitors 
 (A) Superposition of Inhibitors 1, 7, 8, 9 and 10, highlighting their related binding modes. I-1 – 
dark green; I-7 – lawn green; I-8 – lime green; I-9 – pale green; I-10 – yellow green. (B) Electron 
density (blue) surrounding each of the S1 inhibitors. Inhibitor number indicated for each image. 
(C) Close-up of each inhibitor within the nucleotide-binding pocket of RET. Key residues within 
the pocket have side chains visible (grey), with dotted lines indicating hydrogen bonds between 
the inhibitor (green) and side chains or solvent (red). (D) Superimposed inhibitors (green) within 
the nucleotide-binding pocket (grey ribbon), with Van der Waals contacts annotated. 
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5.8.1 Crystallisation of RET KD with S1 inhibitors 6 and 11 
As the core scaffold within I-6 and I-11 is the same as that of other S1 inhibitors, 
the poor potencies and almost no increase in RET KD thermal stability indicates 
specific atoms within the scaffold may hinder RET-binding. For I-6, this may be due 
to the close proximity of the primary amine on the piperidine ring to Arg878 – 
clashing with this residue could prevent the inhibitor from being tolerated within the 
active site. The benzodiazepine system has been flipped – when compared to the 
other S1 inhibitors – so that the R7 carboxyl group would be directed towards the 
RET KD hinge (based on a model seen in Figure 5.22a). By doing so, the carbonyl 
interacting with a water molecule between the other S1 inhibitors and Glu775 is 
removed. As this water molecule appears relatively conserved within the structures, 
the bridge that it creates between the inhibitor and the back of the nucleotide-
binding pocket may be important for inhibitor binding. I-6 also has an amide linker 
between the benzodiazepine system and the benzyl ring, which is not present for 
other S1 inhibitors. While the –NH group is likely to form a hydrogen bond with the 
RET KD hinge, the presence of an extra carboxyl group may hinder the inhibitor’s 
ability to bind.  
 
Figure 5.22 Modelling of the poor-affinity I-6 & 11 in the RET nucleotide-binding 
pocket 
(A) Model of I-6 (green) fitted into the nucleotide-binding pocket of the RET KD (spaghetti view, 
grey), using the RET KD-I-7 PDB and superposition of I-6 with I-7. (B) Model of I-11 (green) 
fitted into the nucleotide-binding pocket of the RET KD (spaghetti view, grey), using the RET 
KD-I-9 PDB and superposition of I-11 with I-9.  
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While these observations are simply based on a model, I-5 – with which 
crystallisation has not been attempted – also contains the flipped benzodiazepine 
system and amide linker. This inhibitor (seen earlier in Figure 5.3) did not cause an 
increase in RET KD stability (Figure 5.12), suggesting that its ability to bind to RET 
KD is similar to that of I-6. This suggests that the points mentioned are in some 
way responsible for the lack of inhibitor potency and should be avoided in future 
designs. For I-11, the sulphoxide group on the benzodiazepine ring was intended to 
interact with the RET gatekeeper residue Val804 and was a hopeful compound for 
RET inhibition, due to data from collaborators showing that it did not inhibit the 
Aurora kinases AURKA and AURKB (the main off-targets). However, the 
sulphoxide group on the benzodiazepine group is very close to Lys758 and Asp892, 
which could also result in clashing and a prevention of inhibitor binding (Figure 
5.22b).  
5.9 Structural characterisation of RET KD with S2 inhibitors  
The crystal structures of RET KD bound to I-4 and PP242 were obtained at 
resolutions of 2.6 Å and 2.26 Å, respectively. The binding mode observed for I-4 
and PP242 is very similar to that found in the already crystallised RET KD-PP1 
structure (PDB code 2IVV). The main pyrazolopyrimidine scaffold takes the position 
of the adenosine ring, with the extended rings shown in Figure 5.23a pushing into 
the interior pocket (Figure 5.23c). The left side of the pyrazolopyrimidine scaffold 
interacts with the kinase hinge, forming a hydrogen bond with the main chain of 
Glu805. This bond is highlighted in Figure 5.23 for PP242 and PP1, and is most 
likely present in I-4 but has not been indicated due to the slightly extended distance 
of 3.12 Å.  
 
Electron density along the extended carbon bond in I-4, between the 
pyrazolopyrimidine scaffold and the benzene ring was very prominent, but 
weakened around the benzene ring itself, suggesting that the ring rotates within the 
interior pocket (Figure 5.23b). Unfortunately, the data was not of a high enough 
quality to define Lys758 or Glu775 – two important residues when examining 
inhibitors that extend into the interior pocket. While writing, datasets have been 
collected for the RET KD bound three other S2 inhibitors synthesised by the same 
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collaborator. The higher resolution obtained will hopefully help to define the position 
of these residue side chains. It is likely that I-4 also forms hydrogen bonds with the 
main chain of Glu805, as seen for the other two S2 inhibitors. Again, refinement of 
the new S2 inhibitor datasets will hopefully help to confirm this.  
 
Figure 5.23 Structural characterisation of RET KD bound to S2 inhibitors 
(A) Superimposition of I-4 (pale blue), PP242 (blue) and PP1 (cyan). (B) Difference electron 
density (blue) surrounding I-4 and 18, at a sigma level of 1.0. (C) Close-up of each inhibitor 
within the nucleotide-binding pocket of RET. Key residues within the pocket have side chains 
visible (grey), with dotted lines indicating hydrogen bonds between the inhibitor (green) and side 
chains (dark grey) or solvent (red). Hydrogen-bonding residues are annotated.  
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PP242 hydrogen bonds with the main chain of Glu805 and extends even further 
into the back pocket, with a phenol ring pointing towards Glu775. As mentioned 
earlier, the extension of this inhibitor actually displaces Lys758, disrupting the 
conserved salt bridge that forms between this residue and Glu775. Neither I-4 nor 
18 appear to hydrogen bond with the main chain of Ala807 within the KD hinge, as 
seen with PP1.  
5.10 Analysis of pre-solved structures of RET KD with S3 
inhibitors  
Dr Kerry Goodman previously solved the structure of the RET KD bound to 
Sunitinib in the McDonald Laboratory, while the structures of the RET KD bound to 
X2K, X2L and X2M were published in 2010. As shown in Figure 5.24, the inhibitors 
engage both Glu805 and Ala807 in the KD hinge. A noticeable difference between 
X2K, X2L and X2M is the lack of an amide group on X2M. It appears that this 
particular amide group in X2K and X2L hydrogen bonds with Asp892 (the first 
residue of the conserved DFG motif), an interaction that is lost when X2M is bound 
(Figure 5.24). Instead, Ser891 hydrogen bonds with a water molecule commonly 
found between an inhibitor at Glu775.  
Chapter 5. Results 
 
 171 
 
Figure 5.24 Structural characterisation of RET KD bound to S3 inhibitors 
Close-up of each inhibitor (green) within the nucleotide-binding pocket of RET (grey ribbon). 
Key residues within the pocket have side chains visible (grey), with dotted lines indicating 
hydrogen bonds between the inhibitor and side chains (dark grey) or solvent (red). Hydrogen-
bonding residues are annotated.  
 
5.11 Structural characterisation of RET KD with S4 inhibitor 
The RET KD-I-3 dataset (collected at a resolution of 2.45 Å) was found to be in the 
C2 space group, but with an extended c edge (doubled from 79.9 Å to 158.7 Å), 
allowing for two molecules within the asymmetric unit instead of the usual single 
dimer (converting the crystallographic dimer into a non-crystallographic one). The 
dataset was found to contain pseudo-translational non-crystallographic symmetry 
and was twinned (as reported using Xtriage). As a result, the Wilson B factor and 
Rwork/free values reported in Table 5.6 are less reliable, as the values obtained from 
twinned data are not directly comparable to that of untwinned data. The inhibitor 
binding may have caused this twinning (especially as a large ΔTm was observed, 
indicating there may have been some conformational change), but it also may have 
occurred during crystal cooling.  
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Structural comparisons of RET KD-I-3 and RET KD-Vandetanib highlight several 
differences within the ATP pocket (Figure 5.25). While Vandetanib hydrogen bonds 
with the KD hinge, it has not been indicated in Figure 5.25 due to the slightly 
extended bond distance (Knowles et al., 2006). I-3 is found to hydrogen bond with 
Glu775 in the αC helix. This is the only inhibitor found to extend far enough back to 
make this connection. Unfortunately, the side chain of Lys758 is disordered, so it is 
unclear as to what effect this interaction has on the position of the residue. It is 
possible that the disruption of the ion-pair between Glu775 and Lys758 by I-3 has 
led to the disorder of the lysine.  
 
 
Figure 5.25 Structural characterisation of the RET KD bound to S4 inhibitors 
(A) Superimposition of I-3 (light coral) and Vandetanib (purple). (B) Difference electron density 
(blue) surrounding I-3 ligand. Sigma = 1.0. (C) Close-up of each inhibitor within the nucleotide-
binding pocket of RET. Key residues within the pocket have side chains visible (grey), with 
dotted lines indicating hydrogen bonds between the inhibitor and side chains (dark grey) or 
solvent (red). Hydrogen-bonding residues are annotated.  
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5.12  Structural characterisation of RET KD with S5 inhibitor 
Based on the earlier TSA data (Figure 5.12), BMS-536924 was believed to be a 
type II inhibitor, due to the fact that the shift in RET KD stability in the presence of 
the compound was very similar to that of DFG-out compound Sorafenib. The 
scaffold adopted by BMS-536924 is also similar to another DFG-out compound 
designed by our collaborators in Arizona: Pz-1 (structure not shown). Efforts to 
crystallise the RET KD with both Sorafenib and Pz-1 have been unsuccessful so far, 
while BMS-536924 was captured within the nucleotide-binding pocket.  
 
The structure of RET KD bound to BMS-536924 was obtained at a resolution of 2.3 
Å. While the majority of RET KD datasets have been collected in the monoclinic C2 
space group, the dataset for RET KD bound to BMS-536924 was collected in the 
tetragonal P43212. As seen in Table 5.6, the ligand B-factor is rather high, 
indicating that further refinement is required – possibly with reduced occupancy on 
portions of the ligand – to be sure of the ligand geometry. The different space 
group suggests slightly altered packing of the protein molecules within the crystal 
lattice, which may have been induced by BMS-536924 binding. Instead of adopting 
a DGF-out binding mechanism, the inhibitor appears to fold around to the otherwise 
unoccupied catalytic region of the pocket (Figure 5.26).  
 
Electron density surrounding the final aromatic ring of BMS-536924 is particularly 
weak, and further refinement may be required to be completely confident of its 
position. While this S5 inhibitor may be presenting a subtly different binding mode, 
it is also possible that its position has been affected by the presence of the vector-
derived αN-helix required for RET KD crystallisation. As mentioned previously, this 
helix sits behind the αC-helix that contains the residues lining the back of the ATP 
pocket, including the DFG motif. It is possible that in solution, BMS-536924 induces 
a DFG-out conformation (consistent with the high shift in RET KD thermal stability) 
that is prevented within the crystal lattice by the αN-helix. Structures of the RET KD 
with Sorafenib and Pz-1 may not have been achieved thus far due to their inability 
to bind within the pocket in a mode other than DFG-out. Possible strategies for 
overcoming this are discussed later in the chapter conclusion. 
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Figure 5.26 Structural characterisation of the RET KD bound to BMS-536924 
(A) Ribbon view of the RET KD (grey) with BMS-536924 (pink) within the ATP pocket. (B) 
Electron density (blue) and difference density (red/green) around BMS-536924, Sigma = 0.8. 
(C) Electrostatic surface view of the RET ATP pocket with BMS-536924 (pink). (D) Close-up of 
BMS-536924 within the nucleotide-binding pocket of RET. Key residues within the pocket have 
side chains visible (grey), with dotted lines indicating hydrogen bonds between the inhibitor and 
side chains (dark grey). (E) Comparison of BMS-536924 (pink) binding in the RET (gold) ATP 
pocket with Sorafenib (light blue) binding into the VEGFR-2 (gold, PDB code 4ASD) ATP 
pocket. BMS-536924 clashes with the DFG motif of VEGFR-2, while Sorafenib clashes with the 
DFG motif of RET. 
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5.13  Development of an updated RET inhibitor pharmacophore 
As discussed in the introduction, there are several RET inhibitors currently being 
used to treat thyroid cancer but their multi-target effects are less than optimal. Due 
to the conserved nature of the tyrosine kinase nucleotide-binding pocket, a great 
deal of inhibitors lack specificity. Therefore, structure-activity relationship (SAR) 
data is collated and analysed to ensure that future generation inhibitors focus on 
what are believed to be the most important characteristics.  
 
A pharmacophore is a description of structural features that are deemed necessary 
for target-protein binding. Once developed, current databases – such as the Kinase 
KnowledgeBase database (Eidogen-Sertanty Inc.) – can be searched for existing 
inhibitors that contain those particular atoms in a specific geometry. There are 
several sources of information that can be used to create a pharmacophore. Firstly, 
X-ray derived structures provide information on hydrogen bonding opportunities. 
While the hydrophobicity of the protein primarily defines the region of inhibitor-
protein binding, hydrogen bonds within the region lead to binding specificity.  
Structures provide information on the geometry on the inhibitor itself, an important 
feature that is used in rational drug design to select compounds that meet particular 
geometric criteria. X-ray structures also allow us to create a picture of the active 
site itself, identifying key residues in inhibitor binding and highlighting regions of 
inhibitor interaction (for example, the hydrophobic interior pocket of the nucleotide-
binding region). This information can be combined with biochemical data reporting 
the in vitro and in vivo effects of the compounds against particular targets (Yang, 
2010). In 2011, Shih et al. published a RET pharmacophore model. In this model, 
inhibitors should contain one hydrogen bond acceptor, one hydrogen bond donor, 
one hydrophobic and one aromatic ring. They compared the SAR information on 76 
inhibitors from the Kinase KnowledgeBase database and used the 3D-QSAR 
Pharmacophore Generation technology to create computational pharmacophore 
hypothesis models. The inhibitors presented in this thesis adhere to this optimal 
pharmacophore model, but still differ greatly in terms of potency. In order to 
understand these differences, the areas of the RET nucleotide-binding pocket 
targeted by each inhibitor were examined. 
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In this thesis, information from the X-ray derived structures of 15 compounds (I-1, I-
3, I-4, I-7, I-8, I-9, I-10, PP242, BMS-356924, PP1, Vandetanib, Sunitinib, X2K, X2L, 
X2M) was combined to highlight key residues (those that may be necessary for 
inhibitor binding) and identify differences between scaffold binding modes (Figure 
5.27). Key residues within the ATP pocket were defined as those within 4 Å of each 
inhibitor (Figure 5.27a); the number of possible interactions (within 4 Å) that residue 
could make with each inhibitor were then counted and entered into the cluster 
analysis program Cluto (http://www.cs.umn.edu/~cluto). Clustering algorithms allow 
datasets to be divided into meaningful groups, so that similarity within a group is 
maximised and the similarity between different groups is minimised. Initially, a heat 
map was generated, highlighting areas within the pocket that had a high and low 
prevalence of inhibitor interaction (Figure 5.27b). Following this, the datasets were 
reanalysed with the request of separating into five clusters: one for each inhibitor 
scaffold (Figure 5.27c). Analysis was carried out using the “vcluster” clustering 
program within Cluto, which uses a “repeated bisection” algorithm. The algorithm 
first splits the data into two groups, and then a further two – this process is 
continued until the number of defined clusters (five, in this case) is reached.  
 
Figure 5.27b highlights residues that are consistently involved in ligand binding, 
irrelevant of the scaffold – such as Leu881 in the floor of the pocket or Leu730 in 
the roof – while enabling comparison between the scaffolds themselves. Val804 
and Glu775 in the back pocket region are interacting with both S2 (I-4, PP242 and 
PP1) and S4 (I-3 and Vandetanib) compounds, while appearing less involved in S1, 
S3 and S5 binding. As shown in Figure 5.27c, S1 inhibitors I-7, I-8 and I-9 were 
clustered together, as were S2 inhibitors PP1 and I-4, and S3 inhibitors Sunitinib, 
X2K, X2L and X2M. The divergence between S4 and 5 inhibitors may indicate 
subtle differences between the inhibitors, or the dataset may need to be built upon 
to ensure correct clustering. For future development, this information will be 
combined with hydrogen bonds, TSA data, IC50 data from each collaborator and 
known off-targets.  
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Figure 5.27 Towards a better RET pharmacophore 
(A) View of the RET nucleotide-binding pocket with the side chains of the key residues (Hinge – 
light blue, back pocket - purple, right side - yellow, roof - green, floor - pink.) (B) Heat map 
displaying the number of possible interactions each inhibitor can make with each key residue 
(Red – high prevalence, white – low prevalence). (C) Heat map with separations of inhibitors 
into five clusters, based on the repeated bisection clustering algorithm carried out by the 
vcluster Cluto program. The tree indicated similarity between the clusters: those separating 
early are furthest apart.  
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5.14  Conclusions 
In this chapter I have presented the crystal structures of the RET KD bound to nine 
compounds that have been developed for RET or similar RTK inhibition. I have 
collated this data with the previously solved structures of the RET KD bound to 
Sunitinib, X2K/L/M, Vandetanib and PP1 and have identified various RET-binding 
modes based on five distinct compound scaffolds. I have also presented the crystal 
structure of the RET KD bound to ADP, revealing the unexpected closed 
conformation of the GRL. 
5.14.1 Determining the physiological relevance of the RET KD-ADP structure 
Repeated X-ray analysis of older RET KD-ADP crystals lead to the discovery of 
adenosine within the nucleotide-binding pocket, confirming that ADP is present in 
the RET KD-ADP structure and suggesting that hydrolysis occurs over time. This 
structure currently does not appear to contain magnesium – an important element 
in ATP-KD binding – and future work will need to be carried out in order to identify 
whether this is a physiologically relevant arrangement of ADP within the active site 
of RET. Firstly, a higher resolution dataset (under 2 Å) may reveal the presence of 
magnesium within the active site. The protein could also be crystallised with 
manganese as a substitute for magnesium, as the Mn2+ ion has a larger ionic 
radius of 0.9 Å and crystals could be analysed using SAD (single wavelength 
anomalous dispersion) to determine the presence of manganese within the protein. 
The structure may be forced into a collapsed GRL conformation influenced by the 
presence of the αN helix. The phosphates currently do not engage with the GRL 
and important catalytic residues Lys758 and Asp892 are not involved in the 
positioning of the ligand, as they are in other kinase-ATP structures. As such, this 
structure requires further validation. 
5.14.2 Examining RET KD stability using TSA 
This thesis presents TSA data analysing the effect of various compounds on the 
thermal stability of the RET KD. Strikingly, the inhibitors believed to target the DFG-
out conformation of RET induced an extremely large thermal shift of approximately 
20 °C. This could be due to the flipped DFG motif pushing against the αN helix and 
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forcing it into an alternative conformation. A larger array of DFG-out inhibitors will 
confirm whether this technique is effective in identifying this particular binding mode. 
If so, TSA could be carried out in order to assess whether crystallisation (currently 
only possible with the RET KD in the DFG-in conformation) would be successful.  
 
A large number of the inhibitors did not induce a thermal shift larger than that of 
ATP/Mg2+. While we know from the crystal structures obtained that the inhibitors 
can compete with ATP and bind within the nucleotide-binding pocket of RET, TSA 
should be repeated in the presence of ATP/Mg in all samples. This experiment will 
confirm that the compounds have indeed taken the place of ATP. It could be 
argued that the inhibitors that increase thermal stability more than ATP would be 
the most optimal; but it is currently unclear as to whether the large shift in thermal 
stability in the presence of Sorafenib and Pz-1 is due to a more stable protein or a 
conformational shift of the αN helix. To investigate this, the experiments could be 
repeated with the RET JM-KD recombinant protein that does not contain the 
vector-derived αN helix. 
 
Current TSA experiments have all been carried out using the WT RET KD. While 
this is still physiologically relevant, due to the reports of RET overexpression in 
cancer, it would also be interesting to examine the effects on oncogenic RET KD 
mutants such as MEN2B M918T. It has been reported that the oncogenic form of 
the protein is less stable than the WT and has a higher affinity for ATP, therefore 
compounds may illicit different effects (Plaza-Menacho et al., 2014). At the time of 
writing, the RET KD M918T expression construct was in production.  
 
5.14.3 Chemical scaffolds targeting RET oncogenic gatekeeper mutations 
Missense mutations of the RET gatekeeper residue (Val804) for bulky hydrophobic 
residues Leu and Met are oncogenic and found in MEN2 disease. These MEN2-
associated mutations render several inhibitors – such as PP1 and Vandetanib – 
ineffective. This is presumably because such inhibitors need access to the interior 
hydrophobic pocket of the kinase and access would be restricted or blocked by 
such mutations (Figure 5.28). The mutation of Val804 to the smaller residue glycine 
actually renders the inhibitors PP1 and Vandetanib more potent (Carlomagno et al., 
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2004). S1 inhibitors do not require access to this region, as they sit at the front of 
the nucleotide-pocket. It would therefore be interesting to assess their activity 
against RET gatekeeper mutants, raising possibilities for combination therapies. 
While other inhibitors may be more potent at the start of therapy, S1 inhibitors 
could be subsequently used to target RET mutations that select for gatekeeper 
mutant-dependent resistance. Alternatively, S1 and S2 inhibitors could be used in 
combination therapy. 
 
 
Figure 5.28 Modelling of inhibitor resistance through the RET gatekeeper 
mutation 
Mutation of Val 804 (grey) into Met (gold) or Leu results in reduced access to the hydrophobic 
back pocket within the nucleotide-binding pocket of RET. This MEN2-associated mutation leads 
to drug resistance, as many inhibitors (PP1 shown here, green) require access to this pocket. 
  
5.14.4 Towards a surrogate crystallisation platform for DGF-out inhibitors 
against RET 
To date, capturing the inactive DFG-out conformation of RET in complex with a 
type II inhibitor has been unsuccessful. It is currently assumed that this is due to 
the position of the vector-derived αN-helix, preventing any movement in the DFG 
motif. This conformation of RET is extremely interesting, especially given the 
potential increase in thermal stability caused by DFG-out inhibitors. In order to 
investigate this further, it may be necessary to crystallise the protein without this 
αN-helix. There are several strategies for this: RET KD constructs could be 
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produced with deletions of increasing portions of the αN-helix, in an attempt to find 
the minimal amount of helix required; an inhibitor could be added during RET KD 
(without the αN-helix) expression, in an attempt to stabilise the protein; 
crystallisation of the RET juxtamembrane region (JM) -KD bound to a DFG-out 
inhibitor is currently being attempted within the laboratory, as this does not contain 
the αN-helix and is known to crystallise. This process will require rescreening for 
new crystallisation conditions. Other RTKs have been crystallised with Sorafenib, 
such as VEGFR-2. In the case of VEGFR-2, the structure of the JM-KD in complex 
with Sorafenib has been elucidated, demonstrating the DFG-out conformation 
(McTigue et al., 2012). As this crystallisation platform now exists, it would be 
possible to examine the binding mode of inhibitors that are known to target RET 
and are believed to bind to the DFG-out RET conformer. The similarities between 
the VEGFR-2 and RET nucleotide-binding pocket would allow the confirmation of 
RET-inhibitor binding modes (i.e. DFG-in or DFG-out) and provide insight into 
possible interactions.  
5.14.5 RET inhibition vs. mTOR toxicity 
It has been reported that mTOR inhibitors can cause MAPK pathway activation, 
due to a feedback mechanism depending on the S6K-PI3K-Ras pathway 
(Carracedo et al., 2008). It was shown that chemical inhibition of the MAPK 
pathway enhanced the anti-tumoral effects of mTOR inhibition in vitro and in a 
mouse model. This suggests the need for either RET inhibitors that do not target 
mTOR, or combination therapy with MAPK inhibitors. The structure of RET KD-
PP242 showed that the inhibitor breaks the conserved salt bridge between Lys758 
and Glu775, a structural element required for the catalytic mechanism of the kinase. 
While this indicates that PP242 is an effective RET inhibitor, its potency against 
mTOR could be problematic. Recently, a series of inhibitors based on both S2 and 
Sorafenib structures have been designed to “dial-out” the mTOR inhibition (Dar et 
al., 2012). They identified – using a Drosophila model – that optimal MEN2B 
treatment would require the inhibition of RET, Src, S6K and Raf, but not mTOR. 
The novel inhibitors – whose structures suggest a DFG-out binding mode – were 
shown to inhibit tumour growth with far lower levels of toxicity.  
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Chapter 6. Discussion 
In the preceding chapters, I described results from investigations into two poorly 
understood molecular properties of RET - how it attains a functional native fold 
appropriate for export and how its enzymatic function can be chemically inhibited. 
Both properties have relevance to RET-driven disease. Understanding the 
maturation and export of wild type and HSCR RET raises the possibility of restoring 
HSCR RET function in cell-lines and potentially in models of HSCR. Defining an 
improved pharmacophore for RET by comparing a range of crystal structures of 
chemical scaffolds that all target the RET nucleotide cleft may lead to a new 
generation of more selective and potent RET inhibitors for the treatment of RET-
associated cancers. In the sections below, I have summarised the findings of each 
chapter and suggested strategies for future investigation.  
6.1 Characterisation of RET export and efforts to restore HSCR 
RET function 
6.1.1 Summary of findings 
Chapter 3 presented a description of the characterisation of RET maturation and 
export for both WT and S100M RET, using biochemical and cell-based methods. 
Previous work implementing a surrogate RET ectodomain secretion assay showed 
that mild HSCR RET mutations (represented in this thesis by the mutant S100M 
RET) were not exported to the cell surface (Kjaer et al., 2010). This chapter 
confirmed and extended these findings, using FACS and immunofluorescence 
analysis, to convincingly demonstrate that S100M RET accumulates predominantly 
as an immature intracellular species, presumably retained within the ER. Western 
blot analysis of the MAPK signalling pathway indicates a loss of ERK1/2 
phosphorylation in S100M RET expressing cells in the presence of ligand and co-
receptor, suggesting that the absence of the receptor at the cell surface results in a 
complete loss of ligand-stimulated signalling capabilities.  
 
Kjaer et al. also presented data indicating that restoring proper maturation and 
export of the mild S100M HSCR mutation - within a RET ECD context - also 
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restored ligand and co-receptor binding function (Kjaer et al., 2010). Proper 
maturation was also restored in a full-length S100M HSCR context but the 
signalling capabilities of this mutant receptor were not examined further. Chapter 3 
presents two strategies for successfully restoring S100M RET maturation and 
export: the deletion of unpaired cysteine residues from CLD1-2 (previously reported 
in (Kjaer et al., 2010) or alternatively by the addition of chemical chaperones 4-PBA 
and glycerol. The signalling capability of mature and exported S100M RET under 
both of these conditions still needs to be fully investigated in the near future.  
 
The chapter presents preliminary investigations into the effect of gene silencing on 
WT RET export. ERp44 (involved in thiol-mediated ER retention) knockdown leads 
to a reduction in WT RET cell surface levels, while ATP6V0C (V-ATPase subunit) 
and RAB7A knockdown lead to an increase in WT RET cell surface levels. 
Previous reports (using chemical inhibitors) suggested that V-ATPase inhibition 
affects RET maturation but not cell surface levels (Hirata et al., 2010). Taken 
together these findings suggest that the role of V-ATPase in endocytosis and the 
role of both V-ATPase and Rab7 in lysosomal degradation is to negatively regulate 
the level of WT RET at the plasma membrane.  
6.1.2 Implications of chapter 3 and the future investigations 
Work within this chapter has confirmed that a mild HSCR mutant RET does not 
reach the cell surface and cannot therefore activate downstream signalling 
pathways. Several strategies for increasing cell surface expression levels have 
been identified, although it is currently unknown as to whether this can translate 
into a restoration of full downstream signalling capabilities. I have established a 
system for examining RET export and function outside of an endogenous setting, 
using robust inducible Flp-In mammalian cell lines. A series of HeLa Flp-In cell 
lines expressing S100M* RET have been produced during the writing of this thesis, 
and future investigations should establish the signalling capabilities of WT, S100M 
and S100M* RET using the HeLa Flp-In system. To do this, Flp-In cells would be 
incubated with recombinant GDNF-GFRα1 ligand and probed for RET auto-
phosphorylation. It should be noted that it is well documented that transfected cell 
lines expressing RET are notoriously difficult to obtain a robust GDNF-induced 
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RET activation because of the high level of basal RET autophosphorylation. 
However, the Flp-In cells overcome this problem and will be a useful tool for 
researchers working on RET signal transduction. Cells expressing WT, S100M and 
S100M* RET can also be assessed for downstream pathway activation by western 
blot analysis, examining the phosphorylation state of ERK1/2, Akt or STAT3 
components of discrete signalling pathways. Future work could also examine the 
hypothesis that acquisition of Cys87 and Cys216 (the two unpaired cysteine 
residues removed in S100M* RET) in higher vertebrate RET evolved to reduce the 
level of RET at the cell surface. Mutations within the RET receptor leading to the 
presence of these two cysteine residues may have occurred randomly, followed by 
positive selection. The establishment of inducible cell lines expressing both 
oncogenic (e.g. M918T RET) and WT* RET would allow comparisons to the WT 
protein and identify differences in the effect of each RET species expression of cell 
viability, differentiation or proliferation.  
6.2  The preliminary identification of factors involved in WT 
and HSCR RET export and degradation 
Chapter 4 described the development and implementation of an 
immunofluorescence-based gene silencing assay in RET expressing Flp-In cells. 
The assay was designed to identify factors involved in the folding, export and 
degradation of the RET receptor. The 300-candidate siRNA screen was carried out 
on DLD-1 cells expressing both WT and S100M RET, with a total of 30 genes 
identified as involved in the regulation of WT or S100M RET cell surface 
expression. Six genes were implicated in the negative regulation of both WT and 
S100M RET surface levels; four genes were implicated in the negative regulation of 
WT RET levels; six genes were implicated in the negative regulation of S100M 
RET levels only; 14 genes were implicated in the positive regulation of WT RET 
levels alone. These hits were clustered into known cellular pathways; namely, 
ERAD, endocytosis and lysosomal degradation, autophagy and protein folding and 
quality control. Due to the way the screen was performed, we cannot comment on 
whether factors positively influencing WT RET levels also affect S100M RET in the 
same manner. I discuss below some of the most interesting hits identified, the 
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specific pathways they are involved in and future validation experiments required 
for each.   
6.2.1  The E3 ligase CHIP as a putative regulator of both WT RET cell 
surface expression and HSCR RET degradation 
E3 ligases are potential negative regulators of many cell surface receptors and 
individual gene knockdowns for members of this protein family were anticipated. A 
top hit from screen was the CHIP E3 ligase (also known as STUB1), previously 
implicated in both the regulation of oncogenic protein expression and the 
degradation of misfolded proteins (Murata et al., 2001, Zhou et al., 2003). This 
protein was identified as a hit in both WT and S100M RET siRNA screens as gene 
knockdown resulted in increased cell surface levels of WT and mutant forms of the 
receptor. CHIP activity is known to be inhibited by Hsp90, which itself is chemically 
inhibited by 17-AAG. To validate CHIP indirectly by chemical means, 17-AAG was 
added to cells resulting in reduced levels of both the WT and S100M RET protein 
as seen by western blot. This was in agreement with previous reports that Hsp90 
inhibition increased levels of CHIP ubiquitination and subsequent proteasomal 
degradation of the substrate. 17-AAG addition is a common approach to implicate 
CHIP in the degradation of a protein of interest and has provided preliminary 
validation of our hit (Stanley, 2011, Muller et al., 2008).  
 
CHIP constructs (both WT and the dominant negative mutant P269A affecting the 
CHIP U-box) have been produced and preliminarily tested in DLD-1 cells, so future 
work examining the effect of their overexpression in WT and S100M RET 
expressing DLD-1 cells would further confirm CHIP’s involvement in the 
degradation of the RET receptor. The fact that CHIP can potentially target both 
oncogenic and misfolded proteins for degradation suggests this finding may be of 
particular interest to unravel. WT RET may be targeted for degradation by CHIP 
due to the slow folding nature of the receptor and its role as an oncoprotein, while 
S100M RET may lead to activation of the Hsp90/CHIP axis. Future investigations 
could examine the effect CHIP knockdown has on the viability or proliferation of the 
inducible cell lines, or such investigations could be carried out in an endogenous 
cell line – such as the neuroblastoma cell line SK-N-SH (Takahashi and Cooper, 
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1987). Preliminary antibody tests have confirmed that the cell surface expression 
levels of RET can be examined in this particular endogenous cell line.  
6.2.2  Implicating aggrephagy in the degradation of HSCR RET 
The identification of OPTN and GABARAPL1 as hits lead to the hypothesis that 
S100M RET is targeted for aggrephagy, a specialised type of autophagy that 
targets aggregated protein or pathogens for lysosomal degradation (Lamark and 
Johansen, 2012). This hypothesis was strengthened by the observation that the 
OPTN and GABARAPL1 knockdown selectively increased cell surface expression 
of S100M RET and had no effect on WT RET levels. Preliminary validation was 
carried out using a TBK1 inhibitor developed by Professor Philip Cohen (Clark et al., 
2011), as TBK1 has been found to co-localise with and phosphorylate OPTN at a 
unique site, regulating its ability to interact with autophagy modifiers (Korac et al., 
2013). Surprisingly, TBK1 inhibition resulted in increased cell surface levels of both 
WT and S100M RET – something that was not observed in the original screen. 
siRNAs targeting both TBK1 and OPTN need to be tested in DLD-1 WT and 
S100M RET cells to examine this further. OPTN silencing in the siRNA screen may 
not have been 100% efficient. If this was the case, the effect on RET surface levels 
may only have been apparent for S100M RET due to the higher level of the HSCR 
protein targeted to this pathway in comparison to WT. Western blot analysis of total 
protein levels suggests a larger increase in S100M RET levels under TBK1 
inhibition in comparison to WT. As such, it is possible that the OPTN-aggrephagy 
pathway is degrading misfolded protein that has been targeted for degradation and 
translocated out of the ER into the cytosol. Therefore, a small amount of WT 
protein could be degraded via this pathway, due to the previously mentioned 
intrinsically slow folding nature of the receptor. If correct, the connection between a 
specialised autophagy pathway and the degradation of a poorly folded or misfolded 
transmembrane receptor could establish a novel degradative pathway. Further 
investigations would require an inducible DLD-1 cell line expressing a non-
rescuable severe HSCR mutant such as G93S. Previous work has shown that 
HSCR mutants can be divided into two categories: mild-phenotype mutations (such 
as S100M) that are believed to be targeted for degradation due to slow folding and 
can be rescued, and severe-phenotype mutations (such as G93S) that are 
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terminally misfolded and cannot be rescued (Kjaer et al., 2010). One hypothesis 
from these data is that a larger amount of G93S is targeted for degradation by 
aggrephagy than S100M RET, which could be directly investigated by OPTN 
knockdown (or chemical inhibition of TBK1) in each of these three cell lines.   
6.2.3 Elucidating a potential RET folding pathway through the identification 
of specific chaperones 
Several positive regulators of WT RET surface expression were identified in the 
siRNA screen, including HSPA5 (GRP78/BiP), MESDC2, HYOU1, GRP58, CALR 
and ERN1. The presence of calreticulin (CALR) and BiP in the list of ‘hits’ provides 
a level of validation, as both chaperones have been heavily implicated in the folding 
of glycoproteins (Hebert et al., 1996, Hendershot, 2004). No validation has been 
carried out on these hits as of yet, with repeated siRNA knockdowns required to 
confirm the involvement of each chaperone in WT RET folding. If involved, the 
identification of these factors could create a snapshot of RET folding within the ER 
before continuing to the Golgi apparatus. Future investigations could involve the 
knockdown of each chaperone in an endogenous cell line – such as SK-N-SH – 
and the comparison of the knockdowns in a cell line expressing another RTK, such 
as EGFR. This would provide an indication of the specificity of the chaperones 
identified for RET rather than as a more general receptor tyrosine kinase folding 
mechanism.  
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Figure 6.1 Schematic model of WT, S100M* and S100M RET export 
WT RET (green) is exported to the cell surface, is fully mature and can activate downstream 
signalling pathways. Several factors involved in WT RET folding have been identified. S100M* 
RET (orange) is exported to the cell surface and is fully mature. Future investigations are 
required in order to establish signalling capabilities. S100M RET (red) is degraded via ERAD, 
but is exported to the cell surface upon silencing of OPTN or TBK1. Exported protein is not fully 
glycosylated and cannot activate downstream signalling pathways. Future investigations are 
required to understand the potential role of EDEMosomes and aggrephagy in S100M RET 
degradation.   
6.2.4  Future investigations: a secondary screen to restore functional 
signalling for mild RET HSCR mutations 
Findings in chapters 3 and 4 have shown that restored S100M RET cell surface 
expression, by CHIP or OPTN gene knockdown or through TBK1 chemical 
inhibition, does not appear to enhance the maturation process and therefore is 
unlikely to have restored functional signalling capability onto S100M HSCR. The 
increased levels of immature S100M HSCR RET following aggresome inhibition 
would suggest that this form is present at the cell surface. In the absence of a 
ligand-induced pERK1/2 signal or S100M RET auto-phosphorylation, I conclude 
that immature S100M RET is not competent to bind a GDNF-GFR1 ligand leading 
to receptor auto-phosphorylation. This leads us to conclude that maturation is the 
key to restoring functional RET signalling and not simply cell surface localisation. 
Nevertheless, the siRNA knockdown hits identified in the screen have provided 
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insights and unexpected leads into new avenues – such as WT RET folding and 
S100M RET aggrephagy. At the time of writing, a 4000 compound screen has been 
carried out in collaboration with the HTS facility on DLD-1 cells expressing S100M 
RET, in an attempt to identify specific compounds that could restore cell surface 
levels. Preliminary analysis identified 2.9% of the screen as a hit, and further 
investigations are required to assess their effects on RET signalling. A cross-
correlation of target hits from the chemical and genetic screens will provide a 
robust set of hits to take forwards into a secondary screen for restoration of 
functional RET signalling. 
 
In considering how to set up a secondary screen, either to run it independently or 
evaluate genes identified through the immunofluorescence-based screen, the best 
suited surrogate for functional RET signalling is phospho-ERK1/2. While western 
blot analysis of ERK1/2 phosphorylation has been used in this thesis, a higher 
throughput method is required. This could be carried out by immunofluorescence 
staining of fixed cells with antibodies against phosphorylated RET or members of 
downstream signalling pathways, as discussed at the end of chapter 4. We are 
currently in discussions with the HTS facility on the possibility of examining ERK1/2 
phosphorylation in fixed cells using our current immunofluorescence assay. 
Alternatively, intramolecular FRET (fluorescence resonance energy transfer) 
biosensors could be used to detect phosphorylated ERK and Akt levels in live cells, 
as developed and optimised by (Komatsu et al., 2011). A combination of this new 
biosensor technology and the utilisation of the piggBac transposase system 
(Miaczynska et al., 2004) could allow rapid establishment of RET-expressing 
biosensor cell lines and lead to the identification of compounds or siRNA 
knockdowns influencing signalling pathways within the cell.  
6.2.5 Translating targets found in cell-based models into animal models of 
Hirschsprung’s disease 
Throughout this thesis, our experiments have used inducible mammalian cell lines 
that lack endogenous WT or mutant RET. These allows for the introduction of 
mutant RET forms into readily transfectable cell-lines. To validate hits required for 
publication, future investigations would benefit from the use of endogenous WT 
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RET cell lines, such as the neuroblastoma cell line SK-N-SH. However, there is 
also an outstanding need for an animal model of Hirschsprung’s disease. 
Especially for validating that functional RET signalling could be restored by gene 
knockdown or chemical inhibition using the proposed secondary pERK1/2 assay. 
 
Currently mouse models for HSCR use only Ret-null, RET C620R or EDNRB-null, 
none of which are appropriate in these investigations. The development of new 
mouse models with specific RET mutations – such as S100M – could be a future 
possibility. Investigations into endogenous HSCR RET mutants could continue in 
primary cultures of neural crest cells isolated from mouse model embryos (Yin et al., 
2007).  
6.3 Towards the development of improved high potency RET 
inhibitors 
Current RET inhibitors that are used in the clinic lack specificity and potency, 
exhibit hERG activity and have dose-limited toxicities from off-target effects. The 
case for developing a new generation of inhibitors is well made. Chapter 5 
describes the elucidation of crystal structures of the RET tyrosine kinase bound to 
a variety of DFG-in chemical inhibitors with distinct molecular scaffold backbones. 
These scaffolds appear to interact with distinct but overlapping interaction hot spots 
within the RET KD nucleotide-binding pocket.  
6.3.1 Using differential scanning fluorimetry to examine RET KD-inhibitor 
binding and stabilisation of protein melting curves 
Differential scanning fluorimetry was used to calculate the thermal stability of the 
RET KD in the presence of each inhibitor, a method that is commonly used to 
examine enzyme-substrate binding (Niesen et al., 2007). This method is well suited, 
as it appears to distinguish between DFG-in and DFG-out inhibitors, due to the 
large thermal shift induced by DFG-out inhibitors Sorafenib and Pz-1. This method 
could therefore be used to readily characterise newly designed inhibitors and 
assess whether those inhibitors could be crystallised with the existing RET KD 
recombinant protein and conditions. The assay has also been used to examine 
inhibitor selectivity, something that could be examined in the future (Fedorov et al., 
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2012). The selected compounds can be incubated with both RET KD and a 
common off-target (in the case of S1 inhibitors, that could be AURKA) in order to 
identify the most optimal design of inhibitor. Interestingly, the IC50 data provided by 
our collaborators positively correlated with the thermal shifts observed for the RET 
KD bound to each of the S1 inhibitors, suggesting that ΔTm (shift in thermal 
stability) can also give an indication of inhibitor potency. This data is currently 
statistically insignificant, due to the small differences between each ΔTm, but 
optimisation (possibly with higher protein concentrations and focussing on S1 
inhibitors alone) may overcome this. Going forward, it would be more optimal to 
calculate IC50 values (which could be carried out in RET WT DLD-1 cells) on all 
inhibitors together rather than collate data from different collaborators performed at 
different times using different cell lines and protocols.  
 
The arrival of a 20,000-fragment compound screen at the institute also introduces 
the possibility of a large scale high throughout thermal screen to identify new RET 
KD inhibitors. Focussing on the identification of ATP-competitive inhibitors (as the 
crystallisation conditions for this are known), pools of fragments could be added to 
the RET KD and those inducing a positive thermal shift taken forward for 
crystallisation trials, either individually or as pools. Structural elucidation of the KD 
bound to different fragments would encourage the development of new inhibitors, 
and the information could also be compared to the developing RET pharmacophore. 
This fragment based drug discovery approach has been used to identify promising 
compounds against the BRAF kinase, Hsp90 and p38 MAPK (Murray et al., 2012, 
Carr et al., 2004).  
 
Alternatively, there may be pools of fragments that induce a negative thermal shift, 
which could give an indication of protein instability (Dai et al., 2014). In the case of 
oncogenic RET, inducing protein instability could provide an alternate mechanism 
of inhibition. If this were an objective, the screen would need to be carried out on 
both WT and oncogenic (e.g. M918T MEN2B) RET, as differences in native 
stability have been previously reported (Plaza-Menacho et al., 2014).   
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6.3.2  Structural elucidation of nine RET KD-inhibitor complexes 
This thesis has presented the structure of the RET KD bound to nine new inhibitors, 
at resolutions ranging from 1.8 Å to 2.6 Å. The inhibitors were divided into four 
scaffolds (S3 currently consists of inhibitors from previously solved structures), with 
each scaffold exhibiting slightly different binding characteristics within the ATP 
pocket of the RET KD. S1 inhibitors contain a benzodiazepine scaffold that folds 
around the hydrophobic floor (Glu810 and Leu881) of the nucleotide pocket and 
forms hydrogen bonds with the main chain of Ala807 in the KD hinge – it does not 
extend into the interior pocket. S2 (pyrazolopyrimidine) inhibitors extend much 
further back, forming hydrogen bonds with the main chain of Glu805 and extending 
towards Glu775 in the interior pocket. S3 (2-oxo-1H-indolinone) inhibitors appear to 
hydrogen bond with the main chain of both Ala807 and Glu805, while bonding with 
a residue in the catalytic region of the pocket also (Ser891 or Asp892). S4 (4-
anilinoquinazoline) inhibitors sit in a similar position within the nucleotide pocket, 
but Vandetanib hydrogen bonds with the main chain of Ala807, while I-3 only 
hydrogen bonds with Glu775 in the interior pocket – the only inhibitor to make such 
a connection. BMS-536924 (the phenyl-benzimidazole S5) is found to hydrogen 
bond with both Ala807 and Glu805 of the KD hinge, while extending over to the 
catalytic region of the pocket (as defined in chapter 5). The relevance of this 
binding mode needs further investigations, as the current RET KD recombinant 
protein cannot be captured in a DFG-out conformation, which this inhibitor may 
induce. The thermal shift assay gives an indication that this inhibitor is DFG-out, as 
incubation with BMS-536924 elicits a positive shift in thermal stability similar to that 
of Pz-1 and Sorafenib.  
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Figure 6.2 Schematic diagram of scaffold positions within the RET nucleotide 
binding pocket 
Schematic of positions of scaffold 1 (green), 2 (blue), 3 (purple) and 4 (orange) within the RET 
nucleotide binding pocket, with key residues highlighted. The position of scaffold 5 has not been 
added, due to the requirement of further validation.   
 
During the writing of this thesis, datasets for the RET KD bound to three other S2 
inhibitors were collected and require further refinement. Our collaborators have 
also provided us with other inhibitors. While preliminary comparisons suggest a 
strong correlation between the induced thermal stability and inhibitor potency 
(Figure 5.14), there is an urgent need to assemble a comprehensive set of 
biochemical and cellular IC50 values using an identical protocol, reagents and 
performed by the same person. More detailed comparisons and conclusions could 
then be drawn, integrating the structural data described here. 
6.3.3 Preliminary development of an improved RET pharmacophore 
The development of a new RET pharmacophore has begun, through the 
compilation of information provided from each of the RET KD-inhibitor structures. 
Inhibitors have been preliminarily clustered based on the number of interactions 
each residue within the defined ATP-pocket could make with each inhibitor (defined 
as those within 4 Å). This level of data has already begun to separate scaffolds 
successfully, with the addition of more data – such as hydrogen bonds within the 
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hinge, IC50 data and ΔTm values – hopefully leading to the optimisation of the 
database. This database could be greatly built upon if the 20,000 fragment 
compound screen is carried out with the RET KD. If successful, the database could 
be used as a reference point for the design of the next generation of RET inhibitors, 
identifying the most optimal chemical characteristics for potency and specificity.  
6.4  Concluding remarks 
In this thesis I have sought to progress our understanding of the folding, export and 
chemical regulation of the RET receptor tyrosine kinase. I have provided a strategy 
for examining the molecular mechanisms of WT, HSCR and oncogenic RET export, 
and have identified factors that may be responsible for the regulation of both 
pathogenic forms of the receptor. I have also presented the crystal structure of the 
RET KD bound to a range of ATP-competitive inhibitors; with the objective of 
progressing the development of a new generation of more specific and potent RET 
inhibitors. I hope that the work presented in this thesis will further our 
understanding of Hirschsprung’s disease and lead to improved RET-associated 
cancer treatments in the future.  
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Chapter 7. Appendix 
7.1 siRNA screen plates 1-4 layout 
Well allocation for all screen siRNA candidates in plates 1-4 with gene name and 
NCBI reference sequence code. 
Table 7.1 Plate 1 siRNA candidate well allocation 
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Table 7.2 Plate 2 siRNA candidate well allocation 
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Table 7.3 Plate 3 siRNA candidate well allocation 
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Table 7.4 Plate 4 siRNA candidate well allocation 
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7.2 POC scores for all siRNA screen targets 
 
Table 7.5 WT and S100M RET POC scores for all siRNA candidates (1) 
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Table 7.6 WT and S100M RET POC scores for all siRNA candidates (2) 
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Table 7.7 WT and S100M POC scores for all siRNA candidates (3) 
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Table 7.8 WT and S100M POC scores for all siRNA candidates 
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